var title_f35_4_35904="Preimplantation development";
var content_f35_4_35904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Preimplantation developmental time-line in humans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The blastocyst consists of an inner cell mass (which becomes the embryo) and an outer cell mass (cytotrophoblastic shell, which will become the placenta).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Catherine Racowsky, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35904=[""].join("\n");
var outline_f35_4_35904=null;
var title_f35_4_35905="Patient information: Raynaud disease (The Basics)";
var content_f35_4_35905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15533\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/36/583\">",
"         Acute Raynaud phenomenon",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/49/30481\">",
"         Patient information: Raynaud phenomenon (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Raynaud disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/raynaud-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H562195697\">",
"      <span class=\"h1\">",
"       What is Raynaud disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Raynaud disease is a condition that can cause people&rsquo;s fingers and toes to turn white or purple-blue (",
"      <a class=\"graphic graphic_figure graphicRef71633 \" href=\"mobipreview.htm?0/36/583\">",
"       figure 1",
"      </a>",
"      ). Raynaud disease does not always cause symptoms, but people can get an &ldquo;attack&rdquo; when it is cold out, when they feel stressed, or when they are startled. Raynaud disease is more common in women than men.",
"     </p>",
"     <p>",
"      Normally, blood vessels in parts of the body become narrow under certain conditions, such as when it is very cold out. When people have Raynaud disease, the blood vessels become much more narrow than usual during these times. This causes symptoms.",
"     </p>",
"     <p>",
"      Most people with Raynaud disease have normal blood vessels. But some people with Raynaud disease also have another disease that affects their blood vessels.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H562195704\">",
"      <span class=\"h1\">",
"       What are the symptoms of Raynaud disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most often, Raynaud disease affects the fingers. During an attack, people&rsquo;s fingers suddenly become cold and turn white or purple-blue. Attacks usually begin in the index, middle, or ring fingers and then spread to the fingers in both hands. The thumb is not usually affected. During an attack, a person&rsquo;s hand can feel numb, clumsy, or like it has &ldquo;pins and needles.&rdquo;",
"     </p>",
"     <p>",
"      It does not need to be very cold out for people to have an attack. Attacks can happen when people go from a warm area to a cooler area, such as walking into an air-conditioned building.",
"     </p>",
"     <p>",
"      Raynaud disease can also affect other parts of the body. The toes, ears, nose, face, knees, and nipples can become white or blue when they are cold.",
"     </p>",
"     <p>",
"      Once a person warms up or is no longer stressed, the symptoms go away and the skin becomes pink or red. This usually takes 15 to 20 minutes.",
"     </p>",
"     <p>",
"      People who have Raynaud disease plus another disease affecting their blood vessels can have more severe symptoms. Their attacks can last longer, and they can develop pain or open sores on their fingers and toes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H562195711\">",
"      <span class=\"h1\">",
"       Is there a test for Raynaud disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. But your doctor or nurse should be able to tell if you have it by talking with you and doing an exam. Your doctor or nurse might also order blood tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H562195718\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to prevent attacks of Raynaud disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help prevent attacks, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Try not to let your body get cold too quickly and or change temperatures too quickly. Keep your whole body warm and avoid cold breezes or cold places. You can dress warmly by wearing layers of clothes, hats, and mittens or gloves.",
"       </li>",
"       <li>",
"        Don&rsquo;t smoke &ndash; Smoking can make your symptoms worse.",
"       </li>",
"       <li>",
"        Avoid medicines that cause blood vessels to become narrow, such as cold medicines or diet pills",
"       </li>",
"       <li>",
"        Try to relax and reduce the stress in your life",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have an attack, you can try to end it quickly by warming up your hands. Place your hands in warm water or in a warm place, such as in your armpits.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H562195725\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you continue to have attacks after trying the things listed above, talk with your doctor or nurse. Your doctor might prescribe a medicine to help reduce your symptoms. Some people take medicine for Raynaud disease only during the cold winter months.",
"     </p>",
"     <p>",
"      You should also see your doctor or nurse if you have an attack that does not get better. If your symptoms do not go away, your doctor or nurse might send you to the hospital for further treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H562195732\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/49/30481?source=see_link\">",
"       Patient information: Raynaud phenomenon (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/4/35905?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15533 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35905=[""].join("\n");
var outline_f35_4_35905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562195697\">",
"      What is Raynaud disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562195704\">",
"      What are the symptoms of Raynaud disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562195711\">",
"      Is there a test for Raynaud disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562195718\">",
"      Is there anything I can do on my own to prevent attacks of Raynaud disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562195725\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562195732\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15533\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/36/583\">",
"      Acute Raynaud phenomenon",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/49/30481?source=related_link\">",
"      Patient information: Raynaud phenomenon (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_4_35906="Management of unscheduled bleeding in women using contraception";
var content_f35_4_35906=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Management of unscheduled bleeding in women using contraception",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 748px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     COCs: combined oral contraceptives; IUD: intrauterine contraceptive device; POPs: progestin only pills; NSAIDs: nonsteroidal anti-inflammatory drugs; EE: ethinyl estradiol.",
"     <br>",
"      * Not commercially manufactured or not available in the United States.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35906=[""].join("\n");
var outline_f35_4_35906=null;
var title_f35_4_35907="Types of odontogenic infections";
var content_f35_4_35907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Odontogenic infections",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 212px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Dental caries, pulpal infection, and periapical abscess. Panel B: Periodontal infection with destruction of supporting structures. Panel C: Pericoronal infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Chow, AW, Roser, SM, Brady, FA, Ann Intern Med 1978; 88:392.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35907=[""].join("\n");
var outline_f35_4_35907=null;
var title_f35_4_35908="Pramipexole: Patient drug information";
var content_f35_4_35908=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pramipexole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     see \"Pramipexole: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mirapex&reg;;",
"     </li>",
"     <li>",
"      Mirapex&reg; ER&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F212310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pramipexole&reg;;",
"     </li>",
"     <li>",
"      Ava-Pramipexole;",
"     </li>",
"     <li>",
"      CO Pramipexole;",
"     </li>",
"     <li>",
"      Mirapex&reg;;",
"     </li>",
"     <li>",
"      PMS-Pramipexole;",
"     </li>",
"     <li>",
"      Sandoz-Pramipexole;",
"     </li>",
"     <li>",
"      Teva-Pramipexole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat restless leg syndrome.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691845",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat fibromyalgia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702776",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pramipexole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hallucinations.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698652",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Falling asleep during activities such as eating or talking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705902",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Strong urges that are hard to control (such as gambling or sex).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting tablet: Swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10988 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35908=[""].join("\n");
var outline_f35_4_35908=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212309\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212310\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019108\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019107\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019112\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019113\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019115\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019110\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019111\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019116\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019117\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=related_link\">",
"      Pramipexole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_4_35909="Estramustine: Drug information";
var content_f35_4_35909=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Estramustine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/45/10965?source=see_link\">",
"    see \"Estramustine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Emcyt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F167309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Emcyt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F167326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Hormone;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Hormone (Estrogen/Nitrogen Mustard)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F167311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostate cancer:",
"     </b>",
"     Oral: Males: 14 mg/kg/day (range: 10-16 mg/kg/day) in 3 or 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Combination therapy with docetaxel (unlabeled dose): 280 mg 3 times/day for 5 days (days 1 through 5) of a 21-day treatment cycle for up to 12 cycles (Petrylak, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F167312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15837958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15837959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F167288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as phosphate sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emcyt&reg;: 140 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F167273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F167291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer on an empty stomach, at least 1 hour before or 2 hours after eating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F167289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palliative treatment of progressive or metastatic prostate cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F167334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Emcyt&reg; may be confused with Eryc&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Estramustine may be confused with exemestane.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F167324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia (75%), breast tenderness (71%), libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (16%), diarrhea (13%), gastrointestinal upset (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: LDH increased (2% to 33%), AST increased (2% to 33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: CHF (3%), MI (3%), cerebrovascular accident (2%), chest pain (1%), flushing (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Lethargy (4%), insomnia (3%), emotional lability (2%), anxiety (1%), headache (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bruising (3%), dry skin (2%), pruritus (2%), hair thinning (1%), rash (1%), skin peeling (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (4%), flatulence (2%), burning throat (1%), gastrointestinal bleeding (1%), thirst (1%), vomiting (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (4%), thrombocytopenia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubin increased (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Leg cramps (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Tearing (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary embolism (2%), upper respiratory discharge (1%), hoarseness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions, anemia, angina, angioedema, cerebrovascular ischemia, confusion, coronary ischemia, depression, glucose tolerance decreased, hyper-/hypocalcemia, hypertension, impotence, muscle weakness, venous thrombosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F167294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to estramustine, estradiol, nitrogen mustard, or any component of the formulation; active thrombophlebitis or thromboembolic disorders (except where tumor mass is the cause of thromboembolic disorder and the benefit may outweigh the risk)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in the U.S. labeling): Severe hepatic or cardiac disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F167277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reaction: Allergic reactions and angioedema, including airway involvement, have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Elevated blood pressure or congestive heart disease may occur. Estrogen treatment for prostate cancer is associated with an increased risk of thrombosis or MI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Estrogenic effects: Estrogen use may cause gynecomastia and/or impotence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid retention: Peripheral edema (new onset or exacerbation) or congestive heart disease may occur. Use with caution in patients where fluid accumulation may be poorly tolerated, including cardiovascular disease (HF or hypertension), migraine, seizure disorder or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (eg, thrombophlebitis, thrombosis, or thromboembolic disease) and cerebrovascular or coronary artery disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may decrease glucose tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment (may be metabolized poorly).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metabolic bone disease: Use with caution in patients with metabolic bone diseases due to the effects on calcium and phosphorus homeostasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoblastic metastases: Patients with osteoblastic metastases should have their calcium monitored regularly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunization: Avoid vaccination with live vaccines during treatment (risk of infection may be increased due to immunosuppression). Although the response to vaccines may be diminished, inactivated vaccines may be administered during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Patients with prostate cancer should have their calcium monitored regularly.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F167282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the absorption of Estramustine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcium Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clodronate: May increase the serum concentration of Estramustine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F167305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Estramustine serum levels may be decreased if taken with milk or other dairy products, calcium supplements, and vitamins containing calcium. Management: Take on an empty stomach at least 1 hour before or 2 hours after eating.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4091591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estramustine is not indicated for use in women. Men who were impotent on estrogen therapy have regained potency while taking estramustine; effective contraception should be used for male patients with partners of childbearing potential.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4091593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estramustine is not indicated for use in women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F167297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken at least 1 hour before or 2 hours after eating. Milk products and calcium-rich foods or supplements may impair the oral absorption of estramustine phosphate sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F167296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Emcyt Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     140 mg (100): $857.66",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F167286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum calcium, liver function tests; blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F167298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Emcyt (MX);",
"     </li>",
"     <li>",
"      Estracyt (AE, AR, AT, BE, BG, BH, CH, CL, CN, CO, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HK, HN, IE, IL, IQ, IR, IT, JO, JP, KP, KW, LB, LY, MT, MY, NL, NO, OM, PL, PT, QA, RU, SA, SE, SG, SK, SY, TR, TW, VE, YE, ZA);",
"     </li>",
"     <li>",
"      Multosin (DE);",
"     </li>",
"     <li>",
"      X-Trant (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F167276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combines the effects of estradiol and nitrogen mustard. It appears to bind to microtubule proteins, preventing normal tubulin function. The antitumor effect may be due solely to an estrogenic effect. Estramustine causes a marked decrease in plasma testosterone and an increase in estrogen levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F167293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GI tract: Initial dephosphorylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Oxidation and hydrolysis; metabolites include estramustine, estrone analog, estrone, and estradiol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 15-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (2.9% to 4.8% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Benson R and Hartley-Asp B, &ldquo;Mechanisms of Action and Clinical Uses of Estramustine,&rdquo;",
"      <i>",
"       Cancer Invest",
"      </i>",
"      , 1990, 8(3-4):375-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/4/35909/abstract-text/2207764/pubmed\" id=\"2207764\" target=\"_blank\">",
"        2207764",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergenheim AT and Henriksson R, &ldquo;Pharmacokinetics and Pharmacodynamics of Estramustine Phosphate,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1998, 34(2):163-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/4/35909/abstract-text/9515186/pubmed\" id=\"9515186\" target=\"_blank\">",
"        9515186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/4/35909/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hudes GR, &ldquo;Estramustine-Based Chemotherapy,&rdquo;",
"      <i>",
"       Semin Urol Oncol",
"      </i>",
"      , 1997, 15(1):13-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/4/35909/abstract-text/9050135/pubmed\" id=\"9050135\" target=\"_blank\">",
"        9050135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kreis W, &ldquo;Estramustine Revisited,&rdquo;",
"      <i>",
"       Cancer Treat Res",
"      </i>",
"      , 1995, 78:163-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/4/35909/abstract-text/8595142/pubmed\" id=\"8595142\" target=\"_blank\">",
"        8595142",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lubiniecki GM, Berlin JA, Weinstein RB, et al, &ldquo;Thromboembolic Events With Estramustine Phosphate-Based Chemotherapy in Patients With Hormone-Refractory Prostate Carcinoma: Results of a Meta-Analysis,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 101(12):2755-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/4/35909/abstract-text/15536625/pubmed\" id=\"15536625\" target=\"_blank\">",
"        15536625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry CM and McTavish D, &ldquo;Estramustine Phosphate Sodium. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Prostate Cancer,&rdquo;",
"      <i>",
"       Drugs Aging",
"      </i>",
"      , 1995, 7(1):49-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/4/35909/abstract-text/7579781/pubmed\" id=\"7579781\" target=\"_blank\">",
"        7579781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Petrylak DP, Tangen CM, Hussain MH, et al, &ldquo;Docetaxel and Estramustine Compared With Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(15):1513-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/4/35909/abstract-text/15470214/pubmed\" id=\"15470214\" target=\"_blank\">",
"        15470214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9423 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-82E6EA8F2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35909=[""].join("\n");
var outline_f35_4_35909=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167308\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167309\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167326\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167311\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167312\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837958\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837959\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167288\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167273\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167291\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167289\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167334\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167324\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167294\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167277\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299287\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167282\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167305\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4091591\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4091593\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167297\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167296\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167286\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167298\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167276\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167293\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9423\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9423|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/45/10965?source=related_link\">",
"      Estramustine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_4_35910="Hereditary kidney cancer syndromes";
var content_f35_4_35910=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hereditary kidney cancer syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35910/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35910/contributors\">",
"     Toni K Choueiri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35910/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35910/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35910/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35910/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/4/35910/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary kidney cancer syndromes were originally described based upon clinical observations that defined the disease phenotype. Family studies and advances in molecular genetics have provided important insights into the molecular pathways underlying the pathogenesis of these syndromes as well as providing new insights into sporadic renal cell carcinoma (RCC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Each of these syndromes has its own molecular alteration, and these are often reflected in distinctive histologic features and clinical course. Less than 5 percent of all renal cell carcinoma (RCC) cases are thought to be due to a hereditary syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inherited kidney cancer syndromes are summarized in Table 1 (",
"    <a class=\"graphic graphic_table graphicRef53600 \" href=\"mobipreview.htm?0/28/460\">",
"     table 1",
"    </a>",
"    ) and are reviewed here. Other topics provide more general discussions of RCC and its management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35336?source=see_link\">",
"     \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18250?source=see_link\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21192?source=see_link\">",
"     \"Prognostic factors in patients with renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEREDITARY PAPILLARY RENAL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary papillary renal carcinoma (HPRC) is a familial cancer syndrome in which affected individuals are at risk for the development of type 1 papillary RCCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HPRC is a highly penetrant, autosomal dominant condition. Both early and late onset forms of HPRC have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. HPRC is manifested primarily by the development of papillary renal tumors, which are often multifocal and bilateral. On imaging studies, the lesions are relatively hypovascular and grow slowly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic linkage analyses found that the HPRC gene (the MET protooncogene) is located on the long arm of chromosome 7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/8\">",
"     8",
"    </a>",
"    ]. This gene codes for a membrane bound receptor for hepatocyte growth factor (HGF) and has an intracellular tyrosine kinase domain. Mutations in MET constitutively activate the tyrosine kinase domain of this protein in patients with HPRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients have bilateral multifocal tumors. As such, nephron-sparing procedures such as partial nephrectomy are preferred to maintain renal function while minimizing the risk of distant metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with tumors less than 3 cm generally are managed with observation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5546?source=see_link&amp;anchor=H20#H20\">",
"     \"Surgical management of localized renal cell carcinoma\", section on 'Nephron-sparing approaches'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2200?source=see_link\">",
"     \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with distant metastases or unresectable disease, agents targeting the MET pathway are being developed. As an example, an interim analysis from a phase II multicenter study of the dual",
"    <span class=\"nowrap\">",
"     MET/vascular",
"    </span>",
"    endothelial growth factor receptor-2 inhibitor GSK1363089 demonstrated tumor shrinkage in three patients with HPRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Germline MET mutation analysis is recommended for patients with HPRC. Techniques are being developed to detect carriers of germline mutations in family members of patients with HPRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a syndrome in which affected family members have cutaneous and uterine leiomyomas,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    papillary type 2 RCCs. This syndrome is also called the multiple cutaneous and uterine leiomyomatosis syndrome (MCUL1) or Reed's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/3/17465?source=see_link&amp;anchor=H23364055#H23364055\">",
"     \"Variants of uterine leiomyomas (fibroids)\", section on 'Hereditary leiomyomatosis and renal cell carcinoma syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Family studies have linked HLRCC to abnormalities in the fumarate hydratase (FH) gene, which is located on the long arm of chromosome 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/12\">",
"     12",
"    </a>",
"    ]. FH is part of the mitochondrial Krebs or tricarboxylic acid cycle. The mechanism by which alterations in FH lead to HLRCC is not completely understood, although it is may involve increased cellular dependence on glycolysis and pseudohypoxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/13\">",
"     13",
"    </a>",
"    ]. One study showed that an antioxidant response element controlled gene, the aldo-keto reductase family 1 member B10 (AKR1B10), is upregulated in FH knockdown and FH null cell lines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/14\">",
"     14",
"    </a>",
"    ]. Other experiments have found that inactivating mutations of FH appear to result in the generation of reactive oxygen species and stabilization of hypoxia-inducing-factor (HIF)-1 alpha, which is necessary for the generation of pseudohypoxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14678?source=see_link&amp;anchor=H3#H3\">",
"     \"Molecular biology and pathogenesis of von Hippel-Lindau disease\", section on 'Hypoxia-inducible factor-1 and 2'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HLRCC is transmitted in an autosomal dominant fashion, and the FH gene is thought to act as a tumor suppressor gene. Germline alterations that have been identified include missense, nonsense, insertion, deletion, and splice-site mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most striking clinical feature of the disease is the occurrence of severely symptomatic uterine fibroids among affected women, often requiring hysterectomy at a young age due to uterine bleeding or discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/17\">",
"     17",
"    </a>",
"    ]. Transformation of leiomyomas to leiomyosarcomas has been reported in rare cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cutaneous leiomyomas are common among individuals with HLRCC. These leiomyomas typically develop on the trunk and extremities and are quite apparent and symptomatic. In a few cases, patients may have only subtle skin findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/17,19\">",
"     17,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal tumors occur in 20 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/12,19\">",
"     12,19",
"    </a>",
"    ]. These renal carcinomas tend to be aggressive, with rapid nodal and distant dissemination even if the primary tumor is relatively small and contained. As an example, in one series one-half of the patients had metastases present at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with suspected HLRCC should undergo a thorough imaging evaluation and early intervention. Complete wide excision including lymph node dissection has been recommended in patients with localized or locally advanced disease. Close follow-up is required after initial treatment. Systemic therapy has not been shown to be effective for patients with metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multidisciplinary approach, including gynecologists, dermatologists, and genetic counselors, is required for optimal patient management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BIRT-HOGG-DUBE SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Birt-Hogg-Dube (BHD) syndrome is an inherited syndrome in which affected individuals are at risk for the development of bilateral, multifocal kidney cancer, as well as various dermatologic and pulmonary lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BHD syndrome is caused by mutations in the folliculin (FLCN) gene (also known as the BHD gene), which is localized to the short arm of chromosome 17 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/23\">",
"     23",
"    </a>",
"    ]. Mutations in the germline of affected individuals have been identified in 90 percent of affected families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/24\">",
"     24",
"    </a>",
"    ]. DNA sequencing of renal tumors from patients with germline FLCN mutations has identified somatic mutations in the wild-type copy of the gene, suggesting that FLCN is a loss-of-function, tumor suppressor gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FLCN gene may be involved in energy, metabolism, and nutrient sensing through the mammalian target of rapamycin (mTOR) pathway. The folliculin-interacting protein, FNIP1, interacts with 5' AMP-activated protein kinase (AMPK), a key molecule for energy sensing to negatively regulate mTOR activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The penetrance of renal cancer in patients with BHD is up to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In the largest series of 124 patients with BHD syndrome, the risk of renal tumors was 27 percent at a mean age of 50 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/27\">",
"     27",
"    </a>",
"    ]. However, the incidence of renal tumors may vary in different families, and BHD may be underdiagnosed in patients with variable skin findings.",
"   </p>",
"   <p>",
"    The histology of renal tumors in patients with BHD syndrome varies. Tumors containing a mixed pattern of chromophobe and oncocytic renal cancer are typical, but other histologies may be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/22,27\">",
"     22,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dermatologic manifestations of BHD syndrome include skin lesions called fibrofolliculomas, which are benign hamartomatous tumors of hair follicles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/22\">",
"     22",
"    </a>",
"    ]. These whitish papules are most common on the nose and cheeks and typically are first observed around age 20 years.",
"   </p>",
"   <p>",
"    Approximately 80 percent of patients with BHD have multiple pulmonary cysts that can be identified by CT of the lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/22\">",
"     22",
"    </a>",
"    ]. Spontaneous pneumothorax may be seen in up to one-fourth of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link&amp;anchor=H5#H5\">",
"     \"Primary spontaneous pneumothorax in adults\", section on 'Family history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The kidney cancers observed in patients with BHD syndrome tend to be bilateral, multifocal, in more than one-half of cases and are usually slow growing. Thus, the recommended management approach includes observation of tumors less than 3 cm; when surgery is recommended, all visible tumors should be removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/32\">",
"     32",
"    </a>",
"    ]. As with hereditary papillary renal carcinoma, nephron-sparing surgery is preferred to radical nephrectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/22,33\">",
"     22,33",
"    </a>",
"    ]. Follow-up in patients undergoing nephron-sparing surgery is important given the high risk of disease recurrence in the ipsilateral kidney.",
"   </p>",
"   <p>",
"    An animal model of BHD has been developed to provide a model for the evaluation of therapeutic approaches to this syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/34\">",
"     34",
"    </a>",
"    ]. In this model, treatment with the mTOR inhibitor rapamycin led to tumor shrinkage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HEREDITARY PARAGANGLIOMA AND PHEOCHROMOCYTOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary paraganglioma and pheochromocytoma (HPP) is an autosomal dominant condition, which is characterized by paragangliomas that typically develop in patients in their thirties. Tumors are most commonly located in the head and neck region, but can also be seen in the thorax, abdomen, pelvis, and urinary bladder. This disease is associated with germline mutations of genes that encode the Krebs cycle, involving the succinate dehydrogenase (SDH) subunits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21351?source=see_link\">",
"     \"Pheochromocytoma in genetic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Kidney cancer can be a manifestation in patients with the hereditary paraganglioma syndrome. SDHB-associated RCC presents at an early age, although the age at diagnosis has ranged from 24 to 73 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In one series of 14 patients treated at the US National Cancer Institute, the median age of diagnosis of 33 years (range, 15 to 62) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/38\">",
"     38",
"    </a>",
"    ]. The histologic type of kidney cancer varies, though most have had either clear cell or chromophobe type RCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Testing for SDH mutations should be considered in patients with early onset kidney cancer (ie, age &lt;45 years), particularly those with a family history of pheochromocytoma or paraganglioma and kidney cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TUBEROUS SCLEROSIS COMPLEX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberous sclerosis complex (TSC, also called tuberous sclerosis) is a hereditary condition that is due to mutations in one of two interacting tumor-suppressor gene products, hamartin (TSC1) or tuberin (TSC2). The clinical manifestations include bilateral, multifocal renal lesions, which typically are angiomyolipomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The predominant management issue for patients with TSC is the risk of growth and bleeding from the renal angiomyolipoma. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43303?source=see_link\">",
"     \"Renal manifestations of tuberous sclerosis and renal angiomyolipoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less than 5 percent of patients with TSC develop RCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/39\">",
"     39",
"    </a>",
"    ]. In one series, the TSC-associated RCC tumors occurred at a younger age than sporadic tumors and occurred primarily in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/40\">",
"     40",
"    </a>",
"    ]. Most tumors displayed clear cell histology. Four of the six patients died of metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VON HIPPEL-LINDAU DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Von Hippel-Lindau (VHL) disease is an inherited, autosomal dominant syndrome manifested by a variety of benign and malignant tumors, including clear cell carcinoma of the kidney. The pathogenesis of VHL syndrome and the management of patients with VHL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14678?source=see_link\">",
"     \"Molecular biology and pathogenesis of von Hippel-Lindau disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     POLYCYSTIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominant polycystic kidney disease is a common disorder, occurring in approximately 1 in every 400 to 1000 live births. It is estimated that less than one-half of these cases are diagnosed during an individual's lifetime, since the disease is often clinically silent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30903?source=see_link\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of RCC in patients with polycystic kidney disease does not appear to be increased compared to the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35910/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. However, the tumors are more often bilateral at presentation (12 versus 1 to 4 percent in sporadic RCC in the general population), multicentric (28 versus 6 percent), and sarcomatoid in type (33 versus 1 to 5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition of the clinical features that are associated with hereditary RCC is the most important step in establishing the diagnosis. These initial clinical findings and the patient's family history continue to be an effective means for identifying affected individuals and family members.",
"   </p>",
"   <p>",
"    The identification of genetic risk factors in a patient or family member may be an indication for a treatment strategy that can minimize or prevent disease-related morbidity. However, one has to be careful about the potential misuse of this genetic information, the potential for causing anxiety, and the social, ethical, and potentially legal considerations involving family disclosure.",
"   </p>",
"   <p>",
"    The consequences associated with genetic screening may not be fully understood. Thus, such discussions should involve a trained genetic counselor who can review any issues with patients prior to proceeding with genetic testing.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/1\">",
"      Hwang JJ, Uchio EM, Linehan WM, Walther MM. Hereditary kidney cancer. Urol Clin North Am 2003; 30:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/2\">",
"      Courtney KD, Choueiri TK. Optimizing recent advances in metastatic renal cell carcinoma. Curr Oncol Rep 2009; 11:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/3\">",
"      Zbar B, Glenn G, Merino M, et al. Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development. J Urol 2007; 177:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/4\">",
"      Zbar B, Tory K, Merino M, et al. Hereditary papillary renal cell carcinoma. J Urol 1994; 151:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/5\">",
"      Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Curr Mol Med 2004; 4:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/6\">",
"      Schmidt LS, Nickerson ML, Angeloni D, et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol 2004; 172:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/7\">",
"      Herts BR, Coll DM, Novick AC, et al. Enhancement characteristics of papillary renal neoplasms revealed on triphasic helical CT of the kidneys. AJR Am J Roentgenol 2002; 178:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/8\">",
"      Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/9\">",
"      Schmidt L, Junker K, Weirich G, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 1998; 58:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/10\">",
"      Herring JC, Enquist EG, Chernoff A, et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 2001; 165:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/11\">",
"      Srinivasan R, Choueiri T, Vaishampayan U, et al. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC) (abstract). J Clin Oncol 2008; 26s:5103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/12\">",
"      Alam NA, Bevan S, Churchman M, et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet 2001; 68:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/13\">",
"      Pollard P, Wortham N, Barclay E, et al. Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J Pathol 2005; 205:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/14\">",
"      Ooi A, Wong JC, Petillo D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 2011; 20:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/15\">",
"      Sudarshan S, Sourbier C, Kong HS, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009; 29:4080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/16\">",
"      Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/17\">",
"      Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003; 73:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/18\">",
"      Ylisaukko-oja SK, Kiuru M, Lehtonen HJ, et al. Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients. Int J Cancer 2006; 119:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/19\">",
"      Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 2006; 43:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/20\">",
"      Grubb RL 3rd, Franks ME, Toro J, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 2007; 177:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/21\">",
"      Sudarshan S, Pinto PA, Neckers L, Linehan WM. Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer. Nat Clin Pract Urol 2007; 4:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/22\">",
"      Menko FH, van Steensel MA, Giraud S, et al. Birt-Hogg-Dub&eacute; syndrome: diagnosis and management. Lancet Oncol 2009; 10:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/23\">",
"      Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dub&eacute; syndrome. Cancer Cell 2002; 2:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/24\">",
"      Schmidt LS, Nickerson ML, Warren MB, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dub&eacute; syndrome. Am J Hum Genet 2005; 76:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/25\">",
"      Vocke CD, Yang Y, Pavlovich CP, et al. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dub&eacute;-associated renal tumors. J Natl Cancer Inst 2005; 97:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/26\">",
"      Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A 2006; 103:15552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/27\">",
"      Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dub&eacute; syndrome. Am J Surg Pathol 2002; 26:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/28\">",
"      Houweling AC, Gijezen LM, Jonker MA, et al. Renal cancer and pneumothorax risk in Birt-Hogg-Dub&eacute; syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families. Br J Cancer 2011; 105:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/29\">",
"      Toro JR, Pautler SE, Stewart L, et al. Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dub&eacute; syndrome. Am J Respir Crit Care Med 2007; 175:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/30\">",
"      Birt AR, Hogg GR, Dub&eacute; WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 1977; 113:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/31\">",
"      Welsch MJ, Krunic A, Medenica MM. Birt-Hogg-Dub&eacute; Syndrome. Int J Dermatol 2005; 44:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/32\">",
"      Pavlovich CP, Grubb RL 3rd, Hurley K, et al. Evaluation and management of renal tumors in the Birt-Hogg-Dub&eacute; syndrome. J Urol 2005; 173:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/33\">",
"      Barrisford GW, Singer EA, Rosner IL, et al. Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol 2011; 2011:658767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/34\">",
"      Baba M, Furihata M, Hong SB, et al. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 2008; 100:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/35\">",
"      Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/36\">",
"      Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 2004; 74:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/37\">",
"      Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 2008; 100:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/38\">",
"      Ricketts CJ, Shuch B, Vocke CD, et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol 2012; 188:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/39\">",
"      Lane BR, Aydin H, Danforth TL, et al. Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. J Urol 2008; 180:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/40\">",
"      Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol 1996; 149:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/41\">",
"      Keith DS, Torres VE, King BF, et al. Renal cell carcinoma in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 4:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35910/abstract/42\">",
"      Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998; 352:1691.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2948 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-ADE86C94E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35910=[""].join("\n");
var outline_f35_4_35910=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEREDITARY PAPILLARY RENAL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BIRT-HOGG-DUBE SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HEREDITARY PARAGANGLIOMA AND PHEOCHROMOCYTOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TUBEROUS SCLEROSIS COMPLEX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VON HIPPEL-LINDAU DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      POLYCYSTIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2948\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2948|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/28/460\" title=\"table 1\">",
"      Hereditary RCC syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2200?source=related_link\">",
"      Diagnostic approach, differential diagnosis, and treatment of a small renal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18250?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14678?source=related_link\">",
"      Molecular biology and pathogenesis of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21351?source=related_link\">",
"      Pheochromocytoma in genetic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21192?source=related_link\">",
"      Prognostic factors in patients with renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30903?source=related_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43303?source=related_link\">",
"      Renal manifestations of tuberous sclerosis and renal angiomyolipoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5546?source=related_link\">",
"      Surgical management of localized renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/3/17465?source=related_link\">",
"      Variants of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_4_35911="Definition and treatment of variants of autoimmune hepatitis";
var content_f35_4_35911=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition and treatment of variants of autoimmune hepatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35911/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35911/contributors\">",
"     Michael A Heneghan, MD, MMedSc, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35911/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35911/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35911/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35911/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/4/35911/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with variant forms of autoimmune hepatitis have clinical and serologic findings of autoimmune hepatitis plus features of other forms of chronic liver disease. As will be discussed below, the taxonomy of these variants (often referred to as overlap syndromes) is controversial. The overlap syndromes of autoimmune hepatitis with primary biliary cirrhosis and primary sclerosing cholangitis will be reviewed here. The discussion is generally consistent with an international consensus statement published in 2011 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune hepatitis is a chronic hepatitis of unknown etiology characterized by hyperglobulinemia, the presence of circulating autoantibodies, and inflammatory changes on liver histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/2\">",
"     2",
"    </a>",
"    ]. Most cases respond to therapy with immunomodulating drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or 6-mercaptopurine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27140?source=see_link\">",
"     \"Classification of autoimmune hepatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=see_link\">",
"     \"Treatment of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with certain cholestatic liver diseases (such as primary biliary cirrhosis and primary sclerosing cholangitis), have clinical and serologic features suggesting the presence of autoimmune hepatitis, and also may respond to immunosuppressive therapy. Conversely, some patients with features predominantly suggesting autoimmune hepatitis have findings compatible with other forms of chronic liver disease. In a report from the Mayo Clinic, for example, 225 patients with either type I autoimmune hepatitis, primary biliary cirrhosis, or primary sclerosing cholangitis (162, 37, and 26 patients, respectively) defined by standard criteria, were analyzed for serologic and clinical features suggesting variant forms of autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/3\">",
"     3",
"    </a>",
"    ]. Among these patients, 18 percent had diseases with overlapping features including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      7 percent with autoimmune",
"      <span class=\"nowrap\">",
"       hepatitis/primary",
"      </span>",
"      biliary cirrhosis",
"     </li>",
"     <li>",
"      6 percent with autoimmune",
"      <span class=\"nowrap\">",
"       hepatitis/primary",
"      </span>",
"      sclerosing cholangitis",
"     </li>",
"     <li>",
"      11 percent with autoimmune",
"      <span class=\"nowrap\">",
"       hepatitis/autoimmune",
"      </span>",
"      cholangitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The nomenclature and diagnostic criteria for these variant forms of autoimmune hepatitis have not been standardized, making interpretation and comparison among studies difficult. Despite these difficulties and the lack of a well established gold standard, overlaps of autoimmune hepatitis with primary biliary cirrhosis and primary sclerosing cholangitis have been widely recognized (",
"    <a class=\"graphic graphic_table graphicRef80676 \" href=\"mobipreview.htm?2/16/2315\">",
"     table 1",
"    </a>",
"    ). [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Some authorities also recognize additional overlap syndromes including \"autoimmune hepatitis-cryptogenic hepatitis\", \"autoimmune hepatitis-sarcoidosis\", and \"autoimmune hepatitis-chronic hepatitis C\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the existence of these disorders as distinct overlap syndromes is less clear. A 2011 international consensus statement proposed that autoimmune liver disease be categorized as autoimmune hepatitis primary biliary cirrhosis, primary sclerosing",
"    <span class=\"nowrap\">",
"     cholangitis/small",
"    </span>",
"    duct primary sclerosing cholangitis, noting that patients with primary sclerosing cholangitis or primary biliary cirrhosis who have features of autoimmune hepatitis be considered for immunosuppressive treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SCORING SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A scoring system proposed by the International Autoimmune Hepatitis Group has had excellent test characteristics for diagnosing autoimmune hepatitis. Their accuracy in diagnosis of autoimmune hepatitis variants requires further study. At present, an international consensus statement recommends it not be used to subclassify autoimmune hepatitis into variants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35528?source=see_link\">",
"     \"Clinical manifestations and diagnosis of autoimmune hepatitis\"",
"    </a>",
"    .) Another classification system (the Paris diagnostic criteria) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/8\">",
"     8",
"    </a>",
"    ] performed better than the International Autoimmune Hepatitis Group system in one validation study, but more data are needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE HEPATITIS-PBC OVERLAPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunologic and clinical characteristics suggest a variant form of autoimmune hepatitis in 1 to 14 percent of patients with primary biliary cirrhosis (PBC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/3,10,11\">",
"     3,10,11",
"    </a>",
"    ]. Features of autoimmune hepatitis may be present at diagnosis or develop during follow-up; clinical recognition is somewhat easier in the latter case. PBC may also develop in patients who present with autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with AIH-PBC overlap generally fall into two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have histologic features of autoimmune hepatitis, but have the serologic findings of PBC (ie, antimitochondrial antibodies [AMA] directed toward enzymes in the 2-oxoacid dehydrogenase family) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/12\">",
"       12",
"      </a>",
"      ]. The clinical course and response to therapy in this variant, which is sometimes referred to as AMA-positive autoimmune hepatitis, appear to be almost identical to that seen in type 1 autoimmune hepatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27140?source=see_link\">",
"       \"Classification of autoimmune hepatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have histologic features suggesting PBC but are often seronegative for AMA, and generally have circulating antinuclear antibodies (ANA)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      smooth muscle antibodies (SMA). This category has been referred to by a variety of terms, including immune cholangiopathy, autoimmune cholangiopathy, immune cholangitis, and autoimmune cholangitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/8,14-18\">",
"       8,14-18",
"      </a>",
"      ]. However, some authorities do not accept the concept of overlap in this situation and consider this syndrome to be AMA-negative PBC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/8,17\">",
"       8,17",
"      </a>",
"      ]. Furthermore, some of these patients have detectable AMA when using the most sensitive assays [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These distinctions have not been apparent in all reports. In one study, for example, the serologic and histologic features of 20 patients with autoimmune hepatitis-PBC overlap (based upon histologic or serologic criteria) were compared to 20 patients with typical PBC and 20 patients with typical autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/20\">",
"     20",
"    </a>",
"    ]. On careful evaluation, the majority of overlap patients had disease more closely resembling PBC. The authors hypothesized that patients with autoimmune hepatitis-PBC overlap have underlying PBC but have a genetic predisposition to develop a more hepatitic pattern of liver histology; they propose the term \"PBC, hepatitic form\" to describe these patients.",
"   </p>",
"   <p>",
"    Similar conclusions were reached in another report that focused on a subset of 16 of 331 patients (4.8 percent) who had participated in a multicenter placebo-controlled trial of UDCA for PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/21\">",
"     21",
"    </a>",
"    ]. The patients (all of whom were AMA positive) also had features suggestive of autoimmune hepatitis including two or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum alanine aminotransferase &gt;5x the upper limit of normal",
"     </li>",
"     <li>",
"      Immunoglobulin G (IgG) &gt;2x the upper limit of normal or positive anti-smooth muscle antibodies",
"     </li>",
"     <li>",
"      Moderate to severe lobular inflammation on pretreatment liver biopsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At the end of two years, the median change in serum biochemical and IgM values were similar to the PBC patients without these autoimmune features. Improvement in biochemical values and serum IgG levels were also observed in the \"overlap\" patients who received placebo. Furthermore, little change in histologic features of autoimmune hepatitis was observed. The authors concluded that the above features of autoimmune hepatitis may be transient in patients with PBC and that such patients may have a similar response to UDCA as PBC patients without these features. These results suggest that the value of adding corticosteroids to the treatment regimen of such patients is questionable.",
"   </p>",
"   <p>",
"    One group found that patients with autoimmune hepatitis-PBC overlap were more likely to have concomitant",
"    <span class=\"nowrap\">",
"     AMA/anti-dsDNA",
"    </span>",
"    seropositivity than patients with pure AMA positive PBC (47 versus 2 percent).",
"    <span class=\"nowrap\">",
"     AMA/ANA",
"    </span>",
"    positivity was present in 60 percent of these overlap patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/22\">",
"     22",
"    </a>",
"    ]. Such patients responded to combination therapy with UDCA and glucocorticoids.",
"   </p>",
"   <p>",
"    In an attempt to clarify the serologic profile of patients who were considered to have autoimmune hepatitis-PBC overlap, one group evaluated 174 patients (79 AMA negative and 95 AMA positive) with extensive serologic testing for a variety of autoantibodies. The serologic profile was compared with histologic and biochemical findings. The authors concluded that there were three distinct subgroups of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      AMA positive or AMA negative patients with ANA-PBC-related antibodies",
"     </li>",
"     <li>",
"      AMA negative patients with non-PBC-related ANAs",
"     </li>",
"     <li>",
"      Patients with autoimmune hepatitis-related antibodies together with serum PBC markers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether these categories are important clinically is uncertain. One group suggested that AIH superimposed upon PBC can result in rapid progression to cirrhosis and liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/10\">",
"     10",
"    </a>",
"    ]. Another group found that patients with overlap were more likely to develop esophageal varices, gastrointestinal bleeding, ascites, and liver failure compared with patients with more classical PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/24\">",
"     24",
"    </a>",
"    ]. Further studies will be needed to see whether these groups have a different natural history or response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE HEPATITIS-PSC OVERLAPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with autoimmune hepatitis-primary sclerosing cholangitis (PSC) overlap have serologic features of autoimmune hepatitis but have cholangiographic abnormalities characteristic of primary sclerosing cholangitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/25-30\">",
"     25-30",
"    </a>",
"    ]. The proportion of patients with AIH who have PSC overlap is not well established. A study that included 79 adults with autoimmune hepatitis found that 10 percent had features consistent with PSC on magnetic resonance cholangiography and liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/30\">",
"     30",
"    </a>",
"    ]. By contrast, only 1.7 percent of 59 adults with AIH had cholangiographic abnormalities suggestive of PSC in a later report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/31\">",
"     31",
"    </a>",
"    ]. Studies in children with PSC or AIH have described overlap in an even higher proportion of patients with overlapping features (30 to 50 percent) and are frequently labeled autoimmune sclerosing cholangitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/29,32\">",
"     29,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overlap should be suspected in patients who have clinical and serologic features of autoimmune hepatitis and also have [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pruritus",
"     </li>",
"     <li>",
"      Chronic ulcerative colitis (present in up to 16 percent of patients with autoimmune hepatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/33\">",
"       33",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Bile duct abnormalities on histology (such as portal edema, cholestasis, and fibrous or obliterative cholangitis)",
"     </li>",
"     <li>",
"      Cholestatic laboratory changes (an alkaline phosphatase greater than twice the upper limit of normal)",
"     </li>",
"     <li>",
"      No response to corticosteroid therapy",
"     </li>",
"     <li>",
"      An abnormal cholangiogram (present in up to 42 percent of patients with autoimmune hepatitis and ulcerative colitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/33\">",
"       33",
"      </a>",
"      ])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overlap should also be suspected in patients diagnosed with PSC who have high levels of immunoglobulin G, circulating ANA or SMA (titer &gt;1:40), and moderate to severe interface hepatitis on liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/28\">",
"     28",
"    </a>",
"    ]. Evolution from autoimmune hepatitis to primary sclerosing cholangitis has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study compared the clinical features of 7 patients with AIH-PSC with 34 patients with classical PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients with AIH-PSC were significantly younger at presentation (mean age 21 versus 32), had significantly higher aminotransferases, prevalence of autoantibodies, and serum immunoglobulin levels. The authors stressed the difficulty in establishing the diagnosis. All patients had clinical features of AIH at presentation while PSC was diagnosed subsequently when immunosuppression failed to achieve clinical remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have AMA-positive autoimmune hepatitis-primary biliary cirrhosis overlap should be treated like patients with classic type 1 autoimmune hepatitis; such patients usually respond to corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=see_link\">",
"     \"Treatment of autoimmune hepatitis\"",
"    </a>",
"    .) In contrast, patients with autoimmune hepatitis-AMA negative PBC generally respond poorly to corticosteroids. The approach below is generally consistent with the approach suggested by the International Autoimmune Hepatitis Group (",
"    <a class=\"graphic graphic_algorithm graphicRef73139 \" href=\"mobipreview.htm?41/1/42015\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     AMA positive without histologic evidence of PBC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is usually initiated with 20 to 30 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or its equivalent) per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=see_link\">",
"     \"Treatment of autoimmune hepatitis\"",
"    </a>",
"    .) Younger patients with severe disease may sometimes require higher doses, which are associated with an increased risk of major side effects. In older patients, who may tolerate steroid side effects poorly, initial therapy using a combination of a glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    may be preferable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of therapy should be to obtain normal serum aminotransferase levels and histologic improvement. Normalization of serum aminotransferases usually occurs rapidly (often within one month), and within six months in almost all patients who are destined to respond. Once normal serum aminotransferases are established, patients are maintained on the lowest dose of corticosteroids possible to maintain normal values. We usually perform a follow-up liver biopsy one to two years after initiating treatment to be sure that the biochemical response is accompanied by histologic improvement.",
"   </p>",
"   <p>",
"    In addition to attention to the usual adverse effects of steroid therapy, patients should be monitored for bone loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some cases (usually after one to two years) therapy may be withdrawn without subsequent relapse.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    may be effective as maintenance monotherapy although, in our experience, higher doses may be required compared to those used in type 1 autoimmune hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     ANA and/or SMA-positive with histologic changes suggesting PBC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA) have been recommended for treatment of patients with autoimmune hepatitis-PBC overlap whose liver histology is consistent with primary biliary cirrhosis. In a series of four patients, three responded rapidly to corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/14\">",
"     14",
"    </a>",
"    ]. However, subsequent reports and our own experience suggest that the majority of patients do not respond to corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    UDCA alone may improve serum biochemical values. However, it is unclear if UDCA mitigates the necroinflammatory process and retards progression of the disease. It has been suggested that combining UDCA and corticosteroids has a synergistic effect. The combination of the two drugs was associated with further biochemical improvement and resolution of symptoms in a series of 11 patients with incomplete histologic and biochemical response to UDCA or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/8\">",
"     8",
"    </a>",
"    ]. In a later series from the same group, combination therapy with UDCA plus immunosuppression appeared to be more effective than UDCA alone in improving or stabilizing liver histology with up to seven years of follow-up in those patients conforming to a strictly defined AIH-PBC syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A reasonable approach to treatment of patients with autoimmune hepatitis-PBC overlap is a trial of corticosteroids. Even though only a minority of patients will respond, biochemical and histologic improvement may be achieved. If values of serum aminotransferases and alkaline phosphatase do not improve, corticosteroids should be discontinued, and treatment initiated with UDCA (13",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). In addition, UDCA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    may be added as steroid sparing agents in patients who respond to corticosteroids. We often perform a follow-up liver biopsy after one to two years of treatment to document histologic amelioration in responding patients.",
"   </p>",
"   <p>",
"    The role of other drugs is even less well defined. In a case report, the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    appeared to be beneficial in a patient with autoimmune hepatitis-PBC overlap syndrome who did not respond to corticosteroids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     AIH-PSC overlap",
"    </span>",
"    &nbsp;&mdash;&nbsp;The experience with corticosteroids and other immunomodulators for patients with autoimmune hepatitis-PSC have been limited to small case series. Most have indicated that such patients respond poorly to treatment.",
"   </p>",
"   <p>",
"    Corticosteroids alone are unlikely to result in clinical, biochemical, and histologic remission. In a report from the Mayo Clinic that included nine such patients, clinical remission was observed in only two patients following corticosteroid treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/3\">",
"     3",
"    </a>",
"    ]. Response was more likely if patients had lower levels of alkaline phosphatase and higher serum concentrations of gamma globulin and immunoglobulin G.",
"   </p>",
"   <p>",
"    Regimens that include corticosteroids with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    may be more effective than corticosteroids alone. A series of five patients showed marked responses to combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    and azathioprine, with relapses occurring during reduction or withdrawal of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/28\">",
"     28",
"    </a>",
"    ]. In contrast to the study from the Mayo Clinic, all five patients fulfilled criteria for \"definite\" autoimmune hepatitis. Another report of three patients found a beneficial response to a regimen consisting of corticosteroids, azathioprine, and UDCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A third report compared the clinical course of 7 patients with AIH-PSC with 34 patients with classical PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients with AIH-PSC were treated with a combination of UDCA, corticosteroids, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    while patients with classical PSC received UDCA alone. The Mayo score increased progressively in the classical group but remained stable in the overlap group during five years of follow-up. Serum AST decreased significantly in the AIH-PSC group but other liver biochemical tests were not significantly improved. No significant change in liver biochemical tests was observed in the classical PSC group. There were no deaths in the AIH-PSC group compared with nine in the classical group, suggesting better cumulative survival for AIH-PSC but the sample size was small.",
"   </p>",
"   <p>",
"    A separate study evaluated the long-term outcomes of patients with AIH-PSC overlap seen at King's College Hospital over a 35-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/37\">",
"     37",
"    </a>",
"    ]. A reduction in survival was identified between patients with AIH-PSC and those without, including patients with AIH-PBC (hazard ratio: AIH-PSC versus AIH = 2.08, AIH-PSC versus AIH=PBC = 2.14; P = 0.039).",
"   </p>",
"   <p>",
"    In children with refractory autoimmune liver disease, rescue therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil appears to be less effective in those with autoimmune sclerosing cholangitis than in autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35911/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/56/25474?source=see_link\">",
"       \"Patient information: Autoimmune hepatitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nomenclature and diagnostic criteria for variant forms of autoimmune hepatitis have not been standardized, making interpretation and comparison among studies difficult. Despite these difficulties and the lack of a well established gold standard, overlaps of autoimmune hepatitis with primary biliary cirrhosis and primary sclerosing cholangitis have been widely recognized. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with these variant forms of hepatitis can have a confusing serologic and histologic profile. Diagnosis is generally easier when overlapping disorders occur sequentially over time compared to when they present concurrently. Furthermore, treatment is based upon somewhat subjective interpretation of serologic and biopsy findings and assessment of response to empiric pharmacologic trials. As a result, such patients are probably best managed in referral centers.",
"     </li>",
"     <li>",
"      Our approach is generally consistent with a consensus statement from the International Autoimmune Hepatitis Group (",
"      <a class=\"graphic graphic_algorithm graphicRef73139 \" href=\"mobipreview.htm?41/1/42015\">",
"       algorithm 1",
"      </a>",
"      ). In patients who are AMA positive but histologically appear to have autoimmune hepatitis rather than PBC, we suggest treatment for autoimmune hepatitis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=see_link\">",
"       \"Treatment of autoimmune hepatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who are ANA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      SMA-positive who have histologic changes suggesting PBC with concomitant features of autoimmune hepatitis, we suggest a trial of corticosteroids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients who do not respond biochemically, we suggest discontinuing steroids with a taper and adding UDCA.",
"     </li>",
"     <li>",
"      In patients with autoimmune hepatitis-PSC overlap, optimal treatment is uncertain. Our treatment decision is highly influenced by the findings on liver biopsy. In patients who have features of autoimmune hepatitis, namely significant interface hepatitis, we suggest a trial of corticosteroids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631675962\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. Edward Krawitt, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/1\">",
"      Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/2\">",
"      Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/3\">",
"      Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998; 28:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/4\">",
"      Boberg KM, Fausa O, Haaland T, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996; 23:1369.",
"     </a>",
"    </li>",
"    <li>",
"     Ludwig J, Batts KP. Histopathology of autoimmune liver disease. In: Autoimmune Liver Diseases, 2d ed, Krawitt EL, Wiesner RH, Nishioka M (Eds), Elsevier Science Publishers, Amsterdam 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/6\">",
"      Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996; 125:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/7\">",
"      Perrillo RP, Mason AL, Jacob S, Gerber MA. Hepatitis and cholestasis in a middle-aged woman. Hepatology 1996; 24:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/8\">",
"      Chazouill&egrave;res O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/9\">",
"      Kuiper EM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2010; 8:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/10\">",
"      Poupon R, Chazouilleres O, Corpechot C, Chr&eacute;tien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006; 44:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/11\">",
"      Bonder A, Retana A, Winston DM, et al. Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2011; 9:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/12\">",
"      Davis PA, Leung P, Manns M, et al. M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: epitopes or epiphenomena? Hepatology 1992; 16:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/13\">",
"      O'Brien C, Joshi S, Feld JJ, et al. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008; 48:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/14\">",
"      Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993; 18:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/15\">",
"      Colombato LA, Alvarez F, C&ocirc;t&eacute; J, Huet PM. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology 1994; 107:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/16\">",
"      Duclos-Vall&eacute;e JC, Hadengue A, Ganne-Carri&eacute; N, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by cyclosporine A. Dig Dis Sci 1995; 40:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/17\">",
"      Goodman ZD, McNally PR, Davis DR, Ishak KG. Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases. Dig Dis Sci 1995; 40:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/18\">",
"      Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000; 31:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/19\">",
"      Oertelt S, Rieger R, Selmi C, et al. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007; 45:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/20\">",
"      Lohse AW, zum B&uuml;schenfelde KH, Franz B, et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999; 29:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/21\">",
"      Joshi S, Cauch-Dudek K, Wanless IR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002; 35:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/22\">",
"      Muratori P, Granito A, Pappas G, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2009; 104:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/23\">",
"      Romero-G&oacute;mez M, Wichmann I, Crespo J, et al. Serum immunological profile in patients with chronic autoimmune cholestasis. Am J Gastroenterol 2004; 99:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/24\">",
"      Silveira MG, Talwalkar JA, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007; 102:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/25\">",
"      Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000; 33:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/26\">",
"      van Buuren HR, Terkivatan T, Schalm SW, et al. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000; 33:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/27\">",
"      Gohlke F, Lohse AW, Dienes HP, et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996; 24:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/28\">",
"      McNair AN, Moloney M, Portmann BC, et al. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998; 93:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/29\">",
"      Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/30\">",
"      Abdalian R, Dhar P, Jhaveri K, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008; 47:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/31\">",
"      Lewin M, Vilgrain V, Ozenne V, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009; 50:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/32\">",
"      Wilschanski M, Chait P, Wade JA, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 1995; 22:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/33\">",
"      Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992; 14:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/34\">",
"      Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology 2002; 36:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/35\">",
"      Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005; 100:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/36\">",
"      Chazouill&egrave;res O, Wendum D, Serfaty L, et al. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006; 44:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/37\">",
"      Al-Chalabi T, Portmann BC, Bernal W, et al. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008; 28:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35911/abstract/38\">",
"      Aw MM, Dhawan A, Samyn M, et al. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009; 51:156.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3636 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35911=[""].join("\n");
var outline_f35_4_35911=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SCORING SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      AUTOIMMUNE HEPATITIS-PBC OVERLAPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AUTOIMMUNE HEPATITIS-PSC OVERLAPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      AMA positive without histologic evidence of PBC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANA and/or SMA-positive with histologic changes suggesting PBC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      AIH-PSC overlap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H631675962\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3636\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3636|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?41/1/42015\" title=\"algorithm 1\">",
"      Approach to patients with PBC or PSC and features of AIH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3636|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/16/2315\" title=\"table 1\">",
"      Autoimmune hepatitis variants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27140?source=related_link\">",
"      Classification of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35528?source=related_link\">",
"      Clinical manifestations and diagnosis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/56/25474?source=related_link\">",
"      Patient information: Autoimmune hepatitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_4_35912="Acute urinary retention";
var content_f35_4_35912=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute urinary retention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35912/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35912/contributors\">",
"     Glen W Barrisford, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35912/contributors\">",
"     Graeme S Steele, MBBCh, FCS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35912/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35912/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35912/contributors\">",
"     Robert S Hockberger, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35912/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35912/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/4/35912/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute urinary retention (AUR) is the most common urologic emergency. It occurs most frequently in men over age 60, and is often the result of benign prostatic hyperplasia (BPH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The natural history of BPH is one of clinical progression over time. Over a five year period, AUR occurs in approximately 10 percent of men over the age of 70 and almost one-third of men in their 80's [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/1,3,5\">",
"     1,3,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34104?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and pathogenesis of benign prostatic hyperplasia\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased longevity has resulted in a trend toward increasing prevalence of BPH and related disorders. It is therefore important for medical professionals to become familiar with management of acute urinary retention, related to BPH as well as other etiologies.",
"   </p>",
"   <p>",
"    The risk factors, acute management, medical therapy, and surgical intervention for patients who develop acute urinary retention will be reviewed here. The diagnosis and treatment of BPH, and the diagnosis of acute and chronic urinary retention, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40056?source=see_link\">",
"     \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute urinary retention is most often secondary to obstruction, but may also be related to trauma, medication, neurologic disease, infection, and occasionally psychologic issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/6\">",
"     6",
"    </a>",
"    ]. Often, especially in the older patient, several underlying factors interact to precipitate acute urinary retention. In one series of male patients, the identified causes of AUR were [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Benign prostatic hyperplasia (BPH) &mdash; 53 percent",
"     </li>",
"     <li>",
"      Constipation &mdash; 7.5 percent",
"     </li>",
"     <li>",
"      Prostate cancer &mdash; 7 percent",
"     </li>",
"     <li>",
"      Urethral stricture &mdash; 3.5 percent",
"     </li>",
"     <li>",
"      Postoperative &mdash; 5 percent",
"     </li>",
"     <li>",
"      Neurologic disorder &mdash; 2 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Medications/drugs",
"      </span>",
"      &mdash; 2 percent",
"     </li>",
"     <li>",
"      Urinary tract infection &mdash; 2 percent",
"     </li>",
"     <li>",
"      Urolithiasis &mdash; 2 percent",
"     </li>",
"     <li>",
"      Miscellaneous &mdash; 16 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AUR may also be related to a variety of other factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignancy &mdash; bladder neoplasm, other tumors causing spinal cord compression",
"     </li>",
"     <li>",
"      Phimosis or paraphimosis, which is prolonged foreskin retraction with swelling of the glans constricting the foreskin",
"     </li>",
"     <li>",
"      Pelvic masses",
"     </li>",
"     <li>",
"      Genitourinary infections &mdash; acute prostatitis, urethritis, perianal abscess",
"     </li>",
"     <li>",
"      Other infections &mdash; genital herpes, varicella zoster, infected foreign bodies",
"     </li>",
"     <li>",
"      Other &mdash; anorectal manipulation, acute sickle crisis, malpositioned indwelling urinary catheter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of pathophysiologic mechanisms may be responsible for the development of AUR. Three factors predominate and often overlap: outflow obstruction, neurologic impairment, and overdistension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Outflow obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flow of urine is impeded with outflow obstruction by mechanical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dynamic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/7\">",
"     7",
"    </a>",
"    ]. Mechanical obstruction refers to the physical narrowing of the urethral channel, and is related to the volume of the prostate gland, other mass, or stricture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11290?source=see_link\">",
"     \"Lower urinary tract symptoms in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36617?source=see_link\">",
"     \"Treatment of urethral stricture disease in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dynamic obstruction refers to the tension within and around the urethra. When obstruction is caused by BPH, dynamic obstruction is caused by the prostate capsular tone and smooth muscle tone within the prostate gland itself. Medications and other factors also play a role in selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neurologic impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the neuropathologic model, AUR develops secondary to the interruption of sensory or motor nerve supply to the detrusor muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/2\">",
"     2",
"    </a>",
"    ]. This is most commonly seen in spinal cord injuries, progressive neurologic diseases, diabetic neuropathy, and cerebrovascular accidents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/8\">",
"     8",
"    </a>",
"    ]. Less common, but important, neurologic causes include epidural abscess and epidural metastasis, that can compress the spinal cord and thereby cause urinary retention as well as back pain and lower extremity neurologic impairments.",
"   </p>",
"   <p>",
"    AUR may be related to incomplete relaxation of the urinary sphincter mechanism (dyssynergia), which can result in elevations in both voiding pressures and post-void residual volumes. In other patients, inefficient bladder (detrusor) muscle contraction is the overriding factor leading to urinary retention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overdistention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute urinary retention may result when a precipitating event results in an acute distended bladder in the setting of an inefficient detrusor muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. This most often occurs in patients with obstructive urinary symptoms at baseline, who are then subjected to an insult to the lower urinary tract, such as a fluid challenge (eg, alcohol, intravenous hydration), bladder distention during general anesthesia, or epidural analgesia without an indwelling Foley catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/8,12\">",
"     8,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple medications are implicated in the cause of urinary retention, principally involving anticholinergic and sympathomimetic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/13\">",
"     13",
"    </a>",
"    ]. Medications that have been associated with acute urinary retention are listed in a table (",
"    <a class=\"graphic graphic_table graphicRef75763 \" href=\"mobipreview.htm?26/37/27229\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Two common settings in which urinary retention relates to medication are the postoperative patient and the older male with an upper respiratory infection. The use of opiates or anticholinergic medications in postoperative patients can reduce detrusor contractility and bladder sensation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/14\">",
"     14",
"    </a>",
"    ], and nasal decongestants that contain sympathomimetic agents increase smooth muscle tone in the region of the bladder neck. This is a common problem in the emergency department in the winter months, when elderly men with BPH and upper respiratory tract infections present in urinary retention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much research has focused on identifying risk factors that predispose individuals to the development of AUR, especially in men with BPH. Although some debate exists, the following contributing factors are best established in men with BPH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &mdash; Age over 70 years carries a relative risk (RR) of 7.8 for the development of AUR.",
"     </li>",
"     <li>",
"      Symptom score &mdash; Use of the AUA symptom score (",
"      <a class=\"graphic graphic_table graphicRef57680 \" href=\"mobipreview.htm?21/50/22317\">",
"       table 2",
"      </a>",
"      ) permits quantitation of symptom severity and monitoring of symptom progression over time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/15\">",
"       15",
"      </a>",
"      ]. The International Prostate Symptom Score (IPSS) is a similar score, but adds a question about \"bother\" to the AUA score. These questionnaires are easy and quick to complete. Each category is given a score from 0 to 5. An overall AUA score greater than 7 represents an RR of 3.2 for the development of urinary retention.",
"     </li>",
"     <li>",
"      Prostate volume &mdash; Prostatic volumes greater than 30 mL as measured by transrectal ultrasound have been associated with an RR of 3.0.",
"     </li>",
"     <li>",
"      Urinary flow rate &mdash; Urinary flow rate of less than 12",
"      <span class=\"nowrap\">",
"       mL/sec",
"      </span>",
"      carries an RR of 3.9.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A PSA of greater than 2.5 and a prostatic transition zone index &gt;0.7 (TZI = transition zone",
"    <span class=\"nowrap\">",
"     volume/total",
"    </span>",
"    prostate volume) have also been associated with a greater risk of the development of AUR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;AUR presents as the abrupt inability to pass urine. It is typically associated with lower abdominal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suprapubic discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/8\">",
"     8",
"    </a>",
"    ]. Affected patients are often restless, and may appear in considerable distress. These manifestations may be less pronounced when AUR is superimposed upon chronic urinary retention. Chronic urinary retention is most often painless [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with AUR are likely to present initially to an emergency department or the office of a primary care clinician and are unlikely to go directly to a urologist.",
"   </p>",
"   <p>",
"    Since the duration of obstruction in AUR is typically short (a few hours, not days), there is usually insufficient time for a significant elevation in serum creatinine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient history should focus on a previous history of retention, prostate cancer, surgery, radiation, or pelvic trauma. The patient should also be asked about the presence of hematuria, dysuria, fever, low back pain, neurologic symptoms, or rash. Younger patient age, a history of cancer or intravenous drug abuse, and the presence of back pain or neurologic symptoms suggest the possibility of spinal cord compression. Finally, a complete list of prescribed and over the counter medications should be obtained.",
"   </p>",
"   <p>",
"    The physical examination should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower abdominal palpation &mdash; The urinary bladder may be palpable, either on abdominal or rectal examination. Deep suprapubic palpation will provoke discomfort.",
"     </li>",
"     <li>",
"      Rectal examination &mdash; A rectal examination should be done in both men and women, to evaluate for masses, fecal impaction, perineal sensation, and rectal sphincter tone. A normal prostate examination does not preclude BPH as a cause of obstruction.",
"     </li>",
"     <li>",
"      Pelvic examination &mdash; Women with urinary retention should have a pelvic examination.",
"     </li>",
"     <li>",
"      Neurologic evaluation &mdash; The neurologic examination should include assessment of strength, sensation, reflexes, and muscle tone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A urine sample should be obtained and sent for urinalysis and urine culture, although the sample will probably be available only after catheter insertion. The need for other laboratory testing should be determined based upon findings from the patient's history and physical examination (ie, CBC for suspected infection, serum electrolytes and creatinine if prolonged obstruction, ultrasound if pelvic mass suspected). We generally do not advocate checking a PSA (prostate specific antigen) as it is expected to be elevated during an episode of acute urinary retention. An elevated PSA level offers little value for prostate cancer screening and often leads to patient anxiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1038770\">",
"    <span class=\"h2\">",
"     Post-void residual volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The post-void residual volume (PVR), as determined by a bladder scan, is a&nbsp;piece of data that should be interpreted in the context of the clinical scenario and the status of the patient. There is no &ldquo;absolute&rdquo; value for PVR at which a catheter must be inserted. Many patients have long-standing urinary symptoms and incomplete emptying of the bladder, leading to a larger capacity bladder over time.&nbsp;These patients with chronic urinary retention may still present&nbsp;as \"acute\" urinary retention when they are no longer able to void.",
"    <br/>",
"    <br/>",
"    A patient in discomfort who is unable to void, with any volume on bladder scan, may need a catheter.&nbsp;The bladder scan may be inaccurate due to body habitus, tissue edema, or prior surgery and scarring. If there is uncertainty in the diagnosis of urinary retention, a&nbsp;urethral&nbsp;catheter should&nbsp;be placed, and the volume of urine drained in the first 10 to 15 minutes should be noted and recorded.&nbsp;If this volume exceeds 400cc, the catheter is typically left in&nbsp;place. For volumes of 200 to 400cc, the decision to leave the catheter in place is guided by the clinical scenario; and for volumes less than 200cc, immediate catheter removal for&nbsp;another trial of voiding is appropriate for most patients.&nbsp;However, passive drainage and time are rarely a bad decision in the setting of acute urinary retention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ACUTE MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of acute urinary retention (AUR) involves prompt bladder decompression. This can be accomplished with urethral or suprapubic catheterization. Patients who have had recent urologic surgery (eg, radical prostatectomy or urethral reconstruction) and develop acute retention should not have urethral catheterization; an initial attempt at urethral catheterization is appropriate for most other patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link\">",
"     \"Placement and management of urinary bladder catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no uniform guidelines for bladder decompression. Most urologists prefer urethral catheterization for the initial management of AUR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In two surveys of urologists in France and the United Kingdom, for example, urethral catheters were the preferred intervention for 83 and 98 percent of respondents, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Since patients with AUR more often present to a medical office or emergency department than to a urology office, clinician comfort with urethral catheterization is likely to greatly exceed suprapubic catheterization.",
"   </p>",
"   <p>",
"    A 14 to 18 gauge French Foley catheter should be inserted as first-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/6\">",
"     6",
"    </a>",
"    ]. If obstruction does not allow ready passage of the flexible catheter, the possible cause of the obstruction should be considered. If the patient has had a prior transurethral procedure, such as a transurethral resection of the prostate (TURP), a partially obstructing urethral or prostatic scar may be present. In this case, the obstruction may be bypassed by downsizing the catheter to a 10 or 12 gauge French Foley. In the absence of prior instrumentation, the more common cause of obstruction would be an enlarged prostate. In this case, a larger catheter (20 or 22 gauge) with a firm Coude tip may be needed and may require urologic consultation.",
"   </p>",
"   <p>",
"    Placement of a suprapubic (SP) catheter is sometimes necessary in patients with urethral stricture disease, severe BPH, or other anatomic abnormalities that preclude Foley catheter placement per urethra. Suprapubic catheters are usually placed by a urologist, but may be placed by others on an emergency basis. Ultrasound guidance may be indicated when adhesions are possible from prior abdominal surgery.",
"   </p>",
"   <p>",
"    In cases when no urologist or appropriately trained clinician is available and the patient is in distress, bladder distention can be temporarily relieved with suprapubic aspiration via a needle. However, bladder decompression can make SP placement more difficult. If arrival of an appropriately trained medical professional is anticipated in the near future, needle decompression should be deferred.",
"   </p>",
"   <p>",
"    Suprapubic catheterization is performed under local anesthesia. Using sterile technique, a 22 gauge needle is inserted superior to the symphysis pubis, with steady aspiration until urine is retrieved. A trocar-type suprapubic tube is then passed through a one centimeter skin incision and the catheter advanced over the trocar and sutured in place. If the 22 gauge needle perforates the bowel on initial exploration, urine will not be aspirated and the small size needle puncture generally does not cause a problem.",
"   </p>",
"   <p>",
"    Outcomes with the two modes of bladder decompression were compared in a trial of 60 patients with AUR who were randomly assigned to suprapubic or urethral catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/22\">",
"     22",
"    </a>",
"    ]. The patients undergoing SP catheterization had fewer urinary tract infections and were less uncomfortable than those who were treated with urethral catheters. SP catheters also have the advantage of allowing assessment of the patient's ability to void before removing the catheter. However, SP catheters carry an increased risk for complications associated with placement, including bowel perforation and wound infection.",
"   </p>",
"   <p>",
"    We prefer SP catheters in patients, especially females, who are expected to require long-term bladder drainage. SP catheters prevent bladder neck and urethral dilatation and therefore prevent urinary incontinence due to sphincter dysfunction. Furthermore, SP catheters for men avoid the risk of subsequent urethral stricture, a common complication in men requiring long-term urethral catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Intermittent catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clean intermittent catheterization (CIC) as a decompression strategy has been advocated, with data suggesting improvement in the rate of spontaneous voiding and reduction in urinary infections when compared to indwelling catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/24\">",
"     24",
"    </a>",
"    ]. However, patients with AUR may be uncomfortable with this concept, and significant nursing time is required for teaching this technique and providing ongoing support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Rate of bladder decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;At one time, it was recommended that initial urine drainage be limited to 500 to 1000 mL, to reduce the complications of transient hematuria, hypotension, and postobstructive diuresis. It is now recognized that partial drainage and clamping is not necessary with acute urinary retention and may increase risk for urinary tract infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/18,25\">",
"     18,25",
"    </a>",
"    ]. However, there are no randomized trials comparing rapid and intermittent decompression. Rapid complete bladder decompression can be conducted safely, provided prudent supportive care is available with special attention given to elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pressure within a tense, obstructed bladder is sensitive to small changes in volume; the pressure begins to fall after the removal of only 5 to 15 mL, and is reduced by approximately 50 percent with the removal of 100 mL, and by 75 percent with the removal of 250 mL of fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Therefore, barring the clinically unrealistic strategy of frequent release of very small urine volumes, a rapid fall in bladder pressure is not preventable. Hematuria occurs in 2 to 16 percent of patients but is rarely clinically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relief of urinary tract obstruction can lead to a postobstructive diuresis, which is defined as a diuresis that persists after decompression of the bladder. A postobstructive diuresis is primarily a problem with chronic, not acute, urinary retention and usually represents an appropriate attempt to excrete excess fluid retained during the period of obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12050?source=see_link\">",
"     \"Urine output in urinary tract obstruction and postobstructive diuresis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Indications for hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the bladder is safely decompressed, consideration must be given to hospital admission versus outpatient management. Hospitalization is indicated for patients who are uroseptic or have obstruction related to malignancy or spinal cord compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients can be safely managed as an outpatient once the bladder is decompressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/28\">",
"     28",
"    </a>",
"    ]. Prior to being sent home, patients should be instructed in managing the catheter, emptying their catheter bag, and monitoring their urine output. Prophylactic antibiotics are not indicated for patients with an indwelling urinary catheter.",
"   </p>",
"   <p>",
"    Emergency surgical intervention is not usually performed because of an increased risk of complications and death compared to bladder decompression and delayed surgical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/28\">",
"     28",
"    </a>",
"    ]. On occasion, an acute prostatic abscess is drained via a transurethral resection technique, with immediate relief of both urinary retention and septic sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Trial without catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial bladder decompression can be followed by a trial without catheter (TWOC), which involves catheter removal (usually in two to three days) and determination if the patient can successfully void. Reported success rates for initial TWOC have ranged from 20 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/29\">",
"     29",
"    </a>",
"    ]. Factors that favor a successful trial of voiding include: age less than 65 years, detrusor pressure greater than 35 cmH2O, a drained volume of less than one liter at catheterization, and the identification of a precipitating event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TWOC is usually not definitive therapy. Studies in the era before possibly effective medical management found that one-half of men who initially void successfully will experience a recurrence of AUR within one week, and two-thirds will have a second episode with one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/10,30\">",
"     10,30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Medical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A second TWOC for patients who fail the initial trial has a lower rate of success than the initial TWOC. As a result, some urologists prefer to proceed to surgery after one failed TWOC and leave the catheter in place until elective surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Duration of catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of catheter management prior to a trial of voiding has been evaluated, with some contradictory findings. In an initial randomized trial of 60 patients, the time of catheter removal (0, 24, or 48 hours) did not correlate with the likelihood of spontaneous voiding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/31\">",
"     31",
"    </a>",
"    ]. Similar findings were noted in another trial in which spontaneous voiding occurred successfully in 44 and 51 percent of patients in whom the catheter was removed at 0 and 48 hours, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/32\">",
"     32",
"    </a>",
"    ]. A higher success rate (62 percent) was seen with catheter removal at seven days. We generally have patients return in one to two weeks.",
"   </p>",
"   <p>",
"    A subsequent observational study from France of 2600 men with AUR found that men who were catheterized for three days or less had greater success with spontaneous voiding than men catheterized for more than three days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/19\">",
"     19",
"    </a>",
"    ]. There are two considerations in comparing this observational study to the randomized trial data: the potential for greater underlying comorbidity in the men who were catheterized longer; and 80 percent were treated with an alpha blocker.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Medical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two main classes of drugs used in the treatment of BPH are alpha blockers and 5-alpha reductase inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alpha blockers function to relieve the mechanical obstruction associated with BPH by relaxation of the smooth muscle at the bladder neck and the prostatic capsule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/33\">",
"     33",
"    </a>",
"    ]. The use of alpha blockers in patients with AUR prior to catheter removal has a beneficial effect on a voiding trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several different types of alpha blockers are currently available with similar mechanisms and differing side effect profiles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    .)&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/55/26485?source=see_link\">",
"     Alfuzosin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    have been evaluated in randomized, placebo-controlled trials in conjunction with a trial of voiding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/29,36,37\">",
"     29,36,37",
"    </a>",
"    ]. The Alfuzosin in Acute Urinary Retention trial (ALFAUR) compared alfuzosin (10 mg once daily) to placebo in 360 men with AUR. Alfuzosin significantly increased the successful trial without catheter (TWOC) rate (62 versus 48 percent with placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    5-alpha reductase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    ) provide selective blockade for the conversion of testosterone to dihydrotestosterone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/38\">",
"     38",
"    </a>",
"    ]. They decrease the incidence of acute urinary retention in men with BPH (",
"    <a class=\"graphic graphic_figure graphicRef81016 \" href=\"mobipreview.htm?13/22/13678\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/39-41\">",
"     39-41",
"    </a>",
"    ], but do not reduce the early recurrence rate in men who are able to void successfully after an initial episode. 5-alpha reductase inhibitors do NOT have a role in the management of the acutely symptomatic patient because of the prolonged duration required for a reduction in prostatic size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SURGICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical therapy remains the definitive treatment of AUR. Among symptomatic patients with BPH, transurethral resection of the prostate (TURP) reduces the risk of developing AUR by 85 to 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/42\">",
"     42",
"    </a>",
"    ]. Transurethral resection of the prostate remains the gold standard, although a variety of other modalities are available. The common goal remains the endoscopic ablation of prostatic tissue thought to be the source of the obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40056?source=see_link\">",
"     \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With respect to the timing of surgery, the general recommendation is to wait 30 days or more following an episode of AUR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients who undergo TURP immediately following an episode of AUR are at a greatly increased risk of complications, including intraoperative bleeding, and sepsis related to bacteriuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/28,43\">",
"     28,43",
"    </a>",
"    ]. This was illustrated in a study of 3966 men undergoing prostatectomy in the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/28\">",
"     28",
"    </a>",
"    ]. Men who underwent prostatectomy for AUR, compared to those undergoing elective prostatectomy for symptoms alone, had an excess risk of death at 30 and 90 days after the procedure (relative risk 26.6 and 4.4, respectively) and an increased risk of perioperative complications. Some, but not all of this excess risk could be explained by older age, larger prostate size, and higher comorbidity in the urinary retention group.",
"   </p>",
"   <p>",
"    Many men who are able to void successfully after removal of the catheter will eventually have a recurrent episode of urinary retention. In one study of 228 men, as an example, 56 percent had a recurrence within a week after the initial episode and 68 percent within a year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/30\">",
"     30",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    in patients who have had a successful voiding trial following AUR can delay the recurrence of AUR and need for TURP. In the second phase of the above cited ALFAUR trial, the rate of surgery for recurrence of AUR in the first six months was significantly lower in patients who received alfuzosin (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    as maintenance therapy (17 versus 24 percent with placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/44\">",
"     44",
"    </a>",
"    ]. Surgical risk reduction for alfuzosin was 61, 52, and 29 percent at one, three, and six months respectively.",
"   </p>",
"   <p>",
"    In our view, all patients being evaluated for surgical intervention following an episode of AUR require urodynamic evaluation, to determine whether retention is directly related to outlet obstruction, with concomitant elevation in bladder pressures, or to an inefficient bladder muscle. Patients with bladder impairment are unlikely to benefit from a surgical procedure aimed to reducing outlet resistance.",
"   </p>",
"   <p>",
"    The use of urethral stenting provides only modest improvement and is associated with a variety of complications, including stent migration, infection, encrustation, and calculus formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/45\">",
"     45",
"    </a>",
"    ]. This modality is presently reserved for patients unfit for more invasive surgical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     URINARY RETENTION IN WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whereas bladder dysfunction in women is common, acute urinary retention is less common in women than in men. Outlet obstruction in women, due to anatomic distortion, may be caused by the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35912/abstract/48-57\">",
"     48-57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign tumors (eg fibroids)",
"     </li>",
"     <li>",
"      Malignant tumors of the pelvis, urethra, or vagina",
"     </li>",
"     <li>",
"      Post partum vulvar edema",
"     </li>",
"     <li>",
"      Labial fusion or imperforate hymen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of an anatomic etiology for the obstruction, bladder function should also be evaluated. Urodynamic studies should be performed by a urologist with experience in functional bladder disorders.",
"   </p>",
"   <p>",
"    It is reasonable to manage the patient with clean intermittent catheterization (CIC), or less optimally with indwelling urethral or suprapubic catheter. Indwelling catheters are primarily used in patients who are unable to perform CIC or who do not have assistance from family or nursing care. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link\">",
"     \"Placement and management of urinary bladder catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/0/16386?source=see_link\">",
"       \"Patient information: Neurogenic bladder in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute urinary retention (AUR) is the most common urologic emergency, affecting 1 in 10 men age 70 and older. Benign prostate hyperplasia (BPH) is the most common underlying condition, but multiple etiologies may cause AUR. Medications are frequently implicated (",
"      <a class=\"graphic graphic_table graphicRef75763 \" href=\"mobipreview.htm?26/37/27229\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial management of AUR involves prompt bladder decompression. We suggest initial treatment with a Foley urethral catheter, rather than a suprapubic catheter (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A suprapubic catheter may be indicated when obstruction precludes a urethral catheter and may be preferred in patients who are expected to require longer-term decompression. Clean intermittent catheterization is likely not practical for patients with acute urinary retention. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link\">",
"       \"Placement and management of urinary bladder catheters\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend complete initial drainage of the bladder rather than limiting the volume of initial drainage (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Hematuria, transient hypotension, and postobstructive diuresis are common, but rarely clinically significant. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Rate of bladder decompression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hospitalization is indicated for patients who are uroseptic or who have obstruction related to malignancy or spinal cord compression. Emergency surgery for relief of prostatic obstruction is rarely indicated and carries an increased risk over elective surgery. The majority of patients can be managed as outpatients once bladder decompression is accomplished. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Indications for hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Removal of the catheter after a period of time (\"trial without catheter\" or TWOC) results in successful spontaneous micturition in up to 40 percent of patients with AUR, though recurrent AUR is common. We suggest a trial of catheter removal in one to two weeks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In men with presumed BPH, we recommend use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/55/26485?source=see_link\">",
"       alfuzosin",
"      </a>",
"      10 mg daily, to be initiated at the time of initial catheterization (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients who fail the initial TWOC, we suggest a second trial of TWOC (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Trial without catheter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of men who have BPH and AUR will ultimately require definitive intervention for their BPH. We suggest ongoing treatment with an alpha blocker and 5 alpha reductase inhibitor to delay the recurrence of AUR (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A urodynamic evaluation is suggested prior to prostate surgery for patients who have experienced AUR.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/1\">",
"      Fong YK, Milani S, Djavan B. Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. Curr Opin Urol 2005; 15:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/2\">",
"      Murray K, Massey A, Feneley RC. Acute urinary retention--a urodynamic assessment. Br J Urol 1984; 56:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/3\">",
"      Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/4\">",
"      Kaplan SA, Wein AJ, Staskin DR, et al. Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol 2008; 180:47.",
"     </a>",
"    </li>",
"    <li>",
"     Contemporary Urology. Urology Times 2005 Fact Book. Advanstar Medical Economics Healthcare Communications Secondary Research Services 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/6\">",
"      Curtis LA, Dolan TS, Cespedes RD. Acute urinary retention and urinary incontinence. Emerg Med Clin North Am 2001; 19:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/7\">",
"      Powell PH, Smith PJ, Feneley RC. The identification of patients at risk from acute retention. Br J Urol 1980; 52:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/8\">",
"      Thomas K, Chow K, Kirby RS. Acute urinary retention: a review of the aetiology and management. Prostate Cancer Prostatic Dis 2004; 7:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/9\">",
"      Waterhouse N, Beaumont AR, Murray K, et al. Urinary retention after total hip replacement. A prospective study. J Bone Joint Surg Br 1987; 69:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/10\">",
"      Emberton M, Anson K. Acute urinary retention in men: an age old problem. BMJ 1999; 318:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/11\">",
"      Choong S, Emberton M. Acute urinary retention. BJU Int 2000; 85:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/12\">",
"      Dolin SJ, Cashman JN. Tolerability of acute postoperative pain management: nausea, vomiting, sedation, pruritus, and urinary retention. Evidence from published data. Br J Anaesth 2005; 95:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/13\">",
"      Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf 2008; 31:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/14\">",
"      Raz S, Zeigler M, Caine M. Pharmacological receptors in the prostate. Br J Urol 1973; 45:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/15\">",
"      Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/16\">",
"      Kurita Y, Masuda H, Terada H, et al. Transition zone index as a risk factor for acute urinary retention in benign prostatic hyperplasia. Urology 1998; 51:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/17\">",
"      Roehrborn CG, McConnell JD, Lieber M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/18\">",
"      Nyman MA, Schwenk NM, Silverstein MD. Management of urinary retention: rapid versus gradual decompression and risk of complications. Mayo Clin Proc 1997; 72:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/19\">",
"      Desgrandchamps F, De La Taille A, Doublet JD, RetenFrance Study Group. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia. BJU Int 2006; 97:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/20\">",
"      Manikandan R, Srirangam SJ, O'Reilly PH, Collins GN. Management of acute urinary retention secondary to benign prostatic hyperplasia in the UK: a national survey. BJU Int 2004; 93:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/21\">",
"      Allardice JT, Standfield NJ, Wyatt AP. Acute urinary retention: which catheter? Ann R Coll Surg Engl 1988; 70:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/22\">",
"      Ichsan J, Hunt DR. Suprapubic catheters: a comparison of suprapubic versus urethral catheters in the treatment of acute urinary retention. Aust N Z J Surg 1987; 57:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/23\">",
"      Horgan AF, Prasad B, Waldron DJ, O'Sullivan DC. Acute urinary retention. Comparison of suprapubic and urethral catheterisation. Br J Urol 1992; 70:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/24\">",
"      Patel MI, Watts W, Grant A. The optimal form of urinary drainage after acute retention of urine. BJU Int 2001; 88:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/25\">",
"      Oberst MT, Graham D, Geller NL, et al. Catheter management programs and postoperative urinary dysfunction. Res Nurs Health 1981; 4:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/26\">",
"      Foster MC, Upsdell SM, O'Reilly PH. Urological myths. BMJ 1990; 301:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/27\">",
"      Osius, TG, Hynman, F Jr. Dynamics of acute urinary retention: A manometric, radiographic and clinical study. J Urol 1963; 90:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/28\">",
"      Pickard R, Emberton M, Neal DE. The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol 1998; 81:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/29\">",
"      Fitzpatrick JM, Kirby RS. Management of acute urinary retention. BJU Int 2006; 97 Suppl 2:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/30\">",
"      Klarskov P, Andersen JT, Asmussen CF, et al. Symptoms and signs predictive of the voiding pattern after acute urinary retention in men. Scand J Urol Nephrol 1987; 21:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/31\">",
"      Taube M, Gajraj H. Trial without catheter following acute retention of urine. Br J Urol 1989; 63:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/32\">",
"      Djavan B, et al. Does prolonged catheter drainage improve the chance of recovering voluntary voiding after acute urinary retention of urine (AUR)? Eur Urol 1998; 33:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/33\">",
"      Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/34\">",
"      Zeif HJ, Subramonian K. Alpha blockers prior to removal of a catheter for acute urinary retention in adult men. Cochrane Database Syst Rev 2009; :CD006744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/35\">",
"      de Mey C. alpha(1)-blockers for BPH: are there differences? Eur Urol 1999; 36 Suppl 3:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/36\">",
"      Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int 2005; 95:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/37\">",
"      McNeill SA, Hargreave TB, Members of the Alfaur Study Group. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. J Urol 2004; 171:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/38\">",
"      Andersen JT, Nickel JC, Marshall VR, et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997; 49:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/39\">",
"      McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/40\">",
"      McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/41\">",
"      Bruskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1999; 54:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/42\">",
"      Wasson JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995; 332:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/43\">",
"      Higgins PM, French ME, Chadalavada VS. Management of acute retention of urine: a reappraisal. Br J Urol 1991; 67:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/44\">",
"      McNeill SA, Hargreave TB, Roehrborn CG, Alfaur study group. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology 2005; 65:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/45\">",
"      Isotalo T, Talja M, V&auml;limaa T, et al. A pilot study of a bioabsorbable self-reinforced poly L-lactic acid urethral stent combined with finasteride in the treatment of acute urinary retention from benign prostatic enlargement. BJU Int 2000; 85:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/46\">",
"      Ogiste JS, Cooper K, Kaplan SA. Are stents still a useful therapy for benign prostatic hyperplasia? Curr Opin Urol 2003; 13:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/47\">",
"      Perry MJ, Roodhouse AJ, Gidlow AB, et al. Thermo-expandable intraprostatic stents in bladder outlet obstruction: an 8-year study. BJU Int 2002; 90:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/48\">",
"      Ramsey S, Palmer M. The management of female urinary retention. Int Urol Nephrol 2006; 38:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/49\">",
"      Adam RA, Taghechian S. Acute urinary retention caused by a large hydrosalpinx. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/50\">",
"      Chauleur C, Vulliez L, Seffert P. Acute urine retention in early pregnancy resulting from fibroid incarceration: proposition for management. Fertil Steril 2008; 90:1198.e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/51\">",
"      Ding DC, Hwang KS. Female acute urinary retention caused by anterior deflection of the cervix which was augmented by an uterine myoma. Taiwan J Obstet Gynecol 2008; 47:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/52\">",
"      Gl&uuml;ck G, Mitulescu G, Ungureanu D, St&icirc;ngu C. [Acute urinary retention in primary vaginal carcinoma: therapeutic approach]. Chirurgia (Bucur) 2007; 102:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/53\">",
"      Gupta S, Manyonda IT. Acute complications of fibroids. Best Pract Res Clin Obstet Gynaecol 2009; 23:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/54\">",
"      Haskal ZJ, Armijo-Medina H. Uterine fibroid embolization for patients with acute urinary retention. J Vasc Interv Radiol 2008; 19:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/55\">",
"      Chang JW, Yang LY, Wang HH, et al. Acute urinary retention as the presentation of imperforate hymen. J Chin Med Assoc 2007; 70:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/56\">",
"      Topcuoglu MA, Koc O, Duran B, Donmez M. Labial fusion causing acute urinary retention in a young adult: a case report. Aust N Z J Obstet Gynaecol 2009; 49:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35912/abstract/57\">",
"      Yellamareddygari S, Ahluwalia A. Acute vulval oedema with urinary retention in pregnancy. J Obstet Gynaecol 2006; 26:816.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6883 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35912=[""].join("\n");
var outline_f35_4_35912=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Outflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neurologic impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overdistention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1038770\">",
"      Post-void residual volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ACUTE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Intermittent catheterization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Rate of bladder decompression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Indications for hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Trial without catheter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Duration of catheterization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Medical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SURGICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      URINARY RETENTION IN WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6883\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6883|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/22/13678\" title=\"figure 1\">",
"      Finasteride in BPH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6883|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/37/27229\" title=\"table 1\">",
"      Drug causes of AUR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/50/22317\" title=\"table 2\">",
"      International Prostate Symptom Score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=related_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34104?source=related_link\">",
"      Epidemiology and pathogenesis of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11290?source=related_link\">",
"      Lower urinary tract symptoms in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/0/16386?source=related_link\">",
"      Patient information: Neurogenic bladder in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=related_link\">",
"      Placement and management of urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40056?source=related_link\">",
"      Surgical and other invasive therapies of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36617?source=related_link\">",
"      Treatment of urethral stricture disease in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12050?source=related_link\">",
"      Urine output in urinary tract obstruction and postobstructive diuresis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_4_35913="Cochlear implant infections";
var content_f35_4_35913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cochlear implant infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35913/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35913/contributors\">",
"     Tahaniyat Lalani, MBBS, MHS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35913/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35913/contributors\">",
"     Debara L Tucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35913/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35913/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35913/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35913/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35913/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/4/35913/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cochlear implants are medical devices that electronically stimulate the auditory nerves in the cochlea (inner ear), allowing persons with severe to profound hearing loss to perceive sound.",
"   </p>",
"   <p>",
"    Cochlear implants consist of an internal device implanted surgically behind the ear, and external components that are placed after healing. Implants are composed of four basic parts: a microphone (that detects sound), a speech processor (that selects and arranges sounds), a transmitter (that receives signals from the processor and converts them into electrical impulses), and surgically implanted electrodes (that conduct electrical impulses to the brain) (",
"    <a class=\"graphic graphic_figure graphicRef70810 \" href=\"mobipreview.htm?28/54/29541\">",
"     figure 1",
"    </a>",
"    ). Transmission between the external and internal components takes place via radiofrequency via a magnetic link across the skin.",
"   </p>",
"   <p>",
"    Infection is an important complication of cochlear implants, and the type varies with age. Surgical wound infections are more common in adults, whereas meningitis and the complications of acute otitis media in patients with implants (such as mastoiditis and meningitis) are more common in children.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical presentation, microbiology, diagnosis, prevention, and treatment of cochlear implant infections will be reviewed here. General information about cochlear implants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29927?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of hearing impairment in children\", section on 'Cochlear implants'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39300?source=see_link&amp;anchor=H11#H11\">",
"     \"Hearing amplification in adults\", section on 'Cochlear implants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of prosthetic implant infections involves a complex interaction between the host, the device, and microbes causing the infection. In animal models, the presence of a subcutaneous foreign body reduces the minimal inoculum of Staphylococcus aureus required to cause infection by a factor of more than 100,000, to as little as 100 colony-forming units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/1\">",
"     1",
"    </a>",
"    ]. At least two factors contribute to this increase in risk: foreign bodies do not have a microcirculation, which is crucial for both host defense and the delivery of antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/1\">",
"     1",
"    </a>",
"    ]; and the interaction between neutrophils and the foreign body can induce a neutrophil defect that may enhance susceptibility to infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If bacteria gain access to a cochlear implant, they become adherent to the device and then multiply and elaborate exopolysaccharides, also known as glycocalyx. Eventually, microcolonies of bacteria encased in glycocalyx coalesce to form a structure known as a biofilm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The species of bacteria causing implant infections often reflect the endogenous flora of the anatomic site of implantation. The majority of cochlear implant wound infections are caused by skin flora such as Staphylococcus aureus, which have a propensity to form biofilms. Biofilms containing microcolonies of bacteria encased in a glycocalyx are actually complex bacterial communities, with intraspecies communication and adaptation through a process called quorum-sensing, which regulates both virulence and biofilm formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/5\">",
"     5",
"    </a>",
"    ]. Bacteria near the surface of the biofilm are usually metabolically active with access to nutrients that diffuse through the upper surface of the biofilm. In comparison, organisms deep within the biofilm are metabolically inactive or in various stages of dormancy, and are protected from host defenses such as phagocytes and antimicrobial penetration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42680?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of prosthetic joint infections\", section on 'Biofilm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cochlear implants are also prone to infections with upper respiratory tract pathogens such as Streptococcus pneumoniae and, less often, Haemophilus influenzae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. These pathogens are typically implicated in otitis media and meningitis in cochlear implant recipients. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Microbiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Otitis media is of particular concern since it can lead to bacterial meningitis via spread of bacteria from the middle ear to the inner ear along the pathway of the cochlear implant electrode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of infectious complications following placement of cochlear implants is 1.7 to 4.1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. The most common complications of implant surgery in the early postoperative period include surgical wound problems, such as skin flap necrosis, abscess formation, wound dehiscence, and device extrusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. A history of chronic ear infection has been associated with a higher rate of postoperative infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a high rate of implant infections in patients who develop post-auricular incisional wound problems. Surgical wound complications are reportedly more common in adult implant recipients, whereas other infectious complications (eg, meningitis and those resulting from acute otitis media) are more common in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/10\">",
"     10",
"    </a>",
"    ]. The rate of wound complications has declined as surgeons have gained more experience with cochlear implants and as smaller and better skin flaps have been designed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3509327\">",
"    <span class=\"h2\">",
"     Otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, acute otitis media can lead to bacterial meningitis in patients with cochlear implants. This is of particular concern in young children, in whom otitis media is most common; children younger than three years of age are receiving cochlear implants with increased frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective study that evaluated 60 otitis media-prone children who received cochlear implants, ventilation tube placement with or without adenoidectomy preoperatively was performed prior to placement of a cochlear implant. All were required to have normal tympanic membranes and no drainage from the ventilation tube for at least two weeks before cochlear surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/14\">",
"     14",
"    </a>",
"    ]. Despite these interventions, 44 percent of otitis media-prone children had at least one episode of acute otitis media following their cochlear implant compared with 8 percent of non-otitis media-prone children during the mean follow-up period of 20 months. Five of 14 (36 percent) cases of otitis media occurred within the first month following implantation.",
"   </p>",
"   <p>",
"    Cases of mastoiditis have also been reported as a complication of otitis media in cochlear implant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk of meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial extension of infection can occur with cochlear implants, resulting in an increased risk of bacterial meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/6,7,16-18\">",
"     6,7,16-18",
"    </a>",
"    ]. The time of onset has varied from less than 24 hours to several years after implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time between implantation and bacterial meningitis is variable, but the risk is highest during the first two months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. In a review of 24 definite and five probable episodes of bacterial meningitis among 26 children with cochlear implants performed in the United States, nine cases of meningitis were perioperative, occurring within 30 days after surgery, and 20 occurred between 1.5 months and two years after surgery (with one exception that occurred at three years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/6\">",
"     6",
"    </a>",
"    ]. Among these 20 episodes, eight (40 percent) occurred in patients with evidence of acute otitis media at presentation. Meningitis occurring as late as 40 months after implantation has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of risk factors for the development of meningitis have been identified in cochlear implant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General risk factors include age less than five years, impaired immune status, presence of other neurologic prostheses such as ventricular shunts, a cerebrospinal fluid (CSF) leak, and a past history of meningitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Otologic risk factors include otitis media post-implantation and a preexisting cochlear malformation (with or without a CSF fistula) such as a Mondini defect or malformed cochlea, which predisposes to meningitis even in the absence of an implant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Surgery-related risk factors include latent bacterial colonization as a result of local surgical trauma, inadequate packing of the cochleostomy (allowing bacteria to spread from the middle ear into the cochlea in the case of otitis media), and use of a positioner.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Role of positioner",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2002, several cases of bacterial meningitis were reported in cochlear implant recipients in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/16\">",
"     16",
"    </a>",
"    ]. These infections were thought to be related to a positioner inserted next to the implanted electrode in order to provide contact between the electrode and the wall of the cochlea to facilitate transmission of the electrical signal.",
"   </p>",
"   <p>",
"    The same association between the use of positioners and the subsequent risk of bacterial meningitis was also observed in the United States and Canada and reported to the US Food and Drug Administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the larger United States experience, there were 24 definite and five probable episodes of bacterial meningitis in 26 children at 24 months after surgery among a cohort of 4264 children who had received cochlear implants before age six years (2.4 cases per 1000 person-years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/6\">",
"     6",
"    </a>",
"    ]. The estimated adjusted odds ratio for infection was 4.5 (95% CI 1.3-17.9) when a positioner was inserted along with a cochlear implant compared with implant models without a positioner. However, the incidence of pneumococcal meningitis in patients with implants without a positioner was still 16 times higher than the rate in the general population for this age group. A second independent risk factor for bacterial meningitis was the combination of a radiographic malformation of the inner ear and cerebrospinal fluid leak.",
"   </p>",
"   <p>",
"    A later report from the United States group identified 12 cases of meningitis among patients with cochlear implants, six of which occurred between 25 and 40 months after implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/19\">",
"     19",
"    </a>",
"    ]. The incidence of meningitis beyond 24 months after implantation among children with positioners was 4.5 per 1000 person-years, compared with no cases in children without positioners.",
"   </p>",
"   <p>",
"    These findings led to the voluntary recall of implant devices that included a positioner in July 2002. Possible explanations for the risk associated with a positioner include the larger cochleostomy required for the insertion, the introduction of an additional foreign body in the inner ear, inner ear trauma related to wedging of the positioner into place,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    incomplete connective tissue seal at the cochleostomy site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with infected cochlear implants usually present with one or more of the following features, depending on the type of infection:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Peri-implant swelling and redness",
"     </li>",
"     <li>",
"      Wound dehiscence with device exposure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mastoiditis",
"     </li>",
"     <li>",
"      Meningitis",
"     </li>",
"     <li>",
"      Acute otitis media, sometimes complicated by tympanic membrane rupture",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      subperiosteal abscess [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/35/8760?source=see_link\">",
"       \"Acute otitis media in children: Diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early recognition of bacterial meningitis permits early intervention, which is vital for both successful treatment of bacterial meningitis and for minimizing permanent neurologic injury. The classic initial manifestations include fever, headache, stiff neck, nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting, photophobia, and mental status changes such as sleepiness or confusion. A young child or infant may have more nonspecific initial signs such as fussiness or diminished appetite. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parents should be counseled about the symptoms and signs of acute otitis media and meningitis and should be instructed to seek immediate medical attention if such findings are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common organisms causing meningitis in patients with cochlear implants are Streptococcus pneumoniae and, less often, Haemophilus influenzae. In a report from the United States, 15 of 24 episodes with a known cause were due to S. pneumoniae (11 associated with bacteremia and one with pneumonia), and five to H. influenzae (two type b) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/6\">",
"     6",
"    </a>",
"    ]. It should be noted that this study began prior to the availability of the pneumococcal conjugate vaccine; in the current era, the risk of invasive pneumococcal infection would be expected to be lower. Neisseria meningitidis has not been reported so far as a cause of meningitis in cochlear implant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among nine cases of bacterial meningitis that developed within 30 days of cochlear implant placement, four were caused by S. pneumoniae, two were caused by Acinetobacter baumannii, and one case each was caused by Escherichia coli, Haemophilus influenzae type b, and Enterococcus spp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    S. aureus is the most common organism isolated from patients with localized wound infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Other causes that have been reported include coagulase-negative staphylococci, streptococci, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Alcaligenes xylosoxidans, and Candida albicans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of cochlear implant surgical wound infection is usually suspected from clinical findings such as redness, swelling, fluctuance,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drainage at the site of implantation. Samples obtained during debridement or drainage of the implant site, middle ear cavity and mastoid are crucial for establishing a microbiologic diagnosis. In comparison, samples obtained from the external auditory canal may be misleading due to contamination by normal flora in the external ear canal.",
"   </p>",
"   <p>",
"    In selected patients, computed tomography (CT) may be required to determine the position of the cochlear electrodes post implantation, and to detect fluid collections associated with the hardware, bony involvement (ie, osteomyelitis),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of a subperiosteal abscess. However, MRI is not performed in the majority of cases due to metallic artifact and the presence of a magnet within most cochlear implants, which is a contraindication for MRI. If absolutely indicated, MRI can be performed within certain limitations and conditions, as advised by the manufacturers of the individual devices.",
"   </p>",
"   <p>",
"    Patients with signs of meningitis should undergo lumbar puncture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'CSF examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6629680\">",
"    <span class=\"h2\">",
"     AAP policy statement",
"    </span>",
"    &nbsp;&mdash;&nbsp;A policy statement on surgical site infections, and the prevention and treatment of acute otitis media and meningitis in children with cochlear implants was published in 2010 by the American Academy of Pediatrics (AAP) Committee on Infectious Diseases and Section on Otolaryngology-Head and Neck Surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ]. Our recommendations are generally in keeping with this statement. Although the recommendations in this policy statement were developed for children, many of the recommendations are also appropriate for adults with cochlear implants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1379129\">",
"    <span class=\"h2\">",
"     Perioperative antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single intravenous dose of a prophylactic antibiotic should be administered within 60 minutes prior to the surgical incision in order to prevent wound and cochlear implant infections during the early postoperative period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/24\">",
"     24",
"    </a>",
"    ]. Antibiotic coverage should target the gram-positive skin flora. Appropriate regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       Cefazolin",
"      </a>",
"      &mdash; 1 g in adults; 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in children",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      &mdash; 600 mg in adults; 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in children",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      &mdash; 1 g in adults; 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in children",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Scheduled dosing of an antibiotic for 24 hours (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    1 g intravenously every 8 hours) is an alternative to a single intravenous dose.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    can be given to patients who are allergic to penicillin. Vancomycin is preferred in patients with a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, recurrent skin infections, or prolonged hospitalization or other risk factors for MRSA.",
"   </p>",
"   <p>",
"    A cohort study has suggested that a course of postoperative macrolide therapy may reduce the incidence of surgical site infection, although further study is needed to determine the efficacy of this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Wound infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound infections can be classified as minor or major.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Minor infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor infections are manifested by erythema and swelling around the implant site without fluctuance, drainage, or intracranial or auditory complications. Such patients can be treated with local wound care and oral antibiotics for 10 to 14 days.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Empiric coverage against methicillin-resistant Staphylococcus aureus (MRSA) should be initiated in all patients with postoperative wound infections. Appropriate regimens include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX; in children: 8 to 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      component divided every 12 hours; in adults: 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of the trimethoprim component divided every 8 or 12 hours [one double strength tablet contains 160 mg of trimethoprim; as examples, TMP-SMX can be given as one double strength tablet every 8 hours or two double strength tablets every 12 hours depending on the patient's weight])",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      30 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided every eight hours in children, 450 mg every eight hours in adults. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=see_link\">",
"       \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33290?source=see_link&amp;anchor=H10#H10\">",
"       \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Approach for children &gt;30 days of age'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every eight hours in children &le;11 years and 600 mg orally every 12 hours in children &gt;11 years and adults.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with MRSA wound infections should be monitored closely for signs of an associated implant infection, which may necessitate debridement or removal of the implant. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Major infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients in whom MRSA infection is excluded, the following regimens may be used:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/56/43912?source=see_link\">",
"       Amoxicillin-clavulanate",
"      </a>",
"      &mdash; In adults and children &gt;40 kg: 875 mg of the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      component orally every 12 hours; in children &ge;3 months of age and less than 40 kg: 75 to 90",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of the amoxicillin component orally divided every 12 hours.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"       Cephalexin",
"      </a>",
"      &mdash; In adults: 500 mg orally every six hours; in children: 75 to 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three or four divided doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Major infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluctuance, auricular proptosis, drainage from the implant site,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    otorrhea suggestive of mastoiditis or intracranial spread are the typical signs seen in patients with major infections. Treatment of these infections requires hospitalization, intravenous antibiotics, and possible revision surgery, with or without explantation of the device.",
"   </p>",
"   <p>",
"    Following the collection of specimens for culture, patients with major infections should be started on empiric antibacterial coverage with a regimen appropriate for meningitis, as discussed below. (See",
"    <a class=\"local\" href=\"#H2891499\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A head computed tomography (CT) scan may be performed to rule out intracranial infection. Approximately 60 percent of patients require surgical drainage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    debridement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment without implant removal is the preferred option in major infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/10\">",
"     10",
"    </a>",
"    ]. Removal of the implant results in significant disability due to deafness, and reimplantation after treatment of the infection is often difficult due to scarring resulting from the infection. Indications for surgery include severe mastoiditis or a poor response to antibiotics. Slowly progressive and late-onset infections are more likely to be resistant to medical therapy, possibly due to concurrent osteomyelitis or biofilm formation around the cochlear implant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/22,26,27\">",
"     22,26,27",
"    </a>",
"    ]. Wound infections that result in exposure of the device are unlikely to respond to conservative therapy, and usually require removal of the cochlear implant to attain cure. In one study, for example, eight of nine such patients required device explantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At surgery, all inflammatory granulation tissue should be removed from the mastoid and middle ear, and the area of the cochleostomy tube should be debrided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. This can often be accomplished without changing the position of the implanted array. If purulent secretions exit the scala tympani upon removal of the tissue sealing the cochleostomy, the surgeon must decide whether or not the device needs to be removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. If a decision is made to remove the receiver stimulator due to infection and infection is not found in the middle ear, it is recommended that the electrode be severed at the facial recess, leaving the intracochlear leads in place to guide future electrode placement if the same ear is reimplanted.",
"   </p>",
"   <p>",
"    Depending upon the severity of infection and the extent of debridement, patients are usually treated with intravenous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oral antibiotics for one to three months. The results of cultures obtained during debridement should guide the selection of antibiotic therapy.",
"   </p>",
"   <p>",
"    When explantation is required, reimplantation can be successfully performed in some patients, although it may be more difficult due to scarring from the infection. In one report, two patients with late onset chronic pseudomonal cochlear implant infections that were unresponsive to local debridement and antibiotics underwent partial explantation with the electrodes left in place [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/28\">",
"     28",
"    </a>",
"    ]. After two to three months of antibiotic therapy, reimplantation was carried out successfully with no recurrence of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early diagnosis and prompt treatment of middle ear infection (otitis media) in cochlear implant recipients are crucial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ]. This recommendation is based upon the observation that some cases of meningitis in cochlear implant recipients have signs of otitis media prior to surgery or before the meningitis developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/6\">",
"     6",
"    </a>",
"    ]. Watchful waiting is not appropriate for cochlear implant recipients with otitis media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The appropriate antimicrobial regimen depends upon the clinical presentation, timing and type of cochlear implant placement, and host factors. Individuals with acute otitis media who meet ALL of the following criteria should be given empiric antimicrobial therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    at a dose of 80 to 90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided every 12 hours in children (and 875 mg every 12 hours in adults) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presentation is more than two months following cochlear implant placement",
"     </li>",
"     <li>",
"      Have no history of anatomic abnormalities (uncorrected Mondini or similar inner ear malformation, CSF-middle ear fistula)",
"     </li>",
"     <li>",
"      Do not appear severely ill and have no clinical evidence of mastoiditis or meningitis",
"     </li>",
"     <li>",
"      Do not have a cochlear implant that includes a",
"      <span class=\"nowrap\">",
"       spacer/positioner",
"      </span>",
"      (Advanced Bionics model AB5100H or AB-5100H-11)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When feasible, middle ear fluid should be obtained through the tympanostomy tube or a tympanocentesis or myringotomy for culture just prior to initiation of antimicrobial therapy, but this should not cause a significant delay in initiation of antibiotics.",
"   </p>",
"   <p>",
"    For patients who do not meet all of the criteria described above, including patients with implants of unknown type placed between 1999 and August 2002, initial parenteral antimicrobial therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    is recommended.",
"   </p>",
"   <p>",
"    Among patients with recurrent otitis media, placement of tympanostomy tubes, as would be indicated for a child without a cochlear implant, may reduce the risk of otitis media. Many otolaryngologists favor insertion of tympanostomy tubes prior to or at the time of cochlear implant surgery in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42857?source=see_link&amp;anchor=H21#H21\">",
"     \"Acute otitis media in children: Prevention of recurrence\", section on 'Tympanostomy tubes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients in whom acute otitis media is identified at the time of implantation, high volume irrigation, administration of antibiotics, and a more prolonged course of postoperative antibiotics are advisable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/17\">",
"     17",
"    </a>",
"    ]. Some otolaryngologists avoid cochlear implant placement when middle ear fluid is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunizations are particularly important for cochlear implant recipients and their household contacts in order to reduce the incidence of otitis media and meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Vaccination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Meningitis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Principles of prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures to prevent meningitis include vaccination, preoperative evaluation for anatomic abnormalities, and evaluation for and aggressive management of otitis media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8,18,29\">",
"     8,18,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following recommendations for the prevention of meningitis in children with cochlear implants have been made by the American Academy of Pediatrics Committee on Infectious Diseases and Section on Otolaryngology-Head and Neck Surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging of the temporal bone and inner ear should be performed prior to cochlear implant placement in all children with congenital deafness and all patients with profound hearing impairment and a history of bacterial meningitis (if not known to have had normal hearing before meningitis) to identify those with inner ear malformations, including CSF fistulas and ossification of the fistula.",
"     </li>",
"     <li>",
"      The cochleostomy should be carefully packed with fibrous tissue around the implanted electrode to reduce the likelihood that bacteria will enter the inner ear if there is a middle ear infection. This is particularly important for patients with inner ear malformations that are associated with an increased incidence of CSF fistulas after cochlear implant placement (eg, wide vestibular aqueduct syndrome or Mondini malformation).",
"     </li>",
"     <li>",
"      For otitis-prone children or children with persistent middle ear effusion, tympanostomy tube placement should be considered before cochlear implant placement.",
"     </li>",
"     <li>",
"      Children should be vaccinated against the organisms that commonly cause bacterial meningitis before cochlear implant placement. (See",
"      <a class=\"local\" href=\"#H69530491\">",
"       'Children'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      parents should be educated about the signs and symptoms of acute otitis media and meningitis, as well as the necessity of seeking immediate medical attention if such findings are present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"       8",
"      </a>",
"      ]. Early intervention is vital for the successful treatment of bacterial meningitis and for minimizing permanent neurologic injury. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=see_link\">",
"       \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22810?source=see_link\">",
"       \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31656?source=see_link\">",
"       \"Neurologic complications of bacterial meningitis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18280?source=see_link\">",
"       \"Neurologic complications of bacterial meningitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4442?source=see_link\">",
"       \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23080?source=see_link\">",
"       \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Advice about the risk of meningitis from the US Food and Drug Administration for patients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parents is available at:",
"    <a class=\"external\" href=\"file://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PatientAlerts/ucm064737.htm\">",
"     file://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PatientAlerts/ucm064737.htm",
"    </a>",
"   </p>",
"   <p>",
"    Removal of an existing implanted positioner is not recommended, since it is not known if the risk of bacterial meningitis would be reduced and further surgery carries a risk of postoperative complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8,19\">",
"     8,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All cases of meningitis should be reported to the device manufacturers as well as public health authorities: (",
"    <a class=\"external\" href=\"https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm\">",
"     https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cochlear implant candidates should ideally receive necessary vaccines at least two weeks prior to surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69530491\">",
"    <span class=\"h4\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased incidence of bacterial meningitis, particularly pneumococcal meningitis, in patients with cochlear implants has led to the following recommendations for vaccination in children who have or are scheduled to receive a cochlear implant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8,30,31\">",
"     8,30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link&amp;anchor=H16#H16\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Vaccine schedule'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13926?source=see_link&amp;anchor=H6#H6\">",
"     \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Schedule'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All children should receive all doses of the pneumococcal conjugate vaccine and Haemophilus influenzae type b (Hib) vaccine according to the routine schedule. For maximum benefit, children should receive the pneumococcal conjugate vaccine (PCV13) series followed by a single dose of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23) prior to surgery. In addition to the routine administration of these vaccines, the following additional recommendations apply to pediatric cochlear implant candidates and recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children should be vaccinated against Streptococcus pneumoniae as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      According to the routine schedule for all children, PCV13 should be administered at 2, 4, 6, and 12-15 months of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/31\">",
"       31",
"      </a>",
"      ]. Recommendations for pneumococcal vaccination are described in the following table (",
"      <a class=\"graphic graphic_table graphicRef62519 \" href=\"mobipreview.htm?20/63/21501\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Starting at 2 years of age, and at least eight weeks after the last dose of PCV13, one dose of PPSV23 should be given to children awaiting cochlear implant placement or in recipients who have not previously received PPSV23, as well as in children with an inner ear malformation with a CSF communication. Only one dose of PPSV23 is recommended in cochlear implant recipients.",
"     </li>",
"     <li>",
"      A single supplemental dose of PCV13 should be given to children 14 to 71 months of age who have been fully immunized with PCV7. However, the supplemental dose is unnecessary if the fourth dose of pneumococcal conjugate vaccine given at 12 months of age or older was PCV13. A single dose or supplemental dose of PCV13 may be given to cochlear implant candidates or recipients who are 6 to 18 years of age regardless of previous doses of PCV7 or PPSV23.",
"     </li>",
"     <li>",
"      Children &lt;5 years of age should be vaccinated against Haemophilus influenzae type b (Hib) according to the routine schedule (",
"      <a class=\"graphic graphic_table graphicRef77170 \" href=\"mobipreview.htm?5/59/6077\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"       8",
"      </a>",
"      ]. The Hib vaccine is not routinely recommended for cochlear implant candidates over five years of age since most older children and adults are already immune to Hib, even if they were not previously vaccinated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42489?source=see_link&amp;anchor=H5#H5\">",
"       \"Prevention of Haemophilus influenzae infection\", section on 'Hib conjugate vaccine schedules'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since cochlear implant recipients do not appear to be at increased risk of invasive meningococcal disease, such individuals should be vaccinated against meningococcus according to routine recommendations; in other words, they should only receive the meningococcal vaccine if they have a specific indication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link&amp;anchor=H18#H18\">",
"       \"Meningococcal vaccines\", section on 'Country-specific vaccination guidelines'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Annual influenza immunization is recommended for all individuals &ge;6 months of age, but is particularly important for cochlear implant recipients and their household contacts in order to reduce the incidence of otitis media [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link\">",
"       \"Seasonal influenza vaccination in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about the use of vaccines for the prevention of meningitis in patients with cochlear implants is available at:",
"    <a class=\"external\" href=\"file://cdc.gov/vaccines/vpd-vac/mening/cochlear/dis-cochlear-gen.htm\">",
"     file://cdc.gov/vaccines/vpd-vac/mening/cochlear/dis-cochlear-gen.htm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69530498\">",
"    <span class=\"h4\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults who are awaiting or who have undergone cochlear implant placement should be vaccinated against pneumococcus with",
"    <strong>",
"     both",
"    </strong>",
"    the 23-valent polysaccharide pneumococcal vaccine (PPSV23) and the 13-valent pneumococcal conjugate vaccine (PCV13) (",
"    <a class=\"graphic graphic_table graphicRef86782 \" href=\"mobipreview.htm?11/48/12046\">",
"     table 3",
"    </a>",
"    ). For many years, only PPSV23 was recommended for adults with cochlear implants or other conditions that increase the risk of invasive pneumococcal infections. However, in 2012, the United States Advisory Committee on Immunization Practices (ACIP) voted to recommend PCV13 for use in individuals aged 19 or older with certain high-risk conditions, including cochlear implants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/33\">",
"     33",
"    </a>",
"    ]. The evidence supporting the use of pneumococcal conjugate vaccination in high-risk adults comes from a randomized trial of PCV7 in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/34,35\">",
"     34,35",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In accordance with the ACIP, we recommend that cochlear implant candidates and recipients receive PCV13 in addition to PPSV23 as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have not previously received either PCV13 or PPSV23, a single dose of PCV13 should be given, followed by a dose of PPSV23 at least eight weeks later.",
"     </li>",
"     <li>",
"      For patients who have previously received one or more doses of PPSV23, a single dose of PCV13 should be given one or more years after the last PPSV23 dose was received.",
"     </li>",
"     <li>",
"      For patients who require additional doses of PPSV23, the first such dose should be given no sooner than eight weeks after PCV13 and at least five years after the most recent dose of PPSV23.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When more than one dose of a vaccine against S. pneumoniae is indicated, the first dose should be given prior to surgery. Pneumococcal vaccination in adults is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Annual influenza vaccination is recommended for all adults, but is particularly important for cochlear implant recipients and their household contacts in order to reduce the incidence of otitis media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2891499\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who present with possible meningitis, CSF should be obtained immediately for cell counts, Gram stain, and culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ]. If present, middle ear fluid should also be obtained for culture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic therapy is directed at the most likely pathogens. The empiric regimen depends upon the timing following cochlear implant placement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who present more than two months following cochlear implant placement, the choice of empiric antimicrobial therapy for meningitis is the same as for individuals without cochlear implants and should include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      for coverage of antibiotic-resistant Streptococcus pneumoniae, Haemophilus influenzae type b, and Neisseria meningitidis. The dosing of vancomycin is 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV divided every 6 hours in children, and 30 to 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in two or three divided doses in adults. The dosing of ceftriaxone is 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV divided every 12 to 24 hours in children, and 2 g IV every 12 hours in adults. The dosing of cefotaxime is 300",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV divided every 6 to 8 hours in children.",
"     </li>",
"     <li>",
"      Patients who present during the first two months after cochlear implant placement should receive a regimen that includes coverage of gram-negative pathogens such as Acinetobacter baumannii and gram-positive bacteria such as Staphylococcus aureus and Enterococcus spp [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"       8",
"      </a>",
"      ]. An example of such a regimen is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      , but the specific regimen depends upon local microbiology and the individual patient&rsquo;s microbiologic data.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of bacterial meningitis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=see_link\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15306?source=see_link\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cochlear implant recipients with bacterial meningitis should be seen urgently by an otolaryngologist with experience in cochlear implant surgery, and imaging and surgical exploration should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Major infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3508407\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cochlear implants are medical devices that electronically stimulate the auditory nerves in the cochlea (inner ear), allowing persons with severe to profound hearing loss to perceive sound (",
"      <a class=\"graphic graphic_figure graphicRef70810 \" href=\"mobipreview.htm?28/54/29541\">",
"       figure 1",
"      </a>",
"      ). Infection is an important complication of cochlear implants, and the type varies with age. Surgical wound complications are more common in adult implant recipients, whereas other infectious complications (eg, acute otitis media, mastoiditis, meningitis) are more common in children. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The species of bacteria causing implant infections often reflect the endogenous flora of the anatomic site of implantation. The majority of cochlear implant wound infections are caused by skin flora such as Staphylococcus aureus. Cochlear implants are also prone to infections with upper respiratory tract pathogens such as Streptococcus pneumoniae and, less often, Haemophilus influenzae. These pathogens are typically implicated in otitis media and meningitis in cochlear implant recipients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measures to prevent cochlear implant infections include vaccination, preoperative evaluation for anatomic abnormalities, perioperative antibiotic prophylaxis, and evaluation for and aggressive management of otitis media. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Principles of prevention'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1379129\">",
"       'Perioperative antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A single intravenous dose of a prophylactic antibiotic should be administered within 60 minutes prior to the surgical incision for cochlear implant placement. Antibiotic coverage should target gram-positive skin flora. Appropriate agents include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1379129\">",
"       'Perioperative antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minor infections are manifested by erythema and swelling around the implant site without fluctuance, drainage, or intracranial or auditory complications. Patients with minor wound infections should be treated empirically with an oral antibacterial agent with activity against methicillin-resistant Staphylococcus aureus. Appropriate agents include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Minor infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluctuance, auricular proptosis, drainage from the implant site,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      otorrhea suggestive of mastoiditis or intracranial spread are the typical signs seen in patients with major infections. Treatment of these infections requires hospitalization, intravenous antibiotics, and possible revision surgery, with or without explantation of the device. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Major infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cochlear implant candidates should ideally receive necessary vaccines at least two weeks prior to surgery. Vaccination is particularly important among cochlear implant candidates and recipients in order to prevent otitis media and bacterial meningitis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all children be up-to-date with Streptococcus pneumoniae vaccination (",
"      <a class=\"graphic graphic_table graphicRef62519 \" href=\"mobipreview.htm?20/63/21501\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In addition to administering the pneumococcal vaccine according to the routine schedule in children, the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      (PPSV23) is indicated in certain cases. (See",
"      <a class=\"local\" href=\"#H69530491\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children under age five receive the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/14/230?source=see_link\">",
"       Haemophilus influenzae type b conjugate vaccine",
"      </a>",
"      according to the routine immunization guidelines (",
"      <a class=\"graphic graphic_table graphicRef77170 \" href=\"mobipreview.htm?5/59/6077\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H69530491\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since cochlear implant recipients do not appear to be at increased risk of invasive meningococcal disease, such individuals should be vaccinated against meningococcus according to routine recommendations. (See",
"      <a class=\"local\" href=\"#H69530491\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adults who are candidates for or recipients of cochlear implants, we recommend administration of",
"      <strong>",
"       both",
"      </strong>",
"      the 23-valent polysaccharide pneumococcal vaccine and the 13-valent pneumococcal conjugate vaccine (",
"      <a class=\"graphic graphic_table graphicRef86782 \" href=\"mobipreview.htm?11/48/12046\">",
"       table 3",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The schedule for administration of these two vaccines is outlined above. (See",
"      <a class=\"local\" href=\"#H69530498\">",
"       'Adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend annual influenza vaccination for all individuals &ge;6 months of age (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Vaccination is particularly important among cochlear implant candidates and recipients in order to prevent otitis media, which can lead to bacterial meningitis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that the empiric regimen for children and adults who develop bacterial meningitis more than two months following cochlear implant placement be similar to what is used in patients without cochlear implants (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Such a regimen should include coverage for antibiotic-resistant Streptococcus pneumoniae, Haemophilus influenzae type b, and Neisseria meningitidis. The standard regimen includes",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Patients who present with bacterial meningitis during the first two months following cochlear implant placement should receive a regimen that includes broader coverage of gram-negative pathogens in addition to coverage of the organisms described above (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). An example of such a regimen is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2891499\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cochlear implant recipients with bacterial meningitis should be seen urgently by an experienced otolaryngologist, and imaging and surgical exploration should be considered. (See",
"      <a class=\"local\" href=\"#H2891499\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/1\">",
"      Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE. Pathogenesis of foreign body infection: description and characteristics of an animal model. J Infect Dis 1982; 146:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/2\">",
"      Zimmerli W, Lew PD, Waldvogel FA. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J Clin Invest 1984; 73:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/3\">",
"      Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/4\">",
"      Donlan RM. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 2001; 33:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/5\">",
"      Vuong C, Gerke C, Somerville GA, et al. Quorum-sensing control of biofilm factors in Staphylococcus epidermidis. J Infect Dis 2003; 188:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/6\">",
"      Reefhuis J, Honein MA, Whitney CG, et al. Risk of bacterial meningitis in children with cochlear implants. N Engl J Med 2003; 349:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/7\">",
"      Wilson-Clark SD, Squires S, Deeks S, Centers for Disease Control and Prevention (CDC). Bacterial meningitis among cochlear implant recipients--Canada, 2002. MMWR Morb Mortal Wkly Rep 2006; 55 Suppl 1:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/8\">",
"      Rubin LG, Papsin B, Committee on Infectious Diseases and Section on Otolaryngology-Head and Neck Surgery. Cochlear implants in children: surgical site infections and prevention and treatment of acute otitis media and meningitis. Pediatrics 2010; 126:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/9\">",
"      Hoffman RA, Cohen NL. Complications of cochlear implant surgery. Ann Otol Rhinol Laryngol Suppl 1995; 166:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/10\">",
"      Yu KC, Hegarty JL, Gantz BJ, Lalwani AK. Conservative management of infections in cochlear implant recipients. Otolaryngol Head Neck Surg 2001; 125:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/11\">",
"      Telian SA, El-Kashlan HK, Arts HA. Minimizing wound complications in cochlear implant surgery. Am J Otol 1999; 20:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/12\">",
"      Cunningham CD 3rd, Slattery WH 3rd, Luxford WM. Postoperative infection in cochlear implant patients. Otolaryngol Head Neck Surg 2004; 131:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/13\">",
"      Hopfenspirger MT, Levine SC, Rimell FL. Infectious complications in pediatric cochlear implants. Laryngoscope 2007; 117:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/14\">",
"      Luntz M, Teszler CB, Shpak T. Cochlear implantation in children with otitis media: second stage of a long-term prospective study. Int J Pediatr Otorhinolaryngol 2004; 68:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/15\">",
"      Kempf HG, St&ouml;ver T, Lenarz T. Mastoiditis and acute otitis media in children with cochlear implants: recommendations for medical management. Ann Otol Rhinol Laryngol Suppl 2000; 185:25.",
"     </a>",
"    </li>",
"    <li>",
"     Hannoverschen Cochlear Implant-Gesellschaft e.V. Meeting on post cochlear implantation meningitis. Schiphol Airport, Amsterdam, the Netherlands July 5, 2002. Available in German at file://www.hcig.de.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/17\">",
"      Arnold W, Bredberg G, Gst&ouml;ttner W, et al. Meningitis following cochlear implantation: pathomechanisms, clinical symptoms, conservative and surgical treatments. ORL J Otorhinolaryngol Relat Spec 2002; 64:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/18\">",
"      Cohen N, Ramos A, Ramsden R, et al. International consensus on meningitis and cochlear implants. Acta Otolaryngol 2005; 125:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/19\">",
"      Biernath KR, Reefhuis J, Whitney CG, et al. Bacterial meningitis among children with cochlear implants beyond 24 months after implantation. Pediatrics 2006; 117:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/20\">",
"      Phelps PD, King A, Michaels L. Cochlear dysplasia and meningitis. Am J Otol 1994; 15:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/21\">",
"      Teo DT, Tan TY, Eng SP, Chan YM. Spontaneous cerebrospinal fluid otorrhoea via oval window: an obscure cause of recurrent meningitis. J Laryngol Otol 2004; 118:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/22\">",
"      Hoep LS, Merkus P, van Schie A, et al. The value of nuclear scans in cochlear implant infections. Eur Arch Otorhinolaryngol 2006; 263:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/23\">",
"      Migirov L, Yakirevitch A, Kronenberg J. Surgical and medical complications following cochlear implantation: comparison of two surgical approaches. ORL J Otorhinolaryngol Relat Spec 2006; 68:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/24\">",
"      Hirsch BE, Blikas A, Whitaker M. Antibiotic prophylaxis in cochlear implant surgery. Laryngoscope 2007; 117:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/25\">",
"      Garcia-Valdecasas J, Jim&eacute;nez-Moleon JJ, Sainz M, et al. Prophylactic effect of clarithromycin in skin flap complications in cochlear implants surgery. Laryngoscope 2009; 119:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/26\">",
"      Antonelli PJ, Lee JC, Burne RA. Bacterial biofilms may contribute to persistent cochlear implant infection. Otol Neurotol 2004; 25:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/27\">",
"      Pawlowski KS, Wawro D, Roland PS. Bacterial biofilm formation on a human cochlear implant. Otol Neurotol 2005; 26:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/28\">",
"      Germiller JA, El-Kashlan HK, Shah UK. Chronic Pseudomonas infections of cochlear implants. Otol Neurotol 2005; 26:196.",
"     </a>",
"    </li>",
"    <li>",
"     Advice for Patients With Cochlear Implants: New Information on Meningitis Risk (1st advisory) file://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PatientAlerts/ucm064737.htm (Accessed on December 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/30\">",
"      Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices. Pneumococcal vaccination for cochlear implant candidates and recipients: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2003; 52:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:258.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Cochlear implants &amp; meningitis vaccination - Q&amp;A for healthcare professionals file://www.cdc.gov/vaccines/vpd-vac/mening/cochlear/dis-cochlear-faq-hcp.htm (Accessed on May 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/33\">",
"      Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35913/abstract/34\">",
"      French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812.",
"     </a>",
"    </li>",
"    <li>",
"     Advisory Committee on Immunization Practices. Summary Report, February 22-23, 2012. file://www.cdc.gov/vaccines/recs/acip/downloads/min-feb12.pdf (Accessed on June 25, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5534 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35913=[""].join("\n");
var outline_f35_4_35913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3508407\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3509327\">",
"      Otitis media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk of meningitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Role of positioner",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6629680\">",
"      AAP policy statement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1379129\">",
"      Perioperative antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Wound infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Minor infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Major infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Otitis media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Meningitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Principles of prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H69530491\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H69530498\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2891499\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3508407\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5534\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5534|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/54/29541\" title=\"figure 1\">",
"      Cochlear implants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5534|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/63/21501\" title=\"table 1\">",
"      PCV and PPSV23 in high risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/59/6077\" title=\"table 2\">",
"      Hib schedule US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/48/12046\" title=\"table 3\">",
"      Pneumococcal vaccination indications for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/35/8760?source=related_link\">",
"      Acute otitis media in children: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42857?source=related_link\">",
"      Acute otitis media in children: Prevention of recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42680?source=related_link\">",
"      Clinical manifestations and diagnosis of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4442?source=related_link\">",
"      Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23080?source=related_link\">",
"      Dexamethasone to prevent neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33290?source=related_link\">",
"      Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39300?source=related_link\">",
"      Hearing amplification in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22810?source=related_link\">",
"      Initial therapy and prognosis of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18280?source=related_link\">",
"      Neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31656?source=related_link\">",
"      Neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42489?source=related_link\">",
"      Prevention of Haemophilus influenzae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15306?source=related_link\">",
"      Treatment of bacterial meningitis caused by specific pathogens in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29927?source=related_link\">",
"      Treatment of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_4_35914="Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)";
var content_f35_4_35914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35914/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35914/contributors\">",
"     Kimberly Kenton, MD, MS, FACOG, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35914/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35914/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/4/35914/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/4/35914/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/4/35914/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apical prolapse is the descent of uterus, cervix, or vaginal vault. Pelvic organ prolapse (POP) affects millions of women; approximately 200,000 inpatient surgical procedures for prolapse are performed annually in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Eleven to 19 percent of women will undergo surgery for POP or incontinence by age 80 to 85 years, and 30 percent of these women will require an additional POP or incontinence surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Anterior vaginal wall prolapse without concomitant apical prolapse is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/5\">",
"     5",
"    </a>",
"    ], and apical prolapse repair should be included in the majority of pelvic reconstructive surgery procedures.",
"   </p>",
"   <p>",
"    Reconstructive procedures for prolapse of the vaginal apex are reviewed here. Evaluation of women with POP, conservative management, and choosing a primary surgical procedure are discussed separately. Obliterative procedures for POP (colpocleisis) are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40473?source=see_link\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17530?source=see_link\">",
"     \"Vaginal pessary treatment of prolapse and incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9337?source=see_link\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/37/43607?source=see_link\">",
"     \"Pelvic organ prolapse in women: Obliterative procedures (colpocleisis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1631653\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Continence Society defines apical vaginal prolapse as any descent of the vaginal cuff scar or cervix, below a point which is 2 cm less than the total vaginal length about the plane of the hymen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/6\">",
"     6",
"    </a>",
"    ]. The clinical significance of apical descent that is not beyond the hymen is unclear, as half of asymptomatic women presenting for routine gynecologic care have prolapse to the hymen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/7\">",
"     7",
"    </a>",
"    ]. Similarly, studies suggest that prolapse becomes symptomatic when the leading edge protrudes beyond the vaginal opening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/8\">",
"     8",
"    </a>",
"    ]. However, isolated anterior vaginal wall defects are uncommon. Therefore, if the anterior vaginal wall protrudes beyond the hymen, the apex likely has inadequate support, as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/5,9\">",
"     5,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14533665\">",
"    <span class=\"h1\">",
"     ANATOMY AND MECHANISMS OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apical prolapse refers to the downward displacement of the vaginal apex (",
"    <a class=\"graphic graphic_figure graphicRef67287 \" href=\"mobipreview.htm?23/0/23558\">",
"     figure 1",
"    </a>",
"    ). The vaginal apex is either the uterus and cervix or, in women who have undergone subtotal or total hysterectomy, the cervix or vaginal cuff.",
"   </p>",
"   <p>",
"    Support of the vaginal apex is primarily derived from the integrity of the uterosacral and cardinal ligaments, the continuity of the endopelvic fascia, and a neuromuscularly intact levator ani muscle (",
"    <a class=\"graphic graphic_figure graphicRef61643 \" href=\"mobipreview.htm?26/4/26693\">",
"     figure 2",
"    </a>",
"    ). The etiology of apical prolapse is likely related to connective tissue, neural,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    muscular defects in these normal supports.",
"   </p>",
"   <p>",
"    It is rare to find isolated apical prolapse or isolated prolapse of the anterior or posterior vaginal walls, since the defects in the connective tissue, neural pathways, and muscle are not confined to one site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anatomy of the female pelvic floor is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40473?source=see_link&amp;anchor=H690213#H690213\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\", section on 'Anatomy of pelvic support'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for developing apical prolapse are generally the same as for developing anterior or posterior vaginal wall prolapse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40473?source=see_link&amp;anchor=H21524727#H21524727\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common risk factors associated with apical prolapse are vaginal parity (number of vaginal deliveries) and previous hysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The risk of prolapse after hysterectomy was illustrated in a case-control study in which 160,000 women who underwent hysterectomy were significantly more likely than age-matched controls to require subsequent pelvic floor repair (3.2 verus 2.0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/13\">",
"     13",
"    </a>",
"    ]. Women who have prolapse at the time of hysterectomy have an even higher risk of subsequent surgery for POP. A case-control study of women who underwent hysterectomy reported that the risk of subsequent POP repair was 5-fold in those who had a history of vaginal delivery, 8-fold in those who had prior surgery for POP or urinary incontinence, and almost 13-fold in those who had grade 2 or higher prolapse at the time of hysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/14\">",
"     14",
"    </a>",
"    ]. Surgeons should resuspend the vaginal apex when performing hysterectomy for nonprolapse indications to minimize this risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7963411\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR APICAL PROLAPSE REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for apical prolapse repair are generally the same as for other POP repair procedures, ie, symptomatic prolapse in women who decline or fail conservative therapy and who can tolerate surgery. Prolapse is not typically symptomatic until the vagina protrudes through the hymen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9337?source=see_link&amp;anchor=H2327205#H2327205\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Candidates for surgical treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40473?source=see_link&amp;anchor=H21524755#H21524755\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14538830\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION AND PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women planning surgical repair of apical prolapse, surgeons should assess each vaginal compartment (apical, anterior, and posterior) for the presence of support defects or prolapse. In addition, POP often coexists with urinary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anal incontinence. During the history and physical examination, the presence and severity of each of these disorders should be assessed, as this information may alter surgical decision-making.",
"   </p>",
"   <p>",
"    Aspects of preoperative evaluation and preparation that are specific to apical prolapse repair are discussed in this section. General principles of evaluation of women undergoing POP repair are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/46/8937?source=see_link\">",
"     \"Pelvic organ prolapse in women: Diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14539430\">",
"    <span class=\"h2\">",
"     Informed consent and patient goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgeons should discuss with each woman the pelvic symptoms that are bothersome to her and their effects on her quality of life. This helps to set realistic goals for reconstructive surgery and assess postoperative improvement. Patient satisfaction after surgery for POP and urinary incontinence correlates highly with achievement of self-described preoperative surgical goals, but poorly with objective outcome measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Informed consent for repair of apical prolapse should include a discussion of the risk of persistent or recurrent prolapse at the apex, anterior, or posterior vaginal walls. Since some women develop stress urinary incontinence following apical prolapse repair, surgeons should also discuss the risk of developing incontinence, as well as the risks and benefits of performing a prophylactic incontinence procedure versus deferring an incontinence procedure until symptoms develop. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Evaluation of urinary dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other important items to discuss with women planning apical POP surgery include potential postoperative changes in sexual function and mesh-related complications if mesh will be used for the repair. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/62/26602?source=see_link&amp;anchor=H32#H32\">",
"     \"Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical manifestation of prolapse of the vaginal apex is a bulge or protrusion from the vagina (",
"    <a class=\"graphic graphic_picture graphicRef70607 \" href=\"mobipreview.htm?19/54/20320\">",
"     picture 1",
"    </a>",
"    ). Protrusion of the vagina may result in vaginal discharge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding from ulceration. Other symptoms commonly reported by women with apical prolapse are voiding difficulty and constipation; some women need to reduce the prolapse using a finger in the vagina (ie, splint) to urinate or defecate.",
"   </p>",
"   <p>",
"    Women with advanced anterior or posterior vaginal wall prolapse may have similar symptoms and pelvic examination is needed to ascertain the site(s) and stage of prolapse. Investigators demonstrated that restoration of the vaginal apex during prolapse examination fixes anterior vaginal wall defects 50 percent of the time and posterior vaginal wall defects 30 percent of the time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough speculum and bimanual pelvic examination are performed. We perform apical prolapse assessment initially with the woman standing and straining. Each vaginal compartment (apical, anterior, and posterior) should then be examined with the women supine. The apical prolapse can be visualized during speculum examination with the woman straining as the speculum is slowly withdrawn from the upper third of the vagina. In some women with advanced apical prolapse, protrusion of the apex is visible at or beyond the vaginal introitus before the speculum is inserted (",
"    <a class=\"graphic graphic_picture graphicRef70607 \" href=\"mobipreview.htm?19/54/20320\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Since isolated apical prolapse is rare, careful assessment of the anterior and posterior wall is important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The findings of the examination should be recorded using a quantitative and reproducible method for recording POP. The system currently recommended by the International Continence Society and the American Urogynecologic Society is the pelvic organ prolapse quantitation (POP-Q) system (",
"    <a class=\"graphic graphic_figure graphicRef74368 \" href=\"mobipreview.htm?14/54/15202\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57450 \" href=\"mobipreview.htm?3/1/3100\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/46/8937?source=see_link&amp;anchor=H2#H2\">",
"     \"Pelvic organ prolapse in women: Diagnostic evaluation\", section on 'Speculum and bimanual examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Evaluation of urinary dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apical prolapse frequently coexists with urinary incontinence or urinary retention, and women planning apical prolapse repair should be evaluated for these conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7962270\">",
"    <span class=\"h3\">",
"     Urinary incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with symptoms of both POP and stress urinary incontinence are treated with a combined prolapse repair and continence procedure.",
"   </p>",
"   <p>",
"    Many women with stage II or greater apical prolapse remain continent despite loss of anterior vaginal and",
"    <span class=\"nowrap\">",
"     bladder/urethral",
"    </span>",
"    support. However, 13 to 65 percent of continent women develop symptoms of stress incontinence after surgical correction of the prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/7,20-22\">",
"     7,20-22",
"    </a>",
"    ]. This likely occurs because the prolapse kinks and obstructs the urethra; this obstruction is alleviated when the prolapse is repaired. This is referred to as \"occult\" or \"potential\" stress incontinence. Women with stage I POP are unlikely to have urethral obstruction and resultant occult stress incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/7,20-22\">",
"     7,20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All women with apical prolapse should have a preoperative evaluation for occult stress incontinence with clinical or urodynamic urinary stress testing with reduction of prolapse, although preoperative prolapse reduction testing does not accurately predict postoperative urinary incontinence. Approximately 40 percent of women with negative testing will develop postoperative stress incontinence; however, demonstration of stress incontinence during reduction testing is associated with rates of stress urinary incontinence of up to 60 percent of after prolapse surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1546?source=see_link&amp;anchor=H9#H9\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'Detecting occult incontinence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For continent women with stage II or greater POP who undergo abdominal sacral colpopexy, high quality data indicate that bothersome stress incontinence is less likely to develop in women who undergo a concomitant Burch colposuspension rather than sacral colpopexy alone. While there are fewer data regarding prophylactic surgery for stress incontinence in women undergoing transvaginal apical prolapse repair, it appears such preventive surgery is safe and effective in this population. Combined surgery for POP and stress urinary incontinence is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1546?source=see_link&amp;anchor=H15#H15\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'POP with no symptoms of SUI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7962350\">",
"    <span class=\"h3\">",
"     Urinary retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary retention is evaluated by measuring a postvoid residual urine volume (PVR) within 10 minutes after the patient has voided. In general, a PVR of less than 50 mL is considered adequate emptying, and a PVR greater than 200 mL is considered inadequate. An elevated preoperative PVR normalizes after surgical correction of prolapse in over 90 percent of women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14306274\">",
"    <span class=\"h2\">",
"     Evaluation of defecatory dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with pelvic organ prolapse should be asked about symptoms of defecatory dysfunction (eg, constipation, the need to place pressure on, or &ldquo;splint,&rdquo; the posterior vaginal wall to defecate, anal incontinence). Such symptoms should be evaluated prior to surgery, as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40473?source=see_link&amp;anchor=H21524762#H21524762\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\", section on 'Defecatory symptoms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22458?source=see_link\">",
"     \"Fecal incontinence in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7962786\">",
"    <span class=\"h1\">",
"     SURGICAL PLANNING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues specific to planning repair of apical prolapse are discussed in this section. General principles of surgical decision-making regarding POP (eg, obliterative versus reconstructive surgery, concomitant hysterectomy) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9337?source=see_link&amp;anchor=H2327205#H2327205\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Candidates for surgical treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21188326\">",
"    <span class=\"h2\">",
"     Vaginal versus abdominal approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of surgical route for repair of apical prolapse is controversial. Open abdominal repairs are more effective in restoring vaginal topography, but vaginal repairs incur less serious morbidity and have a shorter recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/26\">",
"     26",
"    </a>",
"    ]. Laparoscopic and robotic approaches may offer the improved vaginal support associated with open procedures and the shorter recovery of vaginal procedures.",
"   </p>",
"   <p>",
"    Two common apical prolapse procedures, abdominal sacral colpopexy and vaginal sacrospinous ligament suspension (SSLS), were compared in a meta-analysis of three randomized trials including 321 women. At two-year follow-up, abdominal sacral colpopexy had a significantly lower rate of recurrent vaginal vault prolapse than SSLS (4 versus 15 percent; RR 0.2, 95% CI 0.07-0.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/26\">",
"     26",
"    </a>",
"    ]; however, reoperation rates in the first two years did not differ significantly (7 versus 16 percent; RR 0.5, 95% CI 0.2-1.1). The meta-analysis is limited by the small number of patients and short period of follow-up.",
"   </p>",
"   <p>",
"    Contrary to traditional beliefs, the meta-analysis demonstrated that total complication rates were similar for the vaginal and abdominal approaches. Similarly, another meta-analysis addressed the severity of complications in abdominal sacral colpopexy and transvaginal apical suspension procedures. This study included the same three randomized trials, as well as 103 observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/27\">",
"     27",
"    </a>",
"    ]. Similar to the meta-analysis of randomized trials, total complication rates appeared similar for abdominal compared with vaginal procedures (17.1 versus 15.3). However, the abdominal approach was associated with a higher frequency of complications involving surgical or radiologic intervention (5.8 versus 2.1 percent); tests of statistical significance were not reported.",
"   </p>",
"   <p>",
"    Another difference between surgical procedures is that abdominal sacral colpopexy, but not traditional vaginal procedures, has the potential for mesh-related complications. There were too few mesh-related complications to report in the meta-analysis of randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/26\">",
"     26",
"    </a>",
"    ], but the reported incidence in a systematic review of abdominal sacral colpopexy was approximately 3 percent using polypropylene mesh [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who underwent abdominal sacral colpopexy were less likely to develop postoperative dyspareunia than those who underwent SSLS (16 versus 36 percent; RR 0.4, 95% CI 0.2- 0.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Rates of dyspareunia were high for both surgical approaches; however, the data regarding dyspareunia were only available for 106 patients. A literature review of observational studies reported general improvement in sexual function following sacral colpopexy and dyspareunia rates of 3 to 10 percent after SSLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/32\">",
"     32",
"    </a>",
"    ]. Similarly, sexual function and pain with intercourse improved one year after sacral colpopexy in the colpopexy and urinary reduction efforts (CARE) trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only disadvantages of sacral colpopexy compared with SSLS in the meta-analysis of randomized trials were increased operative duration (an average of 21 minutes longer), recovery time (an average of 8 days longer), and expense [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, abdominal sacral colpopexy is more effective in restoring vaginal topography without a significant increase in morbidity when compared to SSLS and may be more appropriate for women with risk factors for prolapse recurrence, including young age, obesity, stage III or IV POP, and previous failed POP repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. Rare risk factors for recurrent prolapse are bladder exstrophy or spina bifida [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Abdominal procedures also appear to result in a lower incidence of dyspareunia. Other reasons to choose an abdominal approach are: insufficient vaginal length for transvaginal repair and other indications for abdominal surgery (eg, ovarian cystectomy).",
"   </p>",
"   <p>",
"    On the other hand, transvaginal repair is performed in 80 to 90 percent of prolapse surgeries in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/2,3,40\">",
"     2,3,40",
"    </a>",
"    ]. Vaginal surgery has a shorter operative duration and recovery than open abdominal sacral colpopexy. For these reasons, it is often selected for women with increased surgical risk. In addition, the transvaginal approach can be easily combined with other vaginal procedures commonly performed in women with POP (eg, vaginal hysterectomy, midurethral sling placement). With the increasing use of laparoscopic and robotic alternatives to laparotomy when performing sacral colpopexy, the shorter recovery and decreased morbidity associated with vaginal approaches may become less important.",
"   </p>",
"   <p>",
"    In summary, when planning surgery for quality of life disorders, such as apical prolapse, factors beyond simple anatomic outcomes should be considered and weighed by each woman with her surgeon. Selecting the optimal operation for treatment of apical prolapse is complicated and impacted by numerous factors, including individual women&rsquo;s goals for surgery, as well as her risk of prolapse recurrence, ability to tolerate surgery, and preferences regarding recovery time and risk of dyspareunia (",
"    <a class=\"graphic graphic_algorithm graphicRef56020 \" href=\"mobipreview.htm?15/46/16111\">",
"     algorithm 1",
"    </a>",
"    ). Given the current data, abdominal sacral colpopexy offers better anatomic outcomes than SSLS for most women undergoing apical prolapse repair. A vaginal approach is a reasonable alternative for women with primary prolapse who are having concomitant vaginal surgery, risk factors for mesh-related complications (eg, smoking, immunosuppression), or who place a high priority on a short recovery period or avoiding an abdominal incision. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43239?source=see_link&amp;anchor=H32537601#H32537601\">",
"     \"Wound infections following abdominal wall hernia repair: Epidemiology, pathogenesis, and prevention\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/62/26602?source=see_link\">",
"     \"Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No randomized trial data exist that compare abdominal sacral colpopexy with other vaginal apical suspension procedures (uterosacral and iliococcygeus ligament suspension). (See",
"    <a class=\"local\" href=\"#H8286327\">",
"     'Uterosacral ligament suspension'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8286391\">",
"     'Iliococcygeus suspension'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21188619\">",
"    <span class=\"h2\">",
"     Concomitant repair of other sites of prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apical prolapse almost always coexists with other sites of POP (anterior or posterior). It is controversial whether repair of apical prolapse is sufficient to support the anterior and posterior vaginal walls or if additional procedures are required to address anterior",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    posterior prolapse. If the vaginal muscularis is well suspended at the apex, many anterior and posterior defects will also resolve; conversely, correction of anterior or posterior prolapse does not repair apical descent. Anterior vaginal wall prolapse, in particular, is highly correlated with apical prolapse. The approach to concomitant repair of multiple sites of prolapse varies by surgical route and by site of prolapse. A detailed discussion of the concomitant repair of multiple sites of prolapse can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9337?source=see_link&amp;anchor=H2327483#H2327483\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Concomitant repair of apical and anterior or posterior prolapse'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7963057\">",
"    <span class=\"h2\">",
"     Concomitant surgery for stress urinary incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women with apical prolapse have coexisting urinary incontinence, as noted above. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Evaluation of urinary dysfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7962901\">",
"    <span class=\"h3\">",
"     Women with symptomatic urinary incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with symptoms of both POP and stress incontinence are treated with a combined prolapse repair and continence procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1546?source=see_link&amp;anchor=H4#H4\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'Symptomatic prolapse and incontinence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7963180\">",
"    <span class=\"h3\">",
"     Women at risk for occult urinary incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with stage II or greater POP who are undergoing abdominal sacral colpopexy, high quality data support a concomitant Burch colposuspension rather than sacral colpopexy alone. For continent women undergoing transvaginal prolapse repair, the decision of whether to perform a concomitant midurethral sling depends upon patient preference regarding the risk of developing stress urinary incontinence compared with the risk of perioperative complications.",
"   </p>",
"   <p>",
"    Combined surgery for POP and stress incontinence is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1546?source=see_link&amp;anchor=H15#H15\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'POP with no symptoms of SUI'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1546?source=see_link&amp;anchor=H20#H20\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3586512\">",
"    <span class=\"h1\">",
"     EVALUATING APICAL PROLAPSE PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical outcomes of POP treatments have ranged over the years from patients&rsquo; reports that they are &ldquo;happy or cured&rdquo; to strict anatomic criteria for cure regardless of patient satisfaction. Improvement in objectively measured outcomes after surgery do not always correspond to patient satisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. More recently, experts agree that outcomes literature should include both a measure of subjective cure (based upon the patient's report of cure or improvement) and a measure of objective cure using a validated POP measuring system. A study looked at cure rates using a variety of anatomic and subjective definitions in a cohort of women two years after abdominal sacral colpopexy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/41\">",
"     41",
"    </a>",
"    ]. Reported cure rates range widely, from 19 percent to 97 percent, depending on the definition used with patient reports of no bulge beyond the hymen being most associated patients&rsquo; own assessment of improvement. These data should not be over-interpreted to mean objective outcomes are not valuable, as the follow-up period in this study was short (only two years) and anatomic outcomes tend to worsen over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ABDOMINAL SACRAL COLPOPEXY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal repair of apical prolapse is performed by securing the anterior and posterior vaginal walls via surgical mesh to the anterior longitudinal sacral ligament overlying the sacral promontory. This reestablishes a nearly horizontal vaginal axis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/42\">",
"     42",
"    </a>",
"    ]. The ventral abdominal wall and round ligaments should never be used because of the high risk of recurrent prolapse.",
"   </p>",
"   <p>",
"    Abdominal sacral colpopexy (attachment between the sacral promontory and the vagina vault in women who have undergone total hysterectomy) is the most commonly performed procedure. Uterine or cervix sparing procedures include: sacral hysteropexy (attachment between the sacral promontory and the lower uterus) and sacral cervicopexy (attachment between the sacral promontory and the cervix).",
"   </p>",
"   <p>",
"    Typically, a hysterectomy is done at the time of apical POP repair in women with uterovaginal prolapse. While no prospective comparative studies are available to determine if outcomes are improved with concomitant hysterectomy, several small studies suggest that POP outcomes are not worse and operating times are shorter with uterine preservation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. A retrospective cohort study compared three groups (hysterectomy plus sacral colpopexy, sacral hysteropexy, and hysterectomy plus uterosacral suspension) and showed a six-fold increase in POP recurrence in the uterosacral suspension group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concomitant hysterectomy at the time of prolapse repair is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9337?source=see_link&amp;anchor=H2327312#H2327312\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Concomitant hysterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3584652\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open abdominal sacral colpopexy is performed through a lower abdominal incision, typically a Pfannenstiel, although there are increasing numbers of sacral colpopexies being done laparoscopically or with robotic-assisted laparoscopic procedures.",
"   </p>",
"   <p>",
"    A commonly performed technique is to attach a permanent mesh to the posterior vagina to the level of the rectal reflection and to the anterior vagina for a distance of 4 cm, or just above the bladder trigone. It is acceptable to use a mesh fashioned into a Y configuration or to use two separate strips of mesh. Alternatively, the posterior mesh may extend to the perineal body, adding support to this area (sacral colpoperineopexy). Two rows of sutures are then used to widely attach the mesh to the vagina to distribute the tension; the sutures should approximate the mesh to the vaginal walls for a distance of several centimeters. Permanent sutures are typically used to attach the mesh to the vagina and sacrum. Secondary to concern about vaginal erosion of permanent sutures, some surgeons are starting to use delayed absorbable sutures. In the CARE trial of 322 women undergoing abdominal sacral colpopexy with permanent sutures, only three participants had a vaginal erosion of the permanent suture in the first two years after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/46\">",
"     46",
"    </a>",
"    ]. The suture was simply removed in all three patients; two healed without further problem, and the other was lost to follow-up. Given the lack of high quality data supporting comparable anatomic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptomatic outcomes with use of delayed absorbable sutures and the minimal risks associated with permanent suture, patients should be counseled appropriately if nonpermanent sutures are used.",
"   </p>",
"   <p>",
"    Failure to attach the mesh anteriorly results in anterior vaginal wall recurrence rates of almost 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/47\">",
"     47",
"    </a>",
"    ]. The optimal approach for posterior vaginal wall attachment is unclear; however, simply attaching the mesh to the rectovaginal septum to maintain continuity with the perineal body results in high success rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/48\">",
"     48",
"    </a>",
"    ]. The mesh erosion rates reported from abdominovaginal attachment of the mesh to the perineal body have varied widely (7 to 40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After exposing the presacral space, the free end of the mesh is attached to the anterior longitudinal ligament at the sacral promontory using two or three permanent sutures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1614175\">",
"    <span class=\"h3\">",
"     Avoiding presacral hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laceration of the presacral venous plexus leads to profuse hemorrhage. Careful dissection must be used near the sacrum. The sutures are placed through the sacral (anterior longitudinal) ligament just below the sacral promontory since placement lower on the sacrum, at the S3 to S4 level, is more likely to result in presacral hemorrhage and placement on the promontory may deviate the vaginal axis too far forward.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1614182\">",
"    <span class=\"h3\">",
"     Choosing a surgical mesh",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple suturing of the apical vaginal skin to the sacrum is also regarded as insufficient fixation and likely to result in recurrent prolapse. The best type of mesh and suture material remains controversial, but most surgeons agree that synthetic nonabsorbable materials should be used. Synthetic mesh sacral colpopexy has consistently outperformed the biologic graft materials (autologous, allogeneic, xenograft) in randomized trials, but at the expense of higher mesh erosion rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/28,42,51\">",
"     28,42,51",
"    </a>",
"    ]. In a systematic review of 65 studies (three were randomized trials), the average rate of synthetic mesh erosion was 3.4 percent, the lowest rate was for polypropylene (0.5 percent) compared with other types of synthetic mesh, such as polyethylene or polytetrafluoroethylene (3.1 to 5.0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On rare occasions, a surgeon may also face an intraoperative decision on whether to use synthetic or biologic mesh in the face of a bowel injury or concomitant sigmoid resection with reanastomosis for the treatment of rectal prolapse. Since it is often not advisable to place synthetic nonabsorbable materials during procedures contaminated by bowel contents, these choices should be determined by carefully weighing the risk and benefits for an individual patient.",
"   </p>",
"   <p>",
"    Surgical treatment of prolapse of the vaginal apex with vaginal mesh kits is increasingly common, although outcome data are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/52\">",
"     52",
"    </a>",
"    ]. Similar to anterior vaginal mesh placement, use of apical vaginal mesh may be associated with significant complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/27,53\">",
"     27,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3584567\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of studies from 1966 to 2004 reported that anatomic success rates after abdominal sacral colpopexy range from 76 to 100 percent with a 4 percent (range 0 to 18 percent) reoperation rate for prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/28\">",
"     28",
"    </a>",
"    ]. The need for concomitant anterior or posterior vaginal wall repairs at the time of sacral colpopexy is controversial. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9337?source=see_link&amp;anchor=H680302#H680302\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Abdominal route'",
"    </a>",
"    .) One-year outcomes of the CARE trial showed that abdominal sacral colpopexy performed with or without posterior vaginal wall repair resulted in statistically and clinically significant improvements in bowel symptoms including obstructive defecation and posterior vaginal wall topography regardless of concomitant posterior repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/8\">",
"     8",
"    </a>",
"    ]. Likewise, there was no difference in anterior vaginal wall support in women who had a concomitant paravaginal repair and those who did not. Another recent study of 149 women with advanced prolapse who underwent sacral colpopexy without any concomitant repairs demonstrated excellent anatomic outcomes one year after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two-year outcomes of the CARE trial showed that 95 percent of women had support of the vaginal apex within 2 cm of the total vaginal length and 3 percent had undergone reoperation for prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/55\">",
"     55",
"    </a>",
"    ]. Women reported significant improvement in pelvic floor symptoms and sexual function using validated questionnaires. In addition, correction of apical prolapse via abdominal sacral colpopexy with or without Burch colposuspension significantly reduced bladder symptoms other than incontinence, both irritative (eg, urgency, frequency, nocturia) and obstructive (eg, intermittent flow, straining to void, sensation of incomplete emptying, poor stream) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/56\">",
"     56",
"    </a>",
"    ]. At one-year, participants reported a significant decrease in obstructive defecatory symptoms, fecal incontinence and anorectal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/8\">",
"     8",
"    </a>",
"    ]. New onset fecal incontinence with activity, as well as pain prior to and with defecation, were more likely to be reported by women who had a concomitant posterior repair procedure than by those who did not.",
"   </p>",
"   <p>",
"    Long-term studies report that, at 10 to 14 years after abdominal sacral colpopexy, 2 to 26 percent of women had undergone reoperation for prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3584659\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently reported intraoperative and postoperative complications of open abdominal sacral colpopexy include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incisional problems - 4.6 percent",
"     </li>",
"     <li>",
"      Blood transfusion - 4.4 percent",
"     </li>",
"     <li>",
"      Ileus - 3.6 percent",
"     </li>",
"     <li>",
"      Thromboembolic event - 3.3 percent",
"     </li>",
"     <li>",
"      Cystotomy - 3.1 percent",
"     </li>",
"     <li>",
"      Enterotomy - 1.6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies consistently report that gastrointestinal complications, such as small bowel obstruction or ileus, occur after approximately 1 to 5 percent of abdominal sacral colpopexy procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/28,58\">",
"     28,58",
"    </a>",
"    ]. In the CARE trial, 4 of 322 women required reoperation for small bowel obstruction and all were associated with incisional problems. No intraoperative bowel injuries were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Presacral hemorrhage is the most concerning intraoperative complication and can have life-threatening consequences. Reconstructive surgeons should be prepared to manage presacral hemorrhage and have bone wax, concave thumbtacks, and thrombin immediately available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43305?source=see_link\">",
"     \"Management of hemorrhage in gynecologic surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43305?source=see_link&amp;anchor=H17#H17\">",
"     \"Management of hemorrhage in gynecologic surgery\", section on 'Presacral bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mesh erosion rates vary depending on the type of mesh used. Synthetic nonabsorbable mesh is typically used and, as noted above, a systemic review found that the average rate of erosion for all types of synthetic mesh was 3.4 percent, with a rate of 0.5 percent for polypropylene mesh [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1614182\">",
"     'Choosing a surgical mesh'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several studies report higher mesh erosion rates when sacral colpopexy is performed with concomitant total hysterectomy, but this is not universally reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/46,59\">",
"     46,59",
"    </a>",
"    ]. In a large multicenter study of women undergoing abdominal sacral colpopexy, concomitant total hysterectomy was more common in women who developed a mesh or suture erosion (60 percent versus 24 percent), resulting in a nearly five-fold increased risk of mesh erosion in women with a concomitant hysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/46\">",
"     46",
"    </a>",
"    ]. Some data suggest that smoking and use of ePTFE mesh (Gore-tex&reg;) are also risk factors for mesh erosion following sacral colpopexy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/46,60\">",
"     46,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3584985\">",
"    <span class=\"h2\">",
"     Laparoscopic or robotic procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sacral colpopexy is traditionally performed through a laparotomy; however, conventional and robot-assisted laparoscopic approaches have gained popularity. In addition, single port laparoscopic procedures have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/34/27176?source=see_link\">",
"     \"Robot-assisted laparoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/52/9029?source=see_link\">",
"     \"Laparoendoscopic single-site (single port) surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observational data suggest that the conventional laparoscopic and robot-assisted routes result in a shorter hospital stay (eg, one to two versus three to four days), faster time to recovery, and less postoperative pain than laparotomy, with comparable short-term efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/27,62-65\">",
"     27,62-65",
"    </a>",
"    ]. Some retrospective studies have also found a significant decrease in blood loss (eg, 60 to 150 mL less) with laparoscopic procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/62,64\">",
"     62,64",
"    </a>",
"    ]. A disadvantage of laparoscopic procedures is a longer operative duration (eg, one to two hours longer). In addition, robotic procedures are more costly than laparotomy or conventional laparoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Performing sacral colpopexy requires suturing, which is more difficult to do during conventional than during robot-assisted laparoscopy. For this reason, some surgeons prefer robotic-assisted laparoscopy. However, when robotic and conventional laparoscopic sacral colpopexy were compared in a randomized trial (n = 78), robotic procedures had a significantly longer operative duration (67 minutes longer), including longer anesthesia time, total time in operating room, sacral colpopexy time, and suturing time. Women who underwent robotic sacral colpopexy also reported increased pain during postoperative weeks 3 to 5 and used more nonsteroidal anti-inflammatory drugs (median 20 versus 11 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/68\">",
"     68",
"    </a>",
"    ]. Costs were on average US $1936 higher in the robotic group. Both robotic and laparoscopic sacral colpopexy resulted in significantly improved anatomic and functional outcomes one year after surgery.",
"   </p>",
"   <p>",
"    Although further studies are necessary to ascertain the role for robotic versus laparoscopic sacral colpopexy, current data suggest that the laparoscopic route may be more cost effective and confer some benefits to the patients. Some opponents of this view argue that laparoscopic suturing requires more skill and results from tertiary centers may not be generalizable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8286285\">",
"    <span class=\"h1\">",
"     VAGINAL PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the vaginal route is used, the vaginal apex is suspended to a ligament in the pelvis, either the sacrospinous ligament, iliococcygeous fascia, or the uterosacral ligament. Of these, only the sacrospinous is a true ligament. This is typically performed in women who have undergone total hysterectomy, although cervix and uterine sparing procedures are possible. Vaginal procedures require a sufficient vaginal length to reach the supporting ligament.",
"   </p>",
"   <p>",
"    Sacrospinous ligament suspension was the most commonly used transvaginal procedure for apical prolapse repair. However, more recently, uterosacral ligament suspension (ULS) has gained popularity. The uterosacral technique was introduced in the 1920s, but in the half-century that followed, reconstructive surgeons seemed to shift focus away from the uterosacral ligaments to more sturdy sites of fixation, such as the SSLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/69\">",
"     69",
"    </a>",
"    ]. High rates of recurrent anterior vaginal wall prolapse are common after SSLS, so surgeons attempted to find a more anatomic site to attach the apex to prevent defects in other compartments. Uterosacral and iliococcygeus suspension are two such attempts.",
"   </p>",
"   <p>",
"    In general, surgeons in the United States use a ULS when performing concomitant vaginal hysterectomy, while SSLS is used more commonly for post-hysterectomy prolapse repair. However, both procedures may be performed in women with a prior hysterectomy or at the time of concomitant hysterectomy.",
"   </p>",
"   <p>",
"    No high quality evidence is available to guide surgeons regarding uterine preservation at the time of vaginal apical suspension procedures. A small, nonrandomized prospective trial compared women undergoing sacrospinous cervicopexy with uterine preservation and those undergoing SSLS with vaginal hysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/70\">",
"     70",
"    </a>",
"    ]. Uterine preservation was associated with less blood loss and shorter operating times. Anatomic POP outcomes and reoperation for POP were similar for both groups. Uterine conservation at the time of prolapse repair is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9337?source=see_link&amp;anchor=H2327312#H2327312\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Concomitant hysterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8286292\">",
"    <span class=\"h2\">",
"     Sacrospinous ligament suspension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sacrospinous ligament suspension (SSLS; also referred to as sacrospinous ligament fixation) is the most commonly studied transvaginal procedure for treating vaginal vault prolapse.",
"   </p>",
"   <p>",
"    Although SSLS may also improve anterior vaginal wall prolapse, it is less effective for this indication. Thus, women with large anterior wall defects in addition to apical defects may benefit from another type of prolapse repair, which better supports the anterior vagina or concomitant anterior colporrhaphy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9337?source=see_link&amp;anchor=H2327483#H2327483\">",
"     \"Pelvic organ prolapse in women: Choosing a primary surgical procedure\", section on 'Concomitant repair of apical and anterior or posterior prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SSLS is generally performed unilaterally. Most surgeons prefer the right side since the bowel enters the rectum on the left side [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/32\">",
"     32",
"    </a>",
"    ]. Some surgeons have proposed bilateral SSLS, although the value of this modification has not been proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Use of the bilateral technique depends upon adequate vaginal length and width.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8286299\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before starting the procedure, the patient is examined to ensure that the vagina is long enough to reach the sacrospinous ligament. Women who do not have sufficient vaginal length for SSLS may be candidates for abdominal sacral colpopexy.",
"   </p>",
"   <p>",
"    The sacrospinous ligament extends from the ischial spines to the lower portion of the sacrum and coccyx (",
"    <a class=\"graphic graphic_figure graphicRef60078 \" href=\"mobipreview.htm?33/45/34513\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57811 \" href=\"mobipreview.htm?5/56/6026\">",
"     figure 6",
"    </a>",
"    ). The coccygeus muscle follows the same path as the sacrospinous ligament; together they are referred to as the coccygeus muscle-sacrospinous ligament complex (",
"    <a class=\"graphic graphic_figure graphicRef82007 \" href=\"mobipreview.htm?25/8/25736\">",
"     figure 7",
"    </a>",
"    ). The ligament can be identified on pelvic examination by palpating the ischial spine and tracing posteriorly and medially to the sacrum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/73\">",
"     73",
"    </a>",
"    ]. Marking sutures are placed on the vaginal epithelium at the site where it will attach to the sacrospinous ligament.",
"   </p>",
"   <p>",
"    Several techniques are commonly used when performing a SSLS. In one modification, the perirectal space is entered by opening the posterior vagina in the midline from the perineal body to the apex. The vaginal epithelium is then separated from the underlying muscularis. The dissection is continued to the level of the ischial spine. The rectovaginal space is opened by gently pushing the rectum medially then perforating the rectal pillar (areolar tissue that extends from the rectum to the arcus tendineus fascia pelvis and overlies the levator muscle) (",
"    <a class=\"graphic graphic_figure graphicRef51329 \" href=\"mobipreview.htm?6/27/6586\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the perirectal space is entered, the ischial spine can be palpated and the ligament found medially. A long right angle retractor (eg, Briesky-Navratril) is placed on the ischial spine to protect the pudendal neurovascular bundle and two others are used to retract the bladder superiorly and the rectum medially.",
"   </p>",
"   <p>",
"    With the ligament clearly visible, two to three sutures are placed through the ligament approximately one and one-half finger-breadths medial to the ischial spine. Several techniques and devices are available to assist placing the suture through the ligament (eg, Miya hook, Deschamps ligature carrier, laparoscopic suturing devices) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After securing the sutures to the ligament complex, each of the sutures is placed through the muscularis on the undersurface of the posterior vaginal epithelium and tied by a pulley stitch, while the free end of the suture is held. Traction on the free end of the suture draws the vaginal apex directly onto the sacrospinous ligament and the suture is tied.",
"   </p>",
"   <p>",
"    Another common modification of the SSLS is the \"Michigan Modification\" technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/75\">",
"     75",
"    </a>",
"    ]. In the Michigan Modification, all four vaginal walls are directly approximated to the sacrospinous ligament (instead of just the posterior vaginal wall). The point on each vaginal wall that reaches the ligament is identified and the intervening diamond of vaginal epithelium is excised. The sutures are placed through the sacrospinous ligament, as described above, then sewn through to both the anterior and posterior vagina and tied to the ligament. A long-lasting absorbable suture is used. The goal of this modification is to decrease the risk of an anterior vaginal wall recurrence, but it has not been evaluated in comparative studies with standard SSLS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8286306\">",
"    <span class=\"h4\">",
"     Avoiding nerve entrapment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several techniques to decrease the risk of entrapment of the sciatic nerve or its branches when the sutures are placed. One approach is to perforate the sacrospinous ligament with the needle in a vertical rather than horizontal orientation, thereby attempting to place the suture parallel to the course of these nerves. Also, since these nerves did not travel in the lateral third segment of the sacrospinous ligament, placement of the fixation sutures within this region is another approach to decrease the risk of nerve injury. Regional anesthesia of prolonged duration should not be used postoperatively in women undergoing SSLS, since this may mask the symptoms of nerve entrapment. (See",
"    <a class=\"local\" href=\"#H8286320\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8286313\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a literature review of mostly observational studies, cure rates of prolapse-related symptoms ranged from 70 to 98 percent (only four studies reported subjective results) and the range of objective cure rates was 67 to 97 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/32\">",
"     32",
"    </a>",
"    ]. Recurrence of apical prolapse after SSLS has been reported in 2 to 19 percent of women and of anterior vaginal wall prolapse in 6 to 29 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/29,30,75-83\">",
"     29,30,75-83",
"    </a>",
"    ]. Therefore, as noted above, women with large anterior wall defects in addition to apical descent may benefit from an additional type of prolapse repair, which more directly addresses support of the anterior vagina. A study that followed women for 2 to 15 years reported that 16 percent had prolapse symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regarding bowel symptoms, relief of constipation was reported in several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/32\">",
"     32",
"    </a>",
"    ]. Data regarding fecal incontinence were inconsistent, with some studies reporting improvement in patients with preoperative symptoms, and others reporting de novo incontinence in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8286320\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious complications are uncommon following SSLS. A literature review of mostly observational studies that included 1922 SSLS procedures reported the following complication rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystitis &ndash; 4.5 percent",
"     </li>",
"     <li>",
"      Fever, secondary wound healing, abscess, or septicemia &ndash; 4.1 percent",
"     </li>",
"     <li>",
"      Ureteral kinking, problems with urination &ndash; 2.9 percent",
"     </li>",
"     <li>",
"      Pain (unclassified, gluteal, or bladder) &ndash; 2.0 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Hemorrhage/blood",
"      </span>",
"      transfusion &ndash; 1.9 percent",
"     </li>",
"     <li>",
"      Nerve damage (eg, sciatic nerve) &ndash; 1.8 percent &nbsp;",
"     </li>",
"     <li>",
"      Injury to pelvic organs &ndash; 0.8 percent",
"     </li>",
"     <li>",
"      Pelvic or vaginal vault hematoma &ndash; 0.4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infectious complications are the most common type of adverse event, and are generally mild (eg, cystitis).",
"   </p>",
"   <p>",
"    Lower urinary tract complications involving ureteral impingement or injury may also occur; cystotomy is infrequent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/77\">",
"     77",
"    </a>",
"    ]. Enterotomy and postoperative bowel complications are rare, as the procedure is meant to be extraperitoneal. A discussion of lower urinary tract injury in gynecologic surgery can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/27/7609?source=see_link\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemorrhage during SSLS is most commonly due to laceration of the inferior gluteal or pudendal vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/85\">",
"     85",
"    </a>",
"    ]. Pudendal hemorrhage is best treated by tightly packing the ischiorectal fossa and waiting for hemostasis. Further discussion of hemorrhage during gynecologic surgery can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43305?source=see_link\">",
"     \"Management of hemorrhage in gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postoperative pain or nerve dysfunction is likely due to injury to the branches of the sciatic nerve that cross the sacrospinous ligament, based on anatomic studies in cadavers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/86\">",
"     86",
"    </a>",
"    ]. If the sciatic nerve is entrapped in the suture, the classic triad of nerves entrapment will present (paresthesias, pain, temporary relief with injection of local anesthetic). The patient typically awakens with severe buttock pain radiating down the posterior leg. Delay in diagnosis and treatment can result in permanent neuropathy; therefore, as noted above, regional anesthesia of prolonged duration should not be used for this type of surgery. Upon diagnosis of nerve entrapment, the patient should be taken back to the operating room immediately to have the sutures removed.",
"   </p>",
"   <p>",
"    The effect of SSLS on sexual function has not been well studied. Many studies have not evaluated this outcome and some women who undergo apical prolapse repair are not sexually active [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/32\">",
"     32",
"    </a>",
"    ]. The rate of dyspareunia was 36 percent in pooled data from three randomized trials in which SSLS was compared with abdominal sacral colpopexy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21188326\">",
"     'Vaginal versus abdominal approach'",
"    </a>",
"    above.) In contrast, observational studies have reported dyspareunia in 3 to 10 percent of women who underwent SSLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8286327\">",
"    <span class=\"h2\">",
"     Uterosacral ligament suspension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterosacral ligament suspension (ULS) has increased in popularity. The uterosacral ligaments are thought to be one of the main connective tissue supports for the upper vagina. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8286363\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;This procedure is typically performed transvaginally, but it can also be done laparoscopically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25976?source=see_link&amp;anchor=H16#H16\">",
"     \"Laparoscopic surgery for repair of pelvic floor defects\", section on 'Uterosacral ligament vault suspension'",
"    </a>",
"    .) The uterosacral ligaments are made of smooth muscle, connective tissue, and nerves. They originate from the S1 to S4 vertebrae to insert near the cervix (",
"    <a class=\"graphic graphic_figure graphicRef63102 \" href=\"mobipreview.htm?11/15/11507\">",
"     figure 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The key to successful ULS is simultaneous correction of all defects in the apical endopelvic fascia. The anterior and posterior vaginal muscularis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/87\">",
"     87",
"    </a>",
"    ] near the apex should be directly approximated to ensure the continuity of the vaginal muscularis.",
"   </p>",
"   <p>",
"    In the most commonly performed ULS technique, the anterior and posterior vaginal walls are opened in the midline; the enterocele sac is identified, if present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/88\">",
"     88",
"    </a>",
"    ]. The peritoneal cavity is entered and the uterosacral ligaments identified. An Allis clamp can be used to tent the uterosacral ligament, making it easier to identify. The rectum is retracted medially.",
"   </p>",
"   <p>",
"    Two or three permanent sutures are passed through the uterosacral ligament on each side. These are placed 1.5 centimeters medial and 1.5 centimeters posterior to the ischial spine. The sutures are numbered sequentially with labeled Kelly clamps, one through six, to facilitate vaginal placement. In serial fashion, one arm of each suture is passed through the anterior muscularis surrounding the vaginal apex and the other through the posterior endopelvic fascia. The sutures thereby cross the width of the vaginal apex. All sutures are then tied, re-approximating the anterior and posterior vaginal muscularis, closing any potential enterocele defect, and elevating the vaginal apex toward the sacrum.",
"   </p>",
"   <p>",
"    Retrospective chart review of 248 procedures found that 1 percent with permanent sutures had loss of support beyond the hymen versus 6 percent in delayed absorbable group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8286370\">",
"    <span class=\"h4\">",
"     Avoiding or detecting ureteral injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average distance from the lateral aspect of the suspension sutures to the medial border of the ureters was 14 mm in a cadaver study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/90\">",
"     90",
"    </a>",
"    ]. Cystoscopy should be performed after tying the sutures due to a significant rate of ureteral kinking during this procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12349156\">",
"    <span class=\"h4\">",
"     Avoiding nerve entrapment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cadaveric studies suggest a higher risk of sacral nerve entrapment when uterosacral sutures are placed using a deep, dorsal, posterior technique and suggest that sacral nerve injury may be minimized by tenting the ligament ventrally prior to placing sutures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8286377\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 10 observational studies evaluated ULS in 930 women; a successful anatomic outcome was defined as POP-Q stage 0 or 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/92\">",
"     92",
"    </a>",
"    ]. The rates of a successful outcome for each compartment were: apical (98 percent), anterior (81 percent), and posterior (87 percent). Meta-analysis of subjective outcomes was not possible due to methodologic differences across studies; relief of prolapse symptoms was reported by 82 to 100 percent of patients (this outcome was only reported by five studies). Reoperation for symptomatic prolapse was reported in 9 percent of women (reported by four studies). There were few reports of significant improvement in bowel symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8286384\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of ULS are uncommon. The meta-analysis described in the preceding section reported the following complications rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/92\">",
"     92",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ureteral obstruction &ndash; 1.8 percent",
"     </li>",
"     <li>",
"      Blood transfusion &ndash; 1.3 percent &nbsp;",
"     </li>",
"     <li>",
"      Pelvic organ injury &ndash; 0.4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ureteral obstruction is the most common complication. Cystoscopy should be done routinely at the completion of each case to prevent delayed recognition of ureteral injury. Ureteral kinking from the uterosacral suture is found during routine intraoperative cystoscopy in up to 11 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. If both ureters do not efflux briskly, the most lateral suture (closest to the ureter) on that side should be removed. Typically, removing this suture is sufficient to restore brisk ureteral efflux without further sequelae, although ureteral injury requiring ureteroneocystostomy has been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29592?source=see_link&amp;anchor=H13424516#H13424516\">",
"     \"Diagnostic cystourethroscopy for gynecologic conditions\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sacral nerves can be ligated if ULS sutures are placed lateral to the ligament fibers or too deep into the pelvic sidewall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/90,95,96\">",
"     90,95,96",
"    </a>",
"    ]. In a retrospective case series, 7 of 182 women who had undergone a uterosacral ligament suspension developed sensory neuropathy and pain in the S2 to S3 dermatomes immediately postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/96\">",
"     96",
"    </a>",
"    ]. Three of these women had reduction of pain when suspension sutures were removed within four days after surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8286391\">",
"    <span class=\"h2\">",
"     Iliococcygeus suspension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iliococcygeus suspension is similar to the SSLS, but uses the iliococcygeus fascia over the levator plate instead of the sacrospinous ligament. Proposed advantages of the iliococcygeus suspension compared with SSLS are lower risks of anterior vaginal wall recurrence and injury to the pudendal neurovascular bundle, but these benefits remain unproven. There are few data regarding this procedure. In a case-control study of 128 women, one- to two-year follow-up, subjective success rates were similar for iliococcygeus suspension and SSLS (91 versus 94 percent), but objective success occurred significantly more frequently in women who underwent SSLS (53 versus 67 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/97\">",
"     97",
"    </a>",
"    ]. Perioperative complications were similar for the two procedures. Some data suggest that vaginal length may be longer following iliococcygeus suspension compared with SSLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22180329\">",
"    <span class=\"h2\">",
"     Vaginal mesh kits",
"    </span>",
"    &nbsp;&mdash;&nbsp;One systematic review of articles reporting outcomes of vaginal mesh procedures for apical prolapse concluded that vaginal mesh seemed to effectively cure apical POP; however, long-term anatomic and functional data were needed, as well as comparative studies to traditional POP repairs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/53\">",
"     53",
"    </a>",
"    ]. High complication rates were found with apical mesh procedures (up to 17.6 percent) with mesh erosion and dyspareunia most common. In contrast, authors of another systematic review of vaginal mesh procedures for POP concluded that there were insufficient data to determine efficacy of vaginal mesh procedures for apical POP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/52\">",
"     52",
"    </a>",
"    ]. This systematic review also found high complication rates associated with vaginal mesh placement, including graft erosion in up to 30 percent, urinary tract infections in up to 19 percent, and visceral injury in up to 3 percent. A randomized trial compared a total vaginal mesh procedure (Prolift&reg;; this device has now been removed from the market) with laparoscopic sacral colpopexy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/99\">",
"     99",
"    </a>",
"    ]. At two-year follow-up, women in the sacral colpopexy group had a significantly higher objective success rate (77 versus 43 percent) and a lower reoperation rate (5 versus 22 percent). This study was limited by methodologic issues. Safety issues regarding transvaginal placement of mesh or biografts are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/62/26602?source=see_link\">",
"     \"Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8286427\">",
"    <span class=\"h2\">",
"     Comparing among vaginal procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal choice is between SSLS and ULS for surgeons performing transvaginal apical prolapse repair. ULS potentially improves anterior vaginal wall support compared to SSLS. On the other hand, the risk of ureteral injury and need for cystoscopy for ULS are disadvantages for this procedure compared with SSLS, since it adds to operative duration. Unfortunately, no comparative data are yet available to determine if vaginal SSLS or ULS offer superior anatomic or subjective outcomes for uterovaginal or vaginal vault prolapse. A recent meta-analysis suggests ULS results in excellent apical outcomes; however, anterior success (stage 0 or I) rates were only 67 percent in women with preoperative stage III prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/92\">",
"     92",
"    </a>",
"    ]. A multicenter randomized comparative effectiveness trial comparing SSLS and ULS is in progress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/4/35914/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative care is similar for both vaginal and abdominal approaches; however, recovery after abdominal sacral colpopexy may be slower than transvaginal procedures due to the abdominal incision. The postoperative course will also vary according to whether concomitant procedures were performed (eg, hysterectomy, surgery for stress urinary incontinence).",
"   </p>",
"   <p>",
"    We give patients standard instructions regarding postoperative pain control, bleeding, signs of infection, and gastrointestinal function. We advise no sexual intercourse for six weeks to avoid disruption of the repair.",
"   </p>",
"   <p>",
"    We see patients at two weeks postoperatively for routine follow-up. We perform a wound check and speculum examination. Few data are available to guide postoperative care and most recommendations are based on the surgeon's experience and preferences.",
"   </p>",
"   <p>",
"    Routine discharge instructions can be found separately. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/27/28083?source=see_link\">",
"     \"Patient information: Care after gynecologic surgery (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apical prolapse is the descent of uterus, cervix, or vaginal vault (",
"      <a class=\"graphic graphic_figure graphicRef67287 \" href=\"mobipreview.htm?23/0/23558\">",
"       figure 1",
"      </a>",
"      ). The most common clinical manifestation of vaginal vault prolapse is a bulge or protrusion from the vagina. Other symptoms that women with prolapse may report include difficulty voiding and constipation; some women may need to elevate the prolapse to urinate or defecate. Protrusion of the prolapsed vagina may result in chronic vaginal discharge",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bleeding from ulceration. (See",
"      <a class=\"local\" href=\"#H14533665\">",
"       'Anatomy and mechanisms of injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical candidates include women with symptomatic apical prolapse who have failed or declined conservative management of their prolapse. There are no high quality data comparing surgical and conservative treatments for pelvic organ prolapse (POP). Prolapse is typically a chronic problem, and women often prefer surgery to conservative therapy since successful surgery does not require ongoing maintenance to control symptoms. (See",
"      <a class=\"local\" href=\"#H7963411\">",
"       'Candidates for apical prolapse repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Apical prolapse repair via open abdominal sacral colpopexy is more effective at restoring vaginal topography than traditional vaginal repairs, although subjective outcomes are similar after the two types of procedures. We suggest abdominal sacral colpopexy rather than sacrospinous ligament suspension (SSLS) for most women undergoing apical prolapse repair (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A vaginal approach is a reasonable alternative for women who cannot tolerate abdominal surgery, have no risk factors for prolapse recurrence (eg, young age, obesity, stage III or IV POP, previous failed POP repair), are having concomitant vaginal surgery, have risk factors for mesh-related complications (eg, concomitant hysterectomy, smoking, immunosuppression, obesity), or who place a high priority on a short recovery period or avoiding an abdominal incision. (See",
"      <a class=\"local\" href=\"#H21188326\">",
"       'Vaginal versus abdominal approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with apical prolapse undergoing abdominal sacral colpopexy, we recommend synthetic mesh over biografts (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Synthetic mesh use in sacral colpopexy reduces the risk of recurrent apical prolapse. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/62/26602?source=see_link\">",
"       \"Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdominal sacral colpopexy can be performed using conventional or robotic laparoscopy. Observational data suggest that the laparoscopic and robotic routes compared to laparotomy result in shorter hospital stay, shorter recovery times, less pain, and comparable efficacy; however, no evidence exists comparing laparoscopic and vaginal routes. (See",
"      <a class=\"local\" href=\"#H3584985\">",
"       'Laparoscopic or robotic procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal sacral colpopexy may also alleviate irritative and obstructive bladder symptoms, as well as bowel symptoms, and improve sexual function. (See",
"      <a class=\"local\" href=\"#H3584567\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transvaginal procedures require adequate vaginal length to reach the support structure (ie, a ligament attached to the bony pelvis). (See",
"      <a class=\"local\" href=\"#H8286285\">",
"       'Vaginal procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uterosacral ligament suspension potentially improves anterior vaginal wall support compared to SSLS, although no data exist directly comparing these procedures. (See",
"      <a class=\"local\" href=\"#H8286427\">",
"       'Comparing among vaginal procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Apical prolapse often coexists with other sites of prolapse",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      with urinary or anal incontinence. Some women with advanced POP are continent, but will go on to develop stress urinary incontinence after surgical correction of the prolapse. All women planning repair of apical prolapse should be counseled about the possibility of developing incontinence postoperatively. The advantages of prophylactic continence procedures versus staged procedures should be reviewed, as well as the role of reduction stress testing. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation of urinary dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/1\">",
"      Jones KA, Shepherd JP, Oliphant SS, et al. Trends in inpatient prolapse procedures in the United States, 1979-2006. Am J Obstet Gynecol 2010; 202:501.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/2\">",
"      Boyles SH, Weber AM, Meyn L. Procedures for pelvic organ prolapse in the United States, 1979-1997. Am J Obstet Gynecol 2003; 188:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/3\">",
"      Olsen AL, Smith VJ, Bergstrom JO, et al. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997; 89:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/4\">",
"      Asante A, Whiteman MK, Kulkarni A, et al. Elective oophorectomy in the United States: trends and in-hospital complications, 1998-2006. Obstet Gynecol 2010; 116:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/5\">",
"      Rooney K, Kenton K, Mueller ER, et al. Advanced anterior vaginal wall prolapse is highly correlated with apical prolapse. Am J Obstet Gynecol 2006; 195:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/6\">",
"      Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/7\">",
"      Swift S, Woodman P, O'Boyle A, et al. Pelvic Organ Support Study (POSST): the distribution, clinical definition, and epidemiologic condition of pelvic organ support defects. Am J Obstet Gynecol 2005; 192:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/8\">",
"      Bradley CS, Nygaard IE, Brown MB, et al. Bowel symptoms in women 1 year after sacrocolpopexy. Am J Obstet Gynecol 2007; 197:642.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/9\">",
"      Rooney, K, Mueller, E, Kenton, K, et al. Can advanced stages of anterior or posterior vaginal wall prolapse occur without apical involvement? J Pelvic Surgery 2006; 12:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/10\">",
"      Summers A, Winkel LA, Hussain HK, DeLancey JO. The relationship between anterior and apical compartment support. Am J Obstet Gynecol 2006; 194:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/11\">",
"      Mant J, Painter R, Vessey M. Epidemiology of genital prolapse: observations from the Oxford Family Planning Association Study. Br J Obstet Gynaecol 1997; 104:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/12\">",
"      Blandon RE, Bharucha AE, Melton LJ 3rd, et al. Incidence of pelvic floor repair after hysterectomy: A population-based cohort study. Am J Obstet Gynecol 2007; 197:664.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/13\">",
"      Altman D, Falconer C, Cnattingius S, Granath F. Pelvic organ prolapse surgery following hysterectomy on benign indications. Am J Obstet Gynecol 2008; 198:572.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/14\">",
"      D&auml;llenbach P, Kaelin-Gambirasio I, Dubuisson JB, Boulvain M. Risk factors for pelvic organ prolapse repair after hysterectomy. Obstet Gynecol 2007; 110:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/15\">",
"      Elkadry EA, Kenton KS, FitzGerald MP, et al. Patient-selected goals: a new perspective on surgical outcome. Am J Obstet Gynecol 2003; 189:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/16\">",
"      Hullfish KL, Bovbjerg VE, Steers WD. Patient-centered goals for pelvic floor dysfunction surgery: long-term follow-up. Am J Obstet Gynecol 2004; 191:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/17\">",
"      Mahajan ST, Elkadry EA, Kenton KS, et al. Patient-centered surgical outcomes: the impact of goal achievement and urge incontinence on patient satisfaction one year after surgery. Am J Obstet Gynecol 2006; 194:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/18\">",
"      Lowder JL, Park AJ, Ellison R, et al. The role of apical vaginal support in the appearance of anterior and posterior vaginal prolapse. Obstet Gynecol 2008; 111:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/19\">",
"      Brubaker, L, Norton, P. Current Clinical Nomenclature for Description of Pelvic Organ Prolapse. Journal of Pelvic Surgery 1996; 2:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/20\">",
"      Ellerkmann RM, Cundiff GW, Melick CF, et al. Correlation of symptoms with location and severity of pelvic organ prolapse. Am J Obstet Gynecol 2001; 185:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/21\">",
"      Gutman RE, Ford DE, Quiroz LH, et al. Is there a pelvic organ prolapse threshold that predicts pelvic floor symptoms? Am J Obstet Gynecol 2008; 199:683.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/22\">",
"      Mouritsen L, Larsen JP. Symptoms, bother and POPQ in women referred with pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/23\">",
"      Visco AG, Brubaker L, Nygaard I, et al. The role of preoperative urodynamic testing in stress-continent women undergoing sacrocolpopexy: the Colpopexy and Urinary Reduction Efforts (CARE) randomized surgical trial. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/24\">",
"      Abbasy S, Lowenstein L, Pham T, et al. Urinary retention is uncommon after colpocleisis with concomitant mid-urethral sling. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/25\">",
"      Fitzgerald MP, Kulkarni N, Fenner D. Postoperative resolution of urinary retention in patients with advanced pelvic organ prolapse. Am J Obstet Gynecol 2000; 183:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/26\">",
"      Maher C, Feiner B, Baessler K, et al. Surgical management of pelvic organ prolapse in women. Cochrane Database Syst Rev 2010; :CD004014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/27\">",
"      Diwadkar GB, Barber MD, Feiner B, et al. Complication and reoperation rates after apical vaginal prolapse surgical repair: a systematic review. Obstet Gynecol 2009; 113:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/28\">",
"      Nygaard IE, McCreery R, Brubaker L, et al. Abdominal sacrocolpopexy: a comprehensive review. Obstet Gynecol 2004; 104:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/29\">",
"      Benson JT, Lucente V, McClellan E. Vaginal versus abdominal reconstructive surgery for the treatment of pelvic support defects: a prospective randomized study with long-term outcome evaluation. Am J Obstet Gynecol 1996; 175:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/30\">",
"      Maher CF, Qatawneh AM, Dwyer PL, et al. Abdominal sacral colpopexy or vaginal sacrospinous colpopexy for vaginal vault prolapse: a prospective randomized study. Am J Obstet Gynecol 2004; 190:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/31\">",
"      Lo, TS, Wang, AC. Abdominal colposacropexy and sacrospinous ligament suspension for severe uterovaginal prolapse: A comparison. J Gynecol Surg 1998; 14:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/32\">",
"      Beer M, Kuhn A. Surgical techniques for vault prolapse: a review of the literature. Eur J Obstet Gynecol Reprod Biol 2005; 119:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/33\">",
"      Handa VL, Zyczynski HM, Brubaker L, et al. Sexual function before and after sacrocolpopexy for pelvic organ prolapse. Am J Obstet Gynecol 2007; 197:629.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/34\">",
"      Whiteside JL, Weber AM, Meyn LA, Walters MD. Risk factors for prolapse recurrence after vaginal repair. Am J Obstet Gynecol 2004; 191:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/35\">",
"      Diez-Itza I, Aizpitarte I, Becerro A. Risk factors for the recurrence of pelvic organ prolapse after vaginal surgery: a review at 5 years after surgery. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/36\">",
"      Nieminen K, Huhtala H, Heinonen PK. Anatomic and functional assessment and risk factors of recurrent prolapse after vaginal sacrospinous fixation. Acta Obstet Gynecol Scand 2003; 82:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/37\">",
"      Jeon MJ, Chung SM, Jung HJ, et al. Risk factors for the recurrence of pelvic organ prolapse. Gynecol Obstet Invest 2008; 66:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/38\">",
"      Muir TW, Aspera AM, Rackley RR, Walters MD. Recurrent pelvic organ prolapse in a woman with bladder exstrophy: a case report of surgical management and review of the literature. Int Urogynecol J Pelvic Floor Dysfunct 2004; 15:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/39\">",
"      Gill EJ, Hurt WG. Pathophysiology of pelvic organ prolapse. Obstet Gynecol Clin North Am 1998; 25:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/40\">",
"      Brown JS, Waetjen LE, Subak LL, et al. Pelvic organ prolapse surgery in the United States, 1997. Am J Obstet Gynecol 2002; 186:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/41\">",
"      Barber MD, Brubaker L, Nygaard I, et al. Defining success after surgery for pelvic organ prolapse. Obstet Gynecol 2009; 114:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/42\">",
"      Culligan PJ, Blackwell L, Goldsmith LJ, et al. A randomized controlled trial comparing fascia lata and synthetic mesh for sacral colpopexy. Obstet Gynecol 2005; 106:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/43\">",
"      Banu LF. Synthetic sling for genital prolapse in young women. Int J Gynaecol Obstet 1997; 57:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/44\">",
"      Leron E, Stanton SL. Sacrohysteropexy with synthetic mesh for the management of uterovaginal prolapse. BJOG 2001; 108:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/45\">",
"      Jeon MJ, Jung HJ, Choi HJ, et al. Is hysterectomy or the use of graft necessary for the reconstructive surgery for uterine prolapse? Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/46\">",
"      Cundiff GW, Varner E, Visco AG, et al. Risk factors for mesh/suture erosion following sacral colpopexy. Am J Obstet Gynecol 2008; 199:688.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/47\">",
"      Brubaker L. Sacrocolpopexy and the anterior compartment: support and function. Am J Obstet Gynecol 1995; 173:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/48\">",
"      Cundiff GW, Harris RL, Coates K, et al. Abdominal sacral colpoperineopexy: a new approach for correction of posterior compartment defects and perineal descent associated with vaginal vault prolapse. Am J Obstet Gynecol 1997; 177:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/49\">",
"      Visco AG, Weidner AC, Barber MD, et al. Vaginal mesh erosion after abdominal sacral colpopexy. Am J Obstet Gynecol 2001; 184:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/50\">",
"      Su KC, Mutone MF, Terry CL, Hale DS. Abdominovaginal sacral colpoperineopexy: patient perceptions, anatomical outcomes, and graft erosions. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/51\">",
"      FitzGerald MP, Edwards SR, Fenner D. Medium-term follow-up on use of freeze-dried, irradiated donor fascia for sacrocolpopexy and sling procedures. Int Urogynecol J Pelvic Floor Dysfunct 2004; 15:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/52\">",
"      Sung VW, Rogers RG, Schaffer JI, et al. Graft use in transvaginal pelvic organ prolapse repair: a systematic review. Obstet Gynecol 2008; 112:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/53\">",
"      Feiner B, Jelovsek JE, Maher C. Efficacy and safety of transvaginal mesh kits in the treatment of prolapse of the vaginal apex: a systematic review. BJOG 2009; 116:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/54\">",
"      Guiahi M, Kenton K, Brubaker L. Sacrocolpopexy without concomitant posterior repair improves posterior compartment defects. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/55\">",
"      Brubaker L, Nygaard I, Richter HE, et al. Two-year outcomes after sacrocolpopexy with and without burch to prevent stress urinary incontinence. Obstet Gynecol 2008; 112:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/56\">",
"      Burgio KL, Nygaard IE, Richter HE, et al. Bladder symptoms 1 year after abdominal sacrocolpopexy with and without Burch colposuspension in women without preoperative stress incontinence symptoms. Am J Obstet Gynecol 2007; 197:647.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/57\">",
"      Hilger WS, Poulson M, Norton PA. Long-term results of abdominal sacrocolpopexy. Am J Obstet Gynecol 2003; 189:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/58\">",
"      Whitehead WE, Bradley CS, Brown MB, et al. Gastrointestinal complications following abdominal sacrocolpopexy for advanced pelvic organ prolapse. Am J Obstet Gynecol 2007; 197:78.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/59\">",
"      Culligan PJ, Murphy M, Blackwell L, et al. Long-term success of abdominal sacral colpopexy using synthetic mesh. Am J Obstet Gynecol 2002; 187:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/60\">",
"      Lowman JK, Woodman PJ, Nosti PA, et al. Tobacco use is a risk factor for mesh erosion after abdominal sacral colpoperineopexy. Am J Obstet Gynecol 2008; 198:561.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/61\">",
"      White WM, Goel RK, Swartz MA, et al. Single-port laparoscopic abdominal sacral colpopexy: initial experience and comparative outcomes. Urology 2009; 74:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/62\">",
"      Paraiso MF, Walters MD, Rackley RR, et al. Laparoscopic and abdominal sacral colpopexies: a comparative cohort study. Am J Obstet Gynecol 2005; 192:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/63\">",
"      Higgs PJ, Chua HL, Smith AR. Long term review of laparoscopic sacrocolpopexy. BJOG 2005; 112:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/64\">",
"      Geller EJ, Siddiqui NY, Wu JM, Visco AG. Short-term outcomes of robotic sacrocolpopexy compared with abdominal sacrocolpopexy. Obstet Gynecol 2008; 112:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/65\">",
"      Klauschie JL, Suozzi BA, O'Brien MM, McBride AW. A comparison of laparoscopic and abdominal sacral colpopexy: objective outcome and perioperative differences. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/66\">",
"      Patel M, O'Sullivan D, Tulikangas PK. A comparison of costs for abdominal, laparoscopic, and robot-assisted sacral colpopexy. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/67\">",
"      Judd JP, Siddiqui NY, Barnett JC, et al. Cost-minimization analysis of robotic-assisted, laparoscopic, and abdominal sacrocolpopexy. J Minim Invasive Gynecol 2010; 17:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/68\">",
"      Paraiso MF, Jelovsek JE, Frick A, et al. Laparoscopic compared with robotic sacrocolpopexy for vaginal prolapse: a randomized controlled trial. Obstet Gynecol 2011; 118:1005.",
"     </a>",
"    </li>",
"    <li>",
"     Miller, N. A new method of correcting complete inversion of the vagina. Surg Gynecol Obstet 1927; 550.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/70\">",
"      Hefni M, El-Toukhy T, Bhaumik J, Katsimanis E. Sacrospinous cervicocolpopexy with uterine conservation for uterovaginal prolapse in elderly women: an evolving concept. Am J Obstet Gynecol 2003; 188:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/71\">",
"      Shull BL, Capen CV, Riggs MW, Kuehl TJ. Bilateral attachment of the vaginal cuff to iliococcygeus fascia: an effective method of cuff suspension. Am J Obstet Gynecol 1993; 168:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/72\">",
"      Pohl JF, Frattarelli JL. Bilateral transvaginal sacrospinous colpopexy: preliminary experience. Am J Obstet Gynecol 1997; 177:1356.",
"     </a>",
"    </li>",
"    <li>",
"     Karram, MM, Walters, MD. Surgical treatment of vaginal vault prolapse and enterocele. In: Urogynecology and Reconstructive Pelvic Surgery, 3rd ed, Walters, MD, Karram, MM (Eds), Mosby Elsevier, Philadelphia 2007. p.267.",
"    </li>",
"    <li>",
"     Karram, MM, Walters, MD.. Surgical treatment of vaginal vault prolapse and enterocele. In: Urogynecology and Reconstructive Pelvic Surgery, 3rd ed, Walters, MD, Karram, MM (Eds), Mosby Elsevier, Philadelphia 2007. p.271.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/75\">",
"      Morley GW, DeLancey JO. Sacrospinous ligament fixation for eversion of the vagina. Am J Obstet Gynecol 1988; 158:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/76\">",
"      Colombo M, Milani R. Sacrospinous ligament fixation and modified McCall culdoplasty during vaginal hysterectomy for advanced uterovaginal prolapse. Am J Obstet Gynecol 1998; 179:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/77\">",
"      Sze EH, Karram MM. Transvaginal repair of vault prolapse: a review. Obstet Gynecol 1997; 89:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/78\">",
"      Lantzsch T, Goepel C, Wolters M, et al. Sacrospinous ligament fixation for vaginal vault prolapse. Arch Gynecol Obstet 2001; 265:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/79\">",
"      Meschia M, Bruschi F, Amicarelli F, et al. The sacrospinous vaginal vault suspension: Critical analysis of outcomes. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/80\">",
"      Paraiso MF, Ballard LA, Walters MD, et al. Pelvic support defects and visceral and sexual function in women treated with sacrospinous ligament suspension and pelvic reconstruction. Am J Obstet Gynecol 1996; 175:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/81\">",
"      Penalver M, Mekki Y, Lafferty H, et al. Should sacrospinous ligament fixation for the management of pelvic support defects be part of a residency program procedure? The University of Miami experience. Am J Obstet Gynecol 1998; 178:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/82\">",
"      Shull BL, Capen CV, Riggs MW, Kuehl TJ. Preoperative and postoperative analysis of site-specific pelvic support defects in 81 women treated with sacrospinous ligament suspension and pelvic reconstruction. Am J Obstet Gynecol 1992; 166:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/83\">",
"      Sze EH, Kohli N, Miklos JR, et al. A retrospective comparison of abdominal sacrocolpopexy with Burch colposuspension versus sacrospinous fixation with transvaginal needle suspension for the management of vaginal vault prolapse and coexisting stress incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/84\">",
"      Aigmueller T, Riss P, Dungl A, Bauer H. Long-term follow-up after vaginal sacrospinous fixation: patient satisfaction, anatomical results and quality of life. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/85\">",
"      Barksdale PA, Elkins TE, Sanders CK, et al. An anatomic approach to pelvic hemorrhage during sacrospinous ligament fixation of the vaginal vault. Obstet Gynecol 1998; 91:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/86\">",
"      Roshanravan SM, Wieslander CK, Schaffer JI, Corton MM. Neurovascular anatomy of the sacrospinous ligament region in female cadavers: Implications in sacrospinous ligament fixation. Am J Obstet Gynecol 2007; 197:660.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/87\">",
"      DeLancey JO. Structural anatomy of the posterior pelvic compartment as it relates to rectocele. Am J Obstet Gynecol 1999; 180:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/88\">",
"      Shull BL, Bachofen C, Coates KW, Kuehl TJ. A transvaginal approach to repair of apical and other associated sites of pelvic organ prolapse with uterosacral ligaments. Am J Obstet Gynecol 2000; 183:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/89\">",
"      Chung CP, Miskimins R, Kuehl TJ, et al. Permanent suture used in uterosacral ligament suspension offers better anatomical support than delayed absorbable suture. Int Urogynecol J 2012; 23:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/90\">",
"      Wieslander CK, Roshanravan SM, Wai CY, et al. Uterosacral ligament suspension sutures: Anatomic relationships in unembalmed female cadavers. Am J Obstet Gynecol 2007; 197:672.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/91\">",
"      Siddiqui NY, Mitchell TR, Bentley RC, Weidner AC. Neural entrapment during uterosacral ligament suspension: an anatomic study of female cadavers. Obstet Gynecol 2010; 116:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/92\">",
"      Margulies RU, Rogers MA, Morgan DM. Outcomes of transvaginal uterosacral ligament suspension: systematic review and metaanalysis. Am J Obstet Gynecol 2010; 202:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/93\">",
"      Barber MD, Visco AG, Weidner AC, et al. Bilateral uterosacral ligament vaginal vault suspension with site-specific endopelvic fascia defect repair for treatment of pelvic organ prolapse. Am J Obstet Gynecol 2000; 183:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/94\">",
"      Karram M, Goldwasser S, Kleeman S, et al. High uterosacral vaginal vault suspension with fascial reconstruction for vaginal repair of enterocele and vaginal vault prolapse. Am J Obstet Gynecol 2001; 185:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/95\">",
"      Siddique SA, Gutman RE, Sch&ouml;n Ybarra MA, et al. Relationship of the uterosacral ligament to the sacral plexus and to the pudendal nerve. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/96\">",
"      Flynn MK, Weidner AC, Amundsen CL. Sensory nerve injury after uterosacral ligament suspension. Am J Obstet Gynecol 2006; 195:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/97\">",
"      Maher CF, Murray CJ, Carey MP, et al. Iliococcygeus or sacrospinous fixation for vaginal vault prolapse. Obstet Gynecol 2001; 98:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/98\">",
"      Medina CA, Croce C, Candiotti K, Takacs P. Comparison of vaginal length after iliococcygeus fixation and sacrospinous ligament fixation. Int J Gynaecol Obstet 2008; 100:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/99\">",
"      Maher CF, Feiner B, DeCuyper EM, et al. Laparoscopic sacral colpopexy versus total vaginal mesh for vaginal vault prolapse: a randomized trial. Am J Obstet Gynecol 2011; 204:360.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/4/35914/abstract/100\">",
"      Barber MD, Brubaker L, Menefee S, et al. Operations and pelvic muscle training in the management of apical support loss (OPTIMAL) trial: design and methods. Contemp Clin Trials 2009; 30:178.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8073 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-FD0A04FE88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35914=[""].join("\n");
var outline_f35_4_35914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1631653\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14533665\">",
"      ANATOMY AND MECHANISMS OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7963411\">",
"      CANDIDATES FOR APICAL PROLAPSE REPAIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14538830\">",
"      PREOPERATIVE EVALUATION AND PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14539430\">",
"      Informed consent and patient goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Evaluation of urinary dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7962270\">",
"      - Urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7962350\">",
"      - Urinary retention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14306274\">",
"      Evaluation of defecatory dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7962786\">",
"      SURGICAL PLANNING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21188326\">",
"      Vaginal versus abdominal approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21188619\">",
"      Concomitant repair of other sites of prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7963057\">",
"      Concomitant surgery for stress urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7962901\">",
"      - Women with symptomatic urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7963180\">",
"      - Women at risk for occult urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3586512\">",
"      EVALUATING APICAL PROLAPSE PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ABDOMINAL SACRAL COLPOPEXY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3584652\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1614175\">",
"      - Avoiding presacral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1614182\">",
"      - Choosing a surgical mesh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3584567\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3584659\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3584985\">",
"      Laparoscopic or robotic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8286285\">",
"      VAGINAL PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8286292\">",
"      Sacrospinous ligament suspension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8286299\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8286306\">",
"      Avoiding nerve entrapment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8286313\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8286320\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8286327\">",
"      Uterosacral ligament suspension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8286363\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8286370\">",
"      Avoiding or detecting ureteral injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12349156\">",
"      Avoiding nerve entrapment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8286377\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8286384\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8286391\">",
"      Iliococcygeus suspension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22180329\">",
"      Vaginal mesh kits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8286427\">",
"      Comparing among vaginal procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/8073\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8073|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?15/46/16111\" title=\"algorithm 1\">",
"      Choosing a primary procedure for pelvic organ prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8073|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/0/23558\" title=\"figure 1\">",
"      Uterine descent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/4/26693\" title=\"figure 2\">",
"      Delancey levels pelvic support 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/54/15202\" title=\"figure 3\">",
"      Sites pelvic organ support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/1/3100\" title=\"figure 4\">",
"      Three by three grid POP-Q",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/45/34513\" title=\"figure 5\">",
"      Female pelvic bones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/56/6026\" title=\"figure 6\">",
"      Bones and ligaments of the pelvis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/8/25736\" title=\"figure 7\">",
"      Pelvic floor muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/27/6586\" title=\"figure 8\">",
"      Pelvic floor muscles 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/15/11507\" title=\"figure 9\">",
"      Uterosacral ligaments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8073|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/54/20320\" title=\"picture 1\">",
"      Complete vaginal vault prolapse",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40473?source=related_link\">",
"      An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29592?source=related_link\">",
"      Diagnostic cystourethroscopy for gynecologic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22458?source=related_link\">",
"      Fecal incontinence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/52/9029?source=related_link\">",
"      Laparoendoscopic single-site (single port) surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25976?source=related_link\">",
"      Laparoscopic surgery for repair of pelvic floor defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43305?source=related_link\">",
"      Management of hemorrhage in gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/62/26602?source=related_link\">",
"      Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/27/28083?source=related_link\">",
"      Patient information: Care after gynecologic surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1546?source=related_link\">",
"      Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9337?source=related_link\">",
"      Pelvic organ prolapse in women: Choosing a primary surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/46/8937?source=related_link\">",
"      Pelvic organ prolapse in women: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/37/43607?source=related_link\">",
"      Pelvic organ prolapse in women: Obliterative procedures (colpocleisis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/34/27176?source=related_link\">",
"      Robot-assisted laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/27/7609?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17530?source=related_link\">",
"      Vaginal pessary treatment of prolapse and incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43239?source=related_link\">",
"      Wound infections following abdominal wall hernia repair: Epidemiology, pathogenesis, and prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_4_35915="ANCA accuracy in GN in elderly";
var content_f35_4_35915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ANCA results for pauci-immune crescentic glomerulonephritis in older adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical presentation of patient",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence of PI-CGN",
"       </td>",
"       <td class=\"subtitle1\">",
"        PPV for PI-CGN",
"       </td>",
"       <td class=\"subtitle1\">",
"        NPV for PI-CGN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapidly progressive glomerulonephritis*",
"       </td>",
"       <td>",
"        66 percent (82/124)",
"       </td>",
"       <td>",
"        99 percent",
"       </td>",
"       <td>",
"        65 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematuria, proteinuria, and creatinine &gt;3 mg/dL",
"       </td>",
"       <td>",
"        30 percent (147/497)",
"       </td>",
"       <td>",
"        95 percent",
"       </td>",
"       <td>",
"        89 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematuria, proteinuria, and creatinine 1.5-3 mg/dL",
"       </td>",
"       <td>",
"        11 percent (36/311)",
"       </td>",
"       <td>",
"        85 percent",
"       </td>",
"       <td>",
"        97 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematuria, proteinuria, and creatinine &lt;1.5 mg/dL",
"       </td>",
"       <td>",
"        4 percent (7/195)",
"       </td>",
"       <td>",
"        66 percent",
"       </td>",
"       <td>",
"        99 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated positive predictive values (PPV) and negative predictive values (NPV) of ANCA results for pauci-immune crescentic glomerulonephritis (PI-CGN) in older adults (&gt;50 years old) with different clinical presentations using an assay approach (that has a 72.5 percent sensitivity and a 98.4 percent specificity).",
"    <div class=\"footnotes\">",
"     * This clinical presentation presumed from renal biopsy showing &gt;50 percent of glomeruli with crescents.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jennette, JC, Wilkman, AS, Falk, RJ, Kidney Int 1998; 53:796.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35915=[""].join("\n");
var outline_f35_4_35915=null;
var title_f35_4_35916="Autism screening tools";
var content_f35_4_35916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Autism-specific screening tools for young children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tool",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity/specificity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Validation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CHAT",
"       </td>",
"       <td>",
"        18-24 months",
"       </td>",
"       <td>",
"        <p>",
"         9 parent-report items",
"        </p>",
"        <p>",
"         5 observed items",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Sensitivity: 20 to 38 percent",
"        </p>",
"        <p>",
"         Specificity: 98 percent",
"        </p>",
"       </td>",
"       <td>",
"        &gt;16,000 children in the community",
"       </td>",
"       <td>",
"        Validated as first-stage screen, but may be more useful as a second-stage screen.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        M-CHAT",
"       </td>",
"       <td>",
"        16-30 months",
"       </td>",
"       <td>",
"        <p>",
"         23 parent-report items",
"        </p>",
"        <p>",
"         Takes approximately 5 minutes to administer",
"        </p>",
"        <p>",
"         Available in English, Spanish, and other languages (see",
"         <a href=\"file://www2.gsu.edu/~psydlr/Diana_L._Robins,_Ph.D..html\" target=\"_blank\">",
"          file://www2.gsu.edu/~psydlr/Diana_L._Robins,_Ph.D..html",
"         </a>",
"         )",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Sensitivity: 85 percent",
"        </p>",
"        <p>",
"         Specificity: 93 percent",
"        </p>",
"        <p>",
"         Positive predictive value 57 to 76 percent when followed by structured interview (approximately 60 percent when used as first-stage screen)",
"        </p>",
"       </td>",
"       <td>",
"        &gt;5000 children in primary care practices",
"       </td>",
"       <td>",
"        Validated as first-stage screen. Failed screen is followed by structured interview before referral for diagnostic evaluation. (See text for details).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        STAT",
"       </td>",
"       <td>",
"        24-36 months",
"       </td>",
"       <td>",
"        <p>",
"         12 observed activities during 20-minute play session",
"        </p>",
"        <p>",
"         Requires training for administration and scoring",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Sensitivity: 92 percent",
"        </p>",
"        <p>",
"         Specificity: 85 percent",
"        </p>",
"       </td>",
"       <td>",
"        52 children with ASD and other developmental disorders",
"       </td>",
"       <td>",
"        <p>",
"         Not suitable for well-child screening, but is an alternative for second-stage screening.",
"        </p>",
"        <p>",
"         Language comprehension is not required. Requires training for administration and scoring; not suitable for primary care practice.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        CSBC-DP-ITC",
"       </td>",
"       <td>",
"        6-24 months",
"       </td>",
"       <td>",
"        24-item questionnaire",
"       </td>",
"       <td>",
"        Positive predictive value: 75 percent",
"       </td>",
"       <td>",
"        10,479 infants screened at 1-year health supervision visit",
"       </td>",
"       <td>",
"        The CSBC-DP-ITC is a broadband screen for communication delays.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CHAT: Checklist for Autism in Toddlers; M-CHAT: Modified CHAT; STAT: Screening Tool for Autism in Two-Year-Olds; SCQ: Social Communication Questionnaire (formerly the Autism Screening Questionnaire); CSBC-DP-ITC: Communication and Symbolic Behavior Scales Developmental Profile &ndash; Infant Toddler Checklist.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35916=[""].join("\n");
var outline_f35_4_35916=null;
var title_f35_4_35917="LD resources";
var content_f35_4_35917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Resources for healthcare providers, patients, and families of children with learning disabilities*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Resource",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         American Academy of Pediatrics Council on School Health",
"        </p>",
"        <p>",
"         <a href=\"file://www.aap.org/sections/schoolhealth\" target=\"_blank\">",
"          www.aap.org/sections/schoolhealth",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Provides technical assistance and resources to clinicians with an interest in school health",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Council for Exceptional Children",
"        </p>",
"        <p>",
"         <a href=\"file://www.cec.sped.org\" target=\"_blank\">",
"          www.cec.sped.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Provides advocacy and professional development and resources",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Families and Advocates Partnership for Education",
"        </p>",
"        <p>",
"         <a href=\"file://www.fape.org\" target=\"_blank\">",
"          www.fape.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Links to information about IDEA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Family Voices",
"        </p>",
"        <p>",
"         <a href=\"file://www.familyvoices.org\" target=\"_blank\">",
"          www.familyvoices.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Provides information and advocacy for children with special needs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         International Dyslexia Association",
"        </p>",
"        <p>",
"         <a href=\"file://www.interdys.org\" target=\"_blank\">",
"          www.interdys.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Provides comprehensive information, referral services, and advocacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         KidSource Online Overview of ADA, IDEA, and Section 504",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         <a href=\"file://www.kidsource.com/kidsource/content3/ada.idea.html\" target=\"_blank\">",
"          www.kidsource.com/kidsource/content3/ada.idea.html",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Overview of laws pertaining to special education (ADA, IDEA, and Section 504",
"        <sup>",
"         &bull;",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         LD OnLine",
"        </p>",
"        <p>",
"         <a href=\"file://www.ldonline.org\" target=\"_blank\">",
"          www.ldonline.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Provides information and advice about LD and attention deficit hyperactivity disorder for parents, teachers, and other professionals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         The Learning Disabilities Association of America",
"        </p>",
"        <p>",
"         <a href=\"file://www.ldanatl.org\" target=\"_blank\">",
"          www.ldanatl.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Provides advocacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Medical Home Portal",
"        </p>",
"        <p>",
"         <a href=\"file://www.medicalhomeportal.org\" target=\"_blank\">",
"          www.medicalhomeportal.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Provides information for parents and families and professionals (choose appropriate tab and select \"Education &amp; Schools\" from the menu)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         National Center for Learning Disabilities (NCLD)",
"        </p>",
"        <p>",
"         <a href=\"file://www.ncld.org\" target=\"_blank\">",
"          www.ncld.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Provides information to parents, professionals, and individuals with LD, promotes research and programs, and advocates for policies to strengthen educational rights and opportunities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         National Dissemination Center for Children With Disabilities",
"        </p>",
"        <p>",
"         <a href=\"file://www.nichcy.org\" target=\"_blank\">",
"          www.nichcy.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Provides information about disabilities, programs and services for children with disabilities, and laws related to special education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         National Early Childhood Technical Assistance Center",
"        </p>",
"        <p>",
"         IDEA reauthorization 2004",
"        </p>",
"        <p>",
"         <a href=\"file://www.nectac.org/idea/idea.asp\" target=\"_blank\">",
"          www.nectac.org/idea/idea.asp",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Provides information and summaries of IDEA and the 2004 amendments to IDEA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Office of Special Education and Rehabilitative Services",
"        </p>",
"        <p>",
"         <a href=\"file://www2.ed.gov/about/offices/list/osers/osep/index.html\" target=\"_blank\">",
"          www2.ed.gov/about/offices/list/osers/osep/index.html",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Provides leadership and financial support to support children with disabilities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Parent Advocacy Coalition for Educational Rights",
"        </p>",
"        <p>",
"         <a href=\"file://www.pacer.org\" target=\"_blank\">",
"          www.pacer.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Provides assistance to families, workshops, and information for parents and professionals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Technical Assistance Alliance for Parent Centers",
"        </p>",
"        <p>",
"         <a href=\"file://www.taalliance.org\" target=\"_blank\">",
"          www.taalliance.org",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Works to fortify partnerships between parent centers and education systems at local, state, and national levels",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADA: Americans with Disabilities Act; IDEA: Individuals with Disabilities Education Act; LD: learning disability.",
"     <br>",
"      * In this table, \"learning disability\" refers to a heterogeneous group of disorders characterized by the unexpected failure of an individual to acquire, retrieve, and use information competently, rather than intellectual disability (mental retardation).",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Section 504 of the Rehabilitation Act (prohibits discrimination on the basis of disability in program or activities that receive federal financial assistance).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35917=[""].join("\n");
var outline_f35_4_35917=null;
var title_f35_4_35918="Asperg tracheobronchitis";
var content_f35_4_35918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute",
"    <em>",
"     Aspergillus",
"    </em>",
"    tracheobronchitis in a lung transplant recipient at the anastomotic site showing pseudomembrane formation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med 2008; 14:211. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35918=[""].join("\n");
var outline_f35_4_35918=null;
var title_f35_4_35919="Papular urticaria 1";
var content_f35_4_35919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papular urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This healthy adolescent returned from a hike in the woods with itchy bumps on her legs the day before she was evaluated. Note the central crusts where she had been scratching. Linear collections of insect bite like this are referred to as \"breakfast, lunch, and dinner\".",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_4_35919=[""].join("\n");
var outline_f35_4_35919=null;
